Brain microvessels and neuronal excitability: who is exciting who? by Radu, Beatrice Mihaela
 
UNIVERSITÀ’ DEGLI STUDI DI VERONA 
 
DEPARTMENT OF  
Neuroscience, Biomedicine, and Movement 
 
GRADUATE SCHOOL OF 
Life and Health Sciences 
 
DOCTORAL PROGRAM IN  
Neuroscience, Psychology and Psychiatry 
 
 
WITH THE FINANCIAL CONTRIBUTION OF 
Ministerial scholarship D.M. 198/2003 
 
Cycle: ​XXIX cycle 
 
 
 
TITLE OF THE DOCTORAL THESIS 
Brain microvessels and neuronal excitability:  
who is exciting who? 
 
 
S.S.D. ​BIO/16 HUMAN ANATOMY 
(Please complete this space with the S.S.D. of your thesis – mandatory information)* 
 
 
 
Coordinator: Prof. Leonardo Chelazzi 
  
Tutor: Prof. Paolo Francesco Fabene 
 
 
 
Doctoral Student: ​Dott.ssa Beatrice Mihaela Radu 
 
 
 
* For the list of S.S.D. please refer to the Ministerial Decree of 4​th​ October 2000, Attachment A “​Elenco dei 
Settori Scientifico – Disciplinari”​ available at:​ ​http://www.miur.it/atti/2000/alladm001004_01.htm 
 
  
“Nella vita non bisogna mai rassegnarsi, arrendersi       
alla mediocrità, bensì uscire da quella zona grigia in         
cui tutto è abitudine e rassegnazione passiva, bisogna        
coltivare il coraggio di ribellarsi.”  
 
RITA LEVI-MONTALCINI 
 
 
  
1 
 Acknowledgements 
 
 
Firstly, I would like to express my sincere gratitude to my advisor Prof. Paolo              
Francesco Fabene for the continuous support of my Ph.D thesis, for his patience, motivation,              
and for being one of my best friends. I could not have imagined having a better advisor and                  
mentor for my Ph.D study. Thanks Paolo for everything. 
 
 
Additionally, I would like to address a special acknowledgement to Prof. Giuseppe            
Bertini, who patiently helped me drafting all the manuscripts in the last years, and always               
challenged me to become a better scientist. Probably I will never forget how to pronounce               
“acetylcholine”. 
 
 
Besides my advisor, I would like to thank the members of the Doctoral School in               
Neuroscience, Psychology and Psychiatry: Prof. Leonardo Chelazzi, Prof. Giuseppe Busetto,          
Prof. Cristiano Chiamulera, and Prof. Francesco Fumagalli, for their insightful comments           
and encouragement, but also for the hard question which incented me to widen my research               
from various perspectives. Additionally, I would like to express my thanks to Prof. Marcel              
Ameloot from the University of Hasselt, Belgium and to Prof. Gilles Van Luijtelaar from the               
Radboud University, Netherlands, for reviewing this thesis and for the useful suggestions that             
definitely helped me to improve the thesis. 
  
 
My sincere thanks also goes to all the internal and external collaborators Prof.             
Gabriela Constantin, Prof. Michael Assfalg, Prof. Alejandro Giorgetti, Prof. Petr Kacer,           
Prof. Sergio Fucile, Dr. Eda Suku who contributed to this complex research project; without              
their precious support would have been impossible to conduct this research. 
 
 
I thank my fellow labmates for the stimulating discussions, for the help in performing              
experiments, and for all the fun we have had in the last three years. My thoughts I going to                   
you Beatrice, Federico, Emanuele, Inna, Grisha, Cristina, Michele, Valeria, Andrea. A           
special thanks for Marzia and Flavia, who supported me as researchers and friends, and to               
all the other members of the department who warmly encouraged and supported me. 
  
 
Last but not the least, I would like to thank my family: my parents, my husband and                 
my wonderful daughter for their patience and continuous support throughout this thesis and             
for forgiving me for all the time that I have neglected them. 
 
  
2 
 Table of contents 
 
 
Chapter 1. Introduction……………………………………………………………………..6 
1.1. Neurovascular unit components………………………………………………………….​6 
1.1.1. Neurons……………………………………………………………………………………...​7 
1.1.2. The blood–brain barrier…………………………………………………………………..​7 
1.1.3. Glial cells…………………………………………………………………………………....​8 
1.1.4. Pericytes……………………………………………………………………………………..​8 
1.1.5. The humoral network: cytokines………………………………………………………....​9 
1.1.6. Differences in NVU of the cerebral microvasculature………………………………...​9 
1.2. Interactions between neurovascular unit components…………………………………...​10 
1.2.1. Microglia–astrocytes–neurons interactions…………………………………………...​10 
1.2.2. Glia–endothelium interactions………………………………………………..…….…...​11 
1.2.3. Pericyte-endothelium interactions………………………………………………………​12 
1.2.4. Cross-talk between cerebral endothelium and brain parenchyma ………………....​12 
1.3. Neurovascular unit: new insights from ictogenesis……………………………………...​13 
1.3.1. Contribution of 'classical' NVU components to seizures……………………………..​13 
1.3.2. Contribution of leukocytes to seizures……………………………………………….....​14 
1.3.3. Contribution of chemokines to seizures………………………………………………..​.​17 
1.3.4. Contribution of the extracellular matrix to seizures………………………………….​18 
1.3.5. Contribution of the hemodynamic parameters to seizures…………………………...​19 
1.3.6. Contribution of the cross-talk between endothelium and brain parenchyma to           
seizures……………………………………………………………………………………………..​19 
1.4. Open questions…………………………………………………………………………..​20 
 
 
Chapter 2. Aim of the study………………………………………………………………..21 
 
 
Chapter 3. Interaction between Qtracker​®​800 vascular labels and brain endothelial          
microvascular endothelial cells…………………………………………………………….25 
3.1. Summary………………………………………………………………………………...​25 
3.2. State-of-art…………………………………………………………………………........​25 
3.3. Materials and Methods…………………………………………………………………..​27 
3.3.1. Chemicals……………………………………………………………………………….….​27 
3.3.2. Hydrodynamic size measurements by Dynamic light scattering………………..…..​27 
3.3.3. ​Zeta potential measurements……………………………………………………………​.​28 
3.3.4. Animals & QD injection………………………………………………………………….​28 
3.3.5. Transmission electron microscopy……………………………………………………...​29 
3.3.6. Human umbilical vein endothelial cell cultures……………………………………....​29 
3.3.7. Mouse brain endothelial cell cultures……………………………………………….....​29 
3.3.8. In-vitro Qtracker​®​800 studies…………………………………………………………...​30 
3.3.9. Intracellular calcium imaging on endothelial cells…………………………...……...​30 
3.3.10. Endothelial cell viability by Trypan blue assay…………………………………......​30 
3.3.11. Data analysis……………………………………………………………………………..​31 
3.4. Results………………………………………………………………………………...…​32 
3 
 3.4.1. Characterization of nanoparticles (size, hydrodynamic diameter &        
zeta-potential)...........................................................................................................................​32 
3.4.2. Qtracker​®​800 accumulation in mouse brain microvascular endothelium……...….​34 
3.4.3. Qtracker​®​800 treatment does not lead to major cell death in vitro…………….......​34 
3.4.4. Qtracker​®​800 generate intracellular calcium transients in mouse brain endothelial          
cells & human umbilical vein endothelial cells………………………………………...……..​35 
3.5. Discussion………………………………………………………………………...……...​45 
3.5.1. Nontargeted PEGylated near-infrared emitting Qtracker​®​800 accumulate in brain         
vascular endothelium………………………………………………………………………….….​45 
3.5.2. Qtracker​®​800 alters ‘normal’ calcium signaling in brain endothelial cells……....​46 
3.5.3. Qtracker​®​800 might activate different components of the neurovascular unit…....​47 
3.5.4. How suitable are Qtracker®800 for translational studies?....................................​47 
3.6. Conclusion & future perspective………………………………………………………...​48 
3.7. Executive summary……………………………………………………………………...​48 
 
 
Chapter 4. Functional expression of murine muscarinic acetylcholine receptors in CNS           
microvascular endothelium………………………………………………………………...50 
4.1. Summary………………………………………………………………………………...​50 
4.2. State-of-art………………………………………………………………………………​50 
4.3. Materials and Methods……………………………………………………………...…..​53 
4.3.1. Brain endothelial cell cultures………………………………………………....……….​53 
4.3.2. Gene expression via qRT-PCR……………………………………………………….....​53 
4.3.3. Assessment of muscarinic receptor localization via immunofluorescence and         
confocal microscopy……………………………………………………………………………..​54 
4.3.4. Protein  extraction protocol …………………………..…………………………….….​55 
4.3.5. Immunomagnetic isolation followed by MALDI-TOF MS analysis………………..​57 
4.3.6. MALDI-TOF MS analysis……………………………………………………………….​57 
4.3.7. Intracellular calcium imaging measurements………………………………………...​58 
4.3.8. Homology modeling and molecular docking………………………………………....​59 
4.3.9. Data analysis……………………………………………………………………….……..​61 
4.4. Results……………………………………………………………………….………….​62 
4.4.1. All muscarinic acetylcholine receptor subtypes are expressed by mouse brain           
microvascular endothelial cells…………………………………………………………….….​62 
4.4.2. M​1​, M​3, and M​4 are the most abundant receptors in brain microvascular             
endothelial 
cells………………………………………………………….……………………………….…….​66 
4.4.3. Cholinergic activation of calcium signaling pathways in brain microvascular          
endothelial cells depends on muscarinic, but not on nicotinic, receptors…………….….​67 
4.4.4. Selective blocking of M​1 receptors does not, while selective blocking of M​3             
receptors does, reduce ACh-induced calcium signals………………………………...…….​72 
4.4.5. The variability of mouse muscarinic receptors lies in the allosteric binding site..​75 
4.5. Discussion and Conclusions……………………………………………………………..​81 
4.6. Executive summary……………………………………………………………………...​85 
 
 
4 
 Chapter 5. Pilocarpine acts on multiple targets in the CNS microvascular           
endothelium………………………………………………………………………………....86 
5.1. Summary………………………………………………………………………………...​86 
5.2. State-of-art………………………………………………………………………………​86 
5.3. Materials and Methods………………………………………………………………….​87 
5.3.1. Brain endothelial cell cultures………………………………………………………….​87 
5.3.2. In vitro pilocarpine treatment protocol…………………...…………………………...​88 
5.3.3. Gene expression via qRT-PCR………………………………………………………….​88 
5.3.4. Immunofluorescence staining of muscarinic receptors and tight junction proteins in           
brain endothelial cells…………………………………………………………………………..​88 
5.3.5. Immunofluorescence staining of adhesion molecules in brain endothelial cells...​89 
5.3.6. Intracellular calcium imaging measurements………………………………………..​89 
5.3.7. In vitro endothelial cell monolayer permeability assay…………………………….​90 
5.3.8. Viability testing on mouse brain microvascular endothelial cells ………………  ​90 
5.3.9. Cytokine level quantification…………………………………………………………..​90 
5.3.10. Flow cytometry analysis of endothelial–leukocyte adhesion       
molecules……………………............................................................................................​90 
5.3.11. Animals and in vivo pilocarpine      
treatment…………………………………………………………………………………………​91 
5.3.12. Whole-cell recordings on hippocampal pyramidal neurons in rat slices…...….​92 
5.3.13. Molecular docking………………………………………………………………….....​93 
5.3.14. Data analysis………………………………………………………………………...…​93 
5.4. Results………………………………………………………………………………….​94 
5.4.1. Pilocarpine induces the in vivo and in vitro increase of the cytokines             
levels………………………………………………………………………………………....…​94 
5.4.2. Pilocarpine upregulates the expression of adhesion molecules in brain          
microvascular endothelial cells……………………………………………………………..​97 
5.4.3. Pilocarpine elicits calcium transients in brain microvascular endothelial cells but           
is not inducing neuronal epileptic-like discharges………………………………………..​99 
5.4.4. Pilocarpine downregulates the expression of tight junction proteins and          
permeabilizes the monolayers of brain microvascular endothelial cells………………​103 
5.4.5. Pilocarpine competes with acetylcholine on the same binding site of the            
muscarinic receptors and induces changes in these receptors expression………….…​107 
5.5. Discussion and Conclusions……………………………………………………….…..​113 
5.5.1. Pilocarpine triggers the proinflammatory cytokines release and upregulates the          
adhesion molecules…………………………………………………………………………..​113 
5.5.2. Pilocarpine activates brain microvascular endothelial cells and the neuronal          
hyperexcitability might be a secondary phenomenon…………………………………...​114 
5.5.3. Pilocarpine activates brain microvascular endothelial cells by multiple         
mechanisms that contribute to the blood brain barrier permeabilization…………….​116 
5.6. Executive summary…………………………………………………………………....​117 
 
 
Chapter 6. General discussions​…………………………………………………………..​118 
 
 
References…………………………………………………………………………………123  
5 
  
Chapter 1. Introduction 
 
 
 
1.1. Neurovascular unit components 
 
The term ‘neurovascular unit’ (NVU, ​Figure 1.1 ​) refers to the ensemble of structures             
linking the brain parenchyma to its blood vessels and to their coordinated functional response              
(​Abbott et al., 2006​). The NVU is based on the anatomical and functional relationships of               
neurons and glia with blood vessel endothelial cells and pericytes, through the intervening             
extracellular matrix. Functional interactions within the NVU are fundamental in the migration            
and differentiation of neural precursors (​Balenci et al., 2007; Wittko et al., 2009​), and play               
crucial roles in both acute and chronic brain pathology. After acute brain injury, the NVU               
reacts with a coordinated response aimed at minimizing neuronal damage, while promoting            
tissue repair and reorganization. 
 
 
Figure 1.1. Neurovascular unit structure (according to ​Abbott and Yusof, 2010​) 
 
 
 
Parts of this chapter have been published in the paper: Bertini G, Bramanti P, Constantin G, Pellitteri M, ​Radu                   
BM​, Radu M, Fabene PF. (2013) New players in the neurovascular unit: insights from experimental and clinical                 
epilepsy. Neurochem Int. 63(7):652-9.  
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 NVU activity is modulated by molecules traditionally implicated in inflammatory          
activity, which seem to have adapted, in the brain, to serve a variety of physiological roles,                
quite distinct from the immune response. Recent evidence suggests an unexpected role of             
soluble factors (i.e., glutamate, ATP and D-serine) released by glial cells in synaptic plasticity              
underlying memory formation (​Stellwagen and Malenka, 2006​), or to long term potentiation            
(LTP) in the hippocampus (​Halassa and Haydon, 2010; Henneberger et al., 2010​). 
The alternation of sleep and wakefulness, as well as the behavioral and cognitive             
correlates of each state can be modulated by the immune system. For example, some              
cytokines are involved in sleep regulation under physiological conditions, while others can            
modulate sleep by interacting with neurotransmitter, peptide, and/or hormone systems to           
initiate a cascade of responses that subsequently alter sleep–wake behavior (​Krueger et al.,             
1998a; Krueger et al., 1998b; Opp, 2005​). Thus, state-dependent behavior offers unique            
paradigms for the study of such factors. 
 
1.1.1. Neurons 
 
Neuronal activity is the primary source of functional communication in the nervous            
system. Among the major players in cortical neurovascular coupling were identified​: (a)            
projection neurons sending fibers to the neocortex from subcortical centers (​Cauli et al., 2004,              
Elhusseiny and Hamel 2000, Zhang et al. 1995​), (b) local excitatory and inhibitory neurons              
(​Cauli and Hamel, 2010, Lecrux et al., 2011​), and (c) astrocytes (​Attwell et al., 2010,               
Howarth 2014, Zonta et al., 2003 ​), which contribute by means of the released vasoactive              
substances.  
Independently of etiology and progress, brain pathology inevitably leads to          
perturbation of electrical and ligand-dependent responsiveness of neurons. In turn, altered           
neuronal functioning is responsible for the clinical symptoms characteristic of each disease.            
While it is understandable that research efforts have historically been devoted almost            
uniquely to the role of neurons in brain function and disease, such extreme focus may have                
neglected the important contribution of other brain components. It is out of the purpose of this                
thesis to describe this topic. 
 
 
1.1.2. The blood–brain barrier 
 
The blood-brain barrier (BBB) is the regulating interface between circulating blood           
and brain parenchyma. Endothelial cells of brain capillaries, unlike those of the peripheral             
circulation, are characterized by the absence of cell membrane fenestrations, the presence of             
tight junctions, having a high number of cytosolic mitochondria, and minimal pinocytotic            
activity (​Hawkins and Davis, 2005 ​). As an exception, the so-called circumventricular organs            
(CVOs) do possess fenestrated vasculature. In particular, secretory CVOs (median eminence           
and neurohypophysis) present a higher vascular permeability for low-molecular-mass tracers          
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 compared to sensory CVOs (organum vasculosum of lamina terminalis, subfornical organ,           
and area postrema) (​Morita and Miyata, 2012​). 
Anatomical and physiological considerations help understanding the importance of         
cerebrovascular function in neuronal activity (​Winkler et al., 2011​). It has been estimated that              
the total cerebral vascular length is approximately 600–700 km (​Zlokovic, 2005​) in adult             
humans and, in rodents, the distance from each neuronal cell body to a neighboring capillaries               
is ∼15 μm (​Tsai, 2009​). Proper neuronal function necessitates a highly regulated extracellular             
environment, where the concentrations of sodium, potassium, and calcium ions need to be             
maintained within very narrow ranges. In this respect, the active interface between the CNS              
and the peripheral circulatory system, the blood–brain barrier (BBB), is of fundamental            
importance. The BBB functions as a dynamic regulator of ion balance, a facilitator of nutrient               
transport, and a barrier to potentially harmful molecules (​Hawkins and Davis, 2005​). Thanks             
to the BBB, the cerebrovasculature is not simply a passive conduit, but rather a highly               
dynamic multicellular structure capable of integrating and responding to both systemic and            
neural cues (​Winkler et al., 2011 ​). 
 
 
1.1.3. Glial cells 
 
Glial cells, long thought to act as a mere ‘support’ network, have gained increasing              
attention in the last decade as crucial protagonists in a variety of neural functions, including               
information processing. In particular, it has been demonstrated that astrocytes control           
synaptogenesis (​Christopherson et al., 2005​), modulate synaptic strength (​Zhang et al., 2003​),            
cradle and shepherd newborn dentate granule cells of the hippocampus to their final             
destination (​Shapiro et al., 2005​). Furthermore, it has recently been established that astrocytes             
in the visual cortex, like neurons, respond to visual stimuli with a high degree of selectivity                
(​Schummers et al., 2008 ​). Microglia, on the other hand, scan the environment (​Nimmerjahn et              
al., 2005​), phagocytose debris, and present antigens to lymphocytes. Thus, despite the            
classical concept of ‘immune-privilege’ in the brain, mechanisms of innate immune response            
do occur in the central nervous system (CNS) (​Nguyen et al. 2002 ​), and microglia are               
recognized as key players in such response, exerting also neuroprotective functions (​Streit,            
2002​). 
 
 
1.1.4. Pericytes 
 
Pericytes modulate BBB integrity (​Thanabalasundaram et al., 2011; Vandenhaute et          
al., 2011; Winkler et al., 2011; Zlokovic, 2008​) and the contractile proteins (e.g., alpha-SM              
actin) expressed in pericytes contribute to the regulation of capillary blood flow            
(​Bandopadhyay et al., 2001​). Pericytes surrounding endothelial cells (connected via integrin           
molecules, connexin 43, and N-cadherins) are located in the perivascular space of the BBB.              
In general, pericytes contribute to BBB anatomy and physiology, providing vascular stability            
8 
 and modulating vessel diameter and blood flow (​Marchi and Lerner-Natoli, 2013 ​). It has also              
been demonstrated that pericyte deficiency leads to a leaky BBB (​Armulik et al., 2010;              
Armulik et al., 2011 ​). 
 
1.1.5. The humoral network: cytokines 
 
Various cell types in the CNS, especially astrocytes and microglia, secrete cytokines,            
small (810 kD) proteins produced by a variety of hematopoietic and non-hematopoietic cell             
types. While cytokines have been traditionally identified as systemic mediators of both innate             
and acquired immune responses, increasing evidence indicates that these molecules play key            
roles in the modulation of intercellular signaling within the CNS (​Pickering and O’Connor,             
2007; Viviani et al., 2007​). Numerous cytokines can have both pro-inflammatory and            
anti-inflammatory roles, depending on target cells and their specific responsiveness to the            
cytokine (​Sriram and O’Callaghan, 2007​). 
Interestingly, though, the roles played by pro-inflammatory cytokines, such as          
interleukin (IL)-1β and tumor necrosis factor (TNF)-α appear markedly distinct in the brain             
from what has been observed systemically. In particular, the presence of these cytokines is              
not necessarily related to ongoing inflammatory processes (​Galea et al., 2007​). Rather,            
cytokines in the brain seem to subserve highly regulated communication pathways between            
cells of the NVU, contributing to the maintenance of the brain's structural and functional              
integrity, modulating the delicate balance between substrate delivery through blood flow,           
neuronal excitability, and energy demands imposed by neural activity itself (​Abbott et al.,             
2006; Willis et al., 2008​). 
 
1.1.6. Differences of NVU in the cerebral microvasculature 
 
Cerebral microvasculature is formed by brain arterioles, venules (0 - 100 μm in             
diameter) and capillaries (<10 μm diameter). It is very important to emphasize that it was               
evidenced a different control of the cerebrovascular function at the level of arterioles and              
capillaries (​Andreone et al., 2015​), and there are differences in NVU for arterioles and              
capillaries (​Figure 1.2​).  
Cerebral endothelial cells are heterogenous over the microvasculature (​Wilhelm et al.,           
2016​). Arterial and venous endothelial cells present differences in the signalling molecules            
profile, i.e. ephrinB2 and EphB4, members of the Notch signaling, Hedgehog morphogens            
and VEGF-A (​Swift and Weinstein, 2009​), that play essential roles in the regulation of BBB               
functions and in the endothelial cell fate during development (​Swift and Weinstein, 2009,             
Wilhelm et al., 2016​). There is a heterogeneity of the genes profiles in brain microvessels: (i)                
solute transport are preferentially expressed in cerebral capillaries, (ii)         
inflammation-associated genes have a high expression in venules, and (iii) P-glycoprotein           
transporter has a low expression in venules and a high expression in capillaries and arterioles               
(​Macdonald et al., 2010​).  
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Figure 1.2. ​Differences between the neurovascular unit for intracerebral arterioles and intracerebral 
capillaries (according to ​Andreone et al., 2015​)  
 
The neuronal control exerted on the arteriole diameter (i.e. vasodilation or           
vasoconstriction), reflects the NVU integration of the signals controlling the contractile           
properties of vascular smooth muscle cells (​Hamel 2006, Hillman 2014​). CNS capillaries            
were described to lack vascular smooth muscle cells, with approximately 80% of their             
abluminal surface being covered by pericytes (​Armulik et al., 2005, Peppiatt et al., 2006​).              
Pericytes were characterized as contractile cells, contributing to the regulation of capillary            
diameter in response to neural activity (​Hamilton et al., 2010, Itoh and Suzuki, 2012, Peppiatt               
et al., 2006​), without contributing significantly to global cerebral blood flow regulation            
(​Fernandez-Klett et al., 2010​). However, a recent study demonstrated that pericytes increase            
blood flow in the somatosensory cortex through the vasodilation initiated at the capillary             
level (​Hall et al., 2014​).  
 
 
1.2. Interactions between neurovascular unit components 
 
1.2.1. Microglia–astrocytes–neurons interactions 
 
In the healthy brain, resting microglia are constantly scanning their environment with            
long cellular processes that undergo continuous cycles of withdrawal and de novo formation             
at a speed of 1.47 μm/s (​Davalos et al., 2005; Nimmerjahn et al., 2005​). Microglial processes                
establish brief (5 min), direct contacts with neuronal synapses at a frequency of about once               
per hour (​Wake et al., 2009​), suggesting an involvement of microglia in monitoring/restoring             
synaptic activity (​Wake et al., 2009; Ji et al., 2013​). It has recently been shown that microglia                 
actively engulf synaptic material and play a major role in synaptic pruning during postnatal              
development in mice (​Paolicelli et al., 2011​). 
Both in physiological and pathological conditions, as a result of changes in osmolarity             
or neuronal activity, astrocytes increase or decrease in volume (​Hansson et al., 1994;             
10 
 Allansson et al., 1999​). Neuronal activity leads to a rise in extracellular K​+ around astrocytic               
processes, which in turn leads to K​+ entry and astrocytic membrane depolarization (​Kofuji             
and Newman, 2004​). Moreover, astrocytes respond to neuronal activity with an elevation of             
their internal Ca​2+ concentration, as shown by in vitro electrophysiological and calcium            
imaging studies. Calcium increases trigger the release of chemical transmitters from the            
astrocyte itself which, in turn, causes feedback regulation of neuronal activity and synaptic             
strength (​Araque et al., 1999 ​). It should be noted, on the other hand, that in vivo two-photon                 
microscopy indicates the absence of spontaneous Ca​2+ transients in microglia under           
physiological conditions (​Eichhoff et al., 2011​). 
A permanent cross-talk exists between microglia and astrocytes. Studies on          
co-cultures of astrocytes and microglia under physiological conditions and in the presence of             
the inflammatory cytokine interferon-γ have evidenced an ATP-mediated calcium signaling          
mechanism of interaction (​Verderio and Matteoli, 2001​). On the other hand, brain            
endothelium has inductive influence on astrocytes (​Estrada et al., 1990; Spoerri et al., 1997;              
Wagner and Gardner, 2000​). 
An increasing body of evidence points out the role of neuronal cyto-active mediators             
such as tissue-type plasminogen activator (tPA), which can directly affect astrocytes and lead             
to the development and progression of neurodegenerative diseases, as well as the modulation             
of neural function (​Kim et al., 2011; Kwon et al., 2011​). tPA has been recently proposed as an                  
important element in the cross talk between neurons and astrocytes and it could be considered               
a gliotransmitter (​Cassè et al., 2012​). 
 
1.2.2. Glia–endothelium interactions 
 
The endfeet of astrocytes form a lacework of fine lamellae attached to the             
endothelium (​Kacem et al., 1998 ​). Glial–endothelial interactions occur either on a short time             
scale (seconds to minutes) involving receptor-mediated signaling and intracellular calcium          
fluctuations (​Braet et al., 2001, Braet et al., 2004; Paemeleire, 2002​) or on a long time scale,                 
involving alterations in gene expression encoding for BBB tight junction proteins,           
transporters and enzymes (​Dehouck et al., 1990; Schinkel, 1999; Brix et al., 2012​). Among              
the CNS cells, astrocytes are considered responsible for inducing endothelial cells to form the              
tight junctions characteristic of the BBB (​Janzer and Raff, 1987​). Primary cultures or             
immortalized cell lines of brain endothelial cells present a reduction of barrier characteristics             
(down-regulation of tight junction proteins, of enzyme and transport systems) that is partly             
recovered when co-cultured with astrocytes (​Rist et al., 1997; Sobue et al., 1999; Helms et al.,                
2012​). 
Astrocytes send inductive signals to the endothelium (​Abbott, 2002​). In co-culture           
systems it was proven that induction depends on the correct polarity between endothelium             
and glia (​Abbott, 2002​), and it has been speculated that astrocytes release key molecules              
responsible for their inductive signals, such as TGF-β, GDNF, bFGF, IL-6, hydrocortisone            
and angiopoietin 1 (​Hoheisel et al., 1998; Tran et al., 1999; Utsumi et al., 2000; Lee et al.,                  
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 2003​). ​In vivo imaging studies have been also performed to identify the effects exerted by               
astrocytes versus endothelial cells. For example, after systemic 3-chloropropanediol         
administration, male Fisher F344 rats showed astrocytic loss in selected brainstem loci, loss             
of endothelial tight junction protein expression, and loss of BBB integrity (​Willis et al., 2004;               
Willis, 2012​). The affected areas were repopulated 8–28 days later (​Willis et al., 2004​).              
Moreover, under hypoxic stress conditions, increased glial fibrillary acidic protein          
(GFAP)-expression associated with changes in tight junction protein expression and loss of            
BBB integrity (​Willis, 2012​) were demonstrated. Two-photon microscopy on brain mice           
evidenced that damage to a single cortical neuron can induce Ca​2+ elevation in surrounding              
microglia (<50 μm cell body-to-cell body distance) (​Eichhoff et al., 2011​). 
 
 
1.2.3. Pericyte-endothelium interactions 
 
In vitro pericyte/endothelial cell interactions have been studied in various co-culture           
models, both in the presence and absence of glial cells (​Vandenhaute et al., 2011; Al Ahmad                
et al., 2011​). Pericytes in co-culture with glial and endothelial cells stabilize the formation of               
capillary-like structures (​Ramsauer et al., 2002​), and can induce occludin expression in            
endothelial cells (​Hori et al., 2004​). Both astrocytes and pericytes significantly suppress            
endothelial proliferation (​Al Ahmad et al., 2011​). Pericytes induce proper localization of            
barrier proteins, lumen polarization, and functional activity of ABC-transporters similar to           
astrocytes, but the presence of both cells is required to maintain optimal barrier characteristics              
(​Al Ahmad et al., 2011​). Pericyte/endothelial cell interaction increases matrix          
metalloproteinase 9 (MMP-9) activity (​Zozulya et al., 2008​). 
 
1.2.4. Cross-talk between cerebral endothelium and brain parenchyma  
 
There are several pieces of evidence for the crosstalk between cerebral vascular            
endothelium and brain parenchyma, mainly formed by neurons and glial cells.  
Among the factors contributing to the interaction between cerebral endothelium and           
neurons, vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor          
(BDNF) seem to be key players (​Vezzani, 2005, Li et al., 2009​). VEGF was demonstrated to                
play an important role in angiogenesis, neurodegeneration, blood-brain barrier permeability          
and astroglial proliferation (​Krum et al., 2002 ​; Croll et al., 2004a; Croll et al., 2004b;               
Storkebaum et al., 2004​). VEGF is not specific for endothelial cells, by neuroglia or neurons               
might also expressed it (​Vezzani, 2005​). VEGF expression in the rat hippocampal neurons             
enhances neurogenesis, being associated with improved cognition, but independent of          
endothelial cell proliferation (​Cao et al., 2004​). Considering its physiological roles, VEGF            
represents an attractive target to modulate brain function at the neurovascular interface in             
neurological diseases (​Lange et al., 2016​). VEGF and BDNF have been also shown to play an                
important role in the reciprocal modulation of neural stem cells and brain-derived endothelial             
cells in the induction and the maintenance of the neurovascular niche (​Li et al., 2009​).               
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 Another modality of communication between cerebral endothelium and neurons is by means            
of the small vesicles (i.e. secretory exosomes and microvesicles) released in the bloodstream             
that are abundant in microRNAs and mRNAs (​Smalheiser, 2009​).  
Several studies have also indicated the crosstalk between cerebral endothelium and           
oligodendrocytes (​Pham et al., 2012​, ​Miyamoto et al., 2014​), and several factors have been              
demonstrated to contribute to this trophic coupling, e.g. brain-derived neurotrophic factor,           
fibroblast growth factor-2, transforming growth factor-beta, adrenomedullin, vascular        
endothelial growth factor, matrix metalloproteinases, etc. (​Miyamoto et al., 2014). ​This           
crosstalk was suggested to contribute to vascular remodeling after white matter injury (​Pham             
et al., 2012 ​). 
 
 
1.3. Neurovascular unit: new insights from ictogenesis 
 
The conventional notion that neurons are exclusively responsible for brain signaling is            
increasingly challenged by the idea that brain function in fact depends on a complex interplay               
between neurons, glial cells, vascular endothelium, and immune-related blood cells, as part of             
NVU. The progressive establishment of the NVU as a key concept in brain function and               
disease triggered the inevitable shift from a purely ‘neurocentric’ perspective to a more             
integrated approach.  
Seizures are correlated with the abnormal excessive or synchronous neuronal activity           
in the brain, but epilepsy could not be reduced only to this phenomenon. In the last decade,                 
cytokines and vascular alterations have been discussed in relation to the pathogenesis of             
epilepsy, suggesting a potential role for inflammation mechanisms in seizure induction.           
Moreover, blood cellular, molecular, and dynamic parameters (e.g. shear stress, pH,           
temperature, platelet counts, etc.) seem to play relevant roles in modulating neuronal            
excitability. 
 
1.3.1. Contribution of 'classical' NVU components to seizures 
 
After decades of preclinical and clinical epilepsy research aimed at elucidating the            
neuronal alterations responsible for seizuring activity, the role of other brain components,            
such as endothelial cells and leukocytes has emerged in recent years (​Fabene et al., 2010;               
Fabene et al., 2013​). 
BBB leakage has been implicated both in the induction of seizures and in the              
progression to chronic epilepsy (​Seiffert et al., 2004; Ivens et al., 2007; Marchi et al., 2007;                
van Vliet et al., 2007​). In addition, BBB opening leads by itself to neuronal              
hypersynchronization and epileptiform activity mediated by exposure of NVU players, in           
particular astrocytes and neuronal cells, to blood albumin or potassium ions, respectively            
(​Seiffert et al., 2004; Ivens et al., 2007; Marchi et al., 2007 ​). Moreover, it has been shown                 
that BBB disruption by intra-arterial injection of mannitol in human patients suffering from             
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 cerebral lymphoma induces focal motor seizures (​Marchi et al., 2007​). ​Seo et al. (2012)              
recently surveyed the potential role of MMPs in BBB dysfunction. MMPs have thus been              
reported to contribute to BBB disruption and permeability, interfering with cell-cell signaling            
in NVU, particularly mediating occludin degradation (​Liu et al., 2012​). MMPs and associated             
NVU mechanisms have been proposed as potential targets in a broader range of CNS              
disorders (​Seo et al., 2012​). 
Recent evidence indicate that astrocytes also contribute to neurologic disorders such           
as epilepsy as equal partners to neurons, and may represent a promising new target for the                
development of antiepileptic drugs (​Kovács et al., 2012​). In fact, activated astrocytes are a              
common hallmark in patients with mesial temporal lobe epilepsy (TLE) and Ammon’s horn             
sclerosis. Status epilepticus is associated with increased permeability of the BBB, which            
allows the ionic composition of serum to modulate neuronal excitability; astrocytic uptake of             
albumin induces transforming growth factor β (TGF-β)-mediated signaling cascades, leading          
to changes in astrocytic properties, resulting in disturbances in spatial K​+ buffering, thereby             
rendering the NVU more prone to seizures (​Kovács et al., 2012​). 
Additionally, pericytes have been indicated as potential players in NVU remodeling in            
the epileptic brain (​Marchi and Lerner-Natoli, 2013​). 
 
 
1.3.2. Contribution of leukocytes to seizures 
 
Recent evidence demonstrates that leukocytes play an active role in promoting the            
physiological neurogenesis that occurs in the adult mammalian brain. In particular, rodents            
housed in an enriched environment showed increased neurogenesis that depended on the            
recruitment of circulating T-cells and on the activation of resident microglia (​Ziv et al.,              
2006​). The same T-cells contributed to spatial learning, suggesting a complex interplay            
between circulating blood cells, non-neuronal brain cells, and neuronal plasticity. The           
involvement of leukocytes in NVU modulation has also been studied in pathological            
conditions such as experimental and clinical epilepsy. In particular, several studies have            
shown that pro-epileptogenic drugs can activate brain endothelium and induce up-regulation           
of adhesion molecules, potentially allowing leukocyte adhesion and transmigration.         
Specifically, in vivo administration of the pro-convulsant agent kainic acid has been reported             
to up-regulate integrin ligands such as intercellular adhesion molecule 1 (ICAM-1) and            
vascular cell adhesion molecule 1 (VCAM-1) on the surface of brain endothelial cells (​Bell              
and Perry, 1995 ​). These results were also recently confirmed and extended by in vivo staining               
data showing increased expression of P-selectin as well as ICAM-1 and VCAM-1 after kainic              
acid-induced status epilepticus (​Fabene et al., 2013​). It was previously demonstrated that            
leukocyte trafficking mechanisms induce BBB damage leading to seizure generation in           
animal models of epilepsy (​Fabene et al., 2008​). The role of immune cells in epilepsy was                
further supported by the study of Kim and collaborators, demonstrating that leukocyte            
migration through the brain endothelium breaks down the BBB and causes severe seizures in              
an animal model of meningitis (​Kim et al., 2009​). 
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 Moreover, we reported that spontaneous recurrent seizures lead to chronic expression           
of VCAM-1, the ligand for α4β1 integrin, potentially contributing to BBB permeability,            
neuroinflammation, and brain damage that could explain, at least in part, the evolution to              
chronic disease with spontaneous seizure generation (​Fabene et al., 2008 ​). It is interesting to              
note that the Th1 (but not Th2) lymphocytic phenotype were preferentially recruited in             
inflamed brain venules after seizures, suggesting that these adaptive immune cells, known to             
play a key role in the induction of autoimmunity and inflammation, may also contribute to the                
progression of epilepsy (​Fabene et al., 2008​). In support to our data, in vitro studies have                
shown that epileptiform activity induced by bicuculline can rapidly up-regulate the           
expression of adhesion molecules on brain endothelium in an experimental model of isolated             
guinea pig brain (​Librizzi et al., 2007​), suggesting that each seizure may induce             
pro-inflammatory mediators able to activate brain endothelium, which in turn may favor the             
generation of more seizures. 
Vascular alterations and lymphocyte accumulation in the brain parenchyma were also           
documented in epileptic patients, independent of disease etiology (​Hildebrandt et al., 2008​;            
Fabene et al., 2008 ​). Altogether, data obtained in experimental models of epilepsy and results              
obtained from humans strongly suggest a key role for leukocytes and vascular inflammation             
mechanisms in the induction of seizures (​Figure 1.2​). Furthermore, the dissociation between            
anatomical lesions and occurrence/severity of the epileptic condition (​Navarro Mora et al.,            
2009​) suggests that future research efforts should move beyond the long-standing focus on             
neuronal damage and loss, and extend to the mechanisms that modulate NVU excitability. 
It is important to point out that treatment of mice with an anti-α4-integrin mAb after               
the onset of status epilepticus inhibited leukocyte recruitment in pilocarpine-induced          
epilepsy, and led to a drastic reduction in seizure frequency, thus suggesting that α4 integrins               
play a role in epileptogenesis (​Fabene et al., 2008​). In addition, preventive therapy with              
anti-α4 integrin inhibited the induction of the acute phase and completely blocked            
spontaneous recurrent seizures and development of epilepsy, suggesting that blockade of α4            
integrins have preventive as well as therapeutic effect in the pilocarpine-induced           
experimental model of epilepsy (​Fabene et al., 2008​). Taken together, these results strongly             
suggest that leukocyte trafficking contribute to NVU dysfunction and seizure generation. 
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Figure 1.2. ​A schematic view of the different cellular and molecular interactions at NVU leading to seizure. 
(​Bertini et al. 2013​) 
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1.3.3. Contribution of chemokines to seizures 
 
Chemokines (chemoattractant cytokines, characterized by the ability to induce         
chemotaxis in nearby responsive cells) are usually secreted by immune cells after pathogen             
detection, and they have also been proposed as a new class of neuromodulators (​Rostene et               
al., 2007; Cardona et al., 2008​). Chemokines and chemokine receptors modulate           
leukocyte-vascular adhesion during seizure induction. CNS vascular activation parallelled by          
upregulation of adhesion molecules and involvement of chemokines and chemokine receptors           
can be provoked by chemo-convulsant agents or by inflammatory pathologies. Activation of            
brain endothelium leads to leukocyte adhesion, which compromises the endothelial barrier           
function resulting in leakage of plasma constituents into the brain parenchyma (​Fabene et al.,              
2008; Fabene et al., 2010; Fabene et al., 2013​). 
It was reviewed recently the clinical and experimental evidence of the active role of              
chemokines in modulating NVU activity in pathological conditions, such as epilepsy (​Fabene            
et al., 2010​). Altered gene expression for chemokines CCL2, CCL3, CCL4 in hippocampi             
surgically removed from TLE patients has been reported (​Lee et al., 2007​). CCL2 and CCL3               
proteins can attract polymorphonuclear leukocytes, monocytes, memory T cells, and dendritic           
cells in the hippocampus of TLE patients. In support of these results, neutrophils and              
activated T cells with Th1 phenotype have been shown to interact with brain endothelium and               
migrate perivascularly or into the brain parenchyma after pilocarpine-induced status          
epilepticus in mice (​Fabene et al., 2008​). Data obtained in TLE patients also showed              
expression of VCAM-1, suggesting that vascular adhesion molecules and chemokines may           
together control leukocyte trafficking during epilepsy (​Fabene et al., 2010​). Astrocytes,           
perivascular microglia, and infiltrating leukocytes have been identified as major cellular sites            
of CCL3 and CCL2 production in the brain (​Karpus and Ransohoff, 1998​) and their receptors               
CCR1 and CCR2 are expressed on the abluminal surface of human brain endothelial cells              
(​Andjelkovic and Pachter, 2000​) and may direct leukocyte trafficking inside brain           
parenchyma during inflammatory responses (​Fabene et al., 2008; Hildebrandt et al., 2008​; see             
Figure 1.2​). 
Expression of CXCR4 may also be related to NVU activity alterations associated with             
pro-epileptogenic conditions. In fact, increases of CXCR4 expression have been reported in            
the hippocampus of TLE patients, mainly in microglia and in a small population of astrocytes               
(​Lee et al., 2007​). Increased expression of CXCR4 could allow for enhanced CXCL12             
binding, thereby inducing microglia to release TNFα, which potentiates         
prostaglandin-dependent Ca​2+ activation and glutamate release (​Lee et al., 2007​), eventually           
leading to NVU altered activity. 
In agreement with human data, CCR2 and CCL2 have been shown to increase in the               
hippocampus following pilocarpine-induced seizures in rats (​Foresti et al., 2009​). After status            
epilepticus, hypertrophic astrocytes exhibited CCR2-labeling, whereas microglial cells were         
more closely apposed to the CCR2-labeled cells in status epilepticus rats (​Foresti et al.,              
2009​), confirming the involvement of non-neuronal cells in the pathology. In addition, CCL2             
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 was induced in reactive glial cells, as well as in blood vessel, at late time-points after                
pilocarpine-induced status epilepticus in mice, which is potentially related to changes in            
permeability of the BBB during epileptogenesis (​Xu et al., 2009​). CCL2 upregulation has also              
been shown following kainate-induced seizures in the rat hippocampus, correlating to the            
temporal profile of BBB permeability and immune cell recruitment at the injury site (​Manley              
et al., 2007​). Other chemokine receptors, such as CCR7, CCR8, CCR9 and CCR10 have been               
reported to be down-regulated during pilocarpine-induced status epilepticus (​Liu et al., 2012​). 
 
 
1.3.4. Contribution of the extracellular matrix to seizures 
 
As a major component of the neurovascular unit, the extracellular matrix (ECM) is             
deeply involved in BBB functionality not only as a support scaffold, but also with specific               
roles in modulating BBB permeability (​Hawkins and Davis, 2005​). The endothelial           
baso-lateral membrane, pericytes, and astrocytic endfeet are in close proximity to the basal             
lamina. This matrix is a dynamic structure that evolves as a function of the physiological state                
of the system and of the complex interactions between cells. ECM constituents such as              
laminin, heparan sulfate proteoglycans, fibronectin, and collagens reside predominantly in          
basement membranes surrounding brain capillary endothelial cells (​Colognato and         
Yurchenco, 2000​). 
The connection between the cells and the basement membrane is primarily established            
by the integrins and dystroglycan, which form the matrix adhesion receptors (​del Zoppo and              
Milner, 2006​). The integrins and dystroglycan are αβ heterodimeric structures that link the             
cytoskeleton to the specific binding sites on the lamina. The role of integrins controlling BBB               
properties is unique and markedly different from other type of blood vessels. Glia-derived             
ECM decreases the permeability of vascular brain endothelial monolayer whereas aortic           
endothelial cell-derived ECM has an opposite effect (​Hartmann et al., 2007​). The roles of              
integrins have been extensively studied in knockout mouse models in which certain α or β               
subunit-encoding genes have been deleted, with dramatic effects on CNS development from            
neonate status to adulthood. Deletion of αv or β8 subunits results in leaky vasculature,              
thereby inducing cerebral hemorrhage and premature death in affected mice (​McCarty et al.,             
2002​). Some results suggest that αvβ8 integrins expressed by astrocytes control the activation             
of TGF-β stabilizing the endothelium (​Cambier et al., 2005 ​). Integrin expression is also             
related to the developmental stage of the brain. The expression of β1-integrin has been              
associated with angiogenesis in the developing mouse CNS (​Milner and Campbell, 2002​).            
Once the development of blood vessels completes, ECM-related protein expression changes:           
(i) β1-integrin is up-regulated, (ii) in the first postnatal day, β1-integrin is expressed together              
with α4- and α5-integrin, switching to α1- and α6-integrin expression in adulthood, and (iii)              
fibronectin is down-regulated while laminin is up-regulated. Considered together, these          
observations suggest a switch from fibronectin-mediated signaling pathway in the early           
phases of microvascular vessels development to a laminin-mediated one in the adult CNS, in              
support of a profound involvement of ECM in modulating NVU functionality. 
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 MMPs form a large family of structurally related zinc-dependent, secreted or           
membrane-bound proteinases, and are considered major executors of ECM remodeling          
throughout the body (​Sternlicht and Werb, 2001​). MMPs are enzymes that are able to              
influence neuronal function through extracellular proteolysis in various normal and          
pathological conditions. Animal studies suggested that MMP-9 plays an important role in            
epileptogenesis (​Mizoguchi et al., 2011; Takács et al., 2010; Wilczynski et al., 2008​). A              
recent study on human epileptogenesis indicates that up-regulation of MMP-9 is prominent            
and consistent in focal cortical dysplasia (FCD) tissue derived from epilepsy surgery,            
regardless of the patient’s age (​Konopka et al., 2012​; see ​Figure 1.2​). 
 
1.3.5. Contribution of the hemodynamic parameters to seizures 
 
Relatively little attention has been paid to the contribution of cerebral hemodynamic            
and metabolism to neurological diseases. However hemodynamic (e.g., blood pressure,          
systemic vascular resistance, etc.) or oxygenation changes (partial pressure of arterial oxygen,            
partial pressure of arterial CO​2​, pH, saturation, etc.) occurring for instance in traumatic brain              
injury, stroke, and epilepsy, result in NVU alterations, related to several pathophysiological            
mechanisms of injury (​Bor-Seng-Shu et al., 2012​). It has been suggested that uncoupling of              
cerebral blood flow from metabolism can trigger secondary brain lesions, particularly in the             
early phases of the primary incident, with consequent worsening of the patient’s outcome             
(​Bor-Seng-Shu et al., 2012​). 
Hemodynamic regulation is influenced by blood gas content, blood viscosity, body           
temperature, cardiac output, altitude, cerebrovascular autoregulation, and neurovascular        
coupling, mediated by chemical agents such as nitric oxide (NO), carbon monoxide (CO),             
eicosanoid products, oxygen-derived free radicals, endothelins, K​+​, H​+​, and adenosine          
(​Bor-Seng-Shu et al., 2012​). Nitric oxide acts as a diffusible cell-to-cell messenger,            
conveying information associated with its concentration dynamics, both the synthesis via           
glutamate stimulus and inactivation pathways determine the profile of NO concentration           
change (​Laranjinha et al., 2012​). 
 
1.3.6. Contribution of the cross-talk between endothelium and brain parenchyma to           
seizures  
 
The cross-talk between cerebral endothelium and CNS neurons was suggested to play            
an important role in ictogenesis. In pilocarpine-induced seizure models, was reported that            
seizures dramatically increased VEGF both in neurons and in glia (​Croll et al., 2004a​).              
Consequently, VEGF binding to VEGFR1 on local microvasculature might contribute to the            
increase in vascular permeability and BBB leakage during seizures (​Croll et al., 2004a​). In              
VEGF-mediated rat brain inflammation, was described the upregulation of intercellular          
adhesion molecule (ICAM)-1 and the chemokine macrophage inflammatory protein         
(MIP)-1α, as well as a preferential extravasation of monocytes (​Croll et al. 2004b​). In the               
same model, VEGF was indicated to cause a dramatic BBB breakdown, which is             
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 characterized by decreased investment of the vasculature with astroglial endfeet (​Croll et al.             
2004b​). Additionally, in a pilocarpine-induced model, VEGF was demonstrated to be           
up-regulated after status epilepticus, to ensure protection against seizure-induced neuronal          
loss in hippocampus (​Nicoletti et al., 2008​), and to preserve learning and memory after status               
epilepticus ( ​Nicoletti et al., 2010​). In a model of epileptiform activity induced with kainate in               
organotypic rat hippocampal cultures, were demonstrated the overexpression of VEGF and           
VEGF receptor-2 associated with vascular remodeling and zonula occludens 1          
downregulation (​Morin-Brureau et al., 2011​).  
The crosstalk between cerebral endothelium and oligodendrocytes was also suggested          
to contribute to vascular remodeling after white matter injury (​Pham et al., 2012​). 
 
1.4. Open questions 
 
Integrating the above described information several open questions have emerged:  
(1) what is the exact sequence of events in ictogenesis, and the alteration in neuronal               
excitability is a primary or secondary event with respect to the blood brain barrier              
permeabilization? 
(2) is brain endothelium the site of action of different stimuli from the bloodstream              
that can trigger the cascade of events leading to seizure-like events? 
(3) if one of the NVU partners is altered then by crosstalk the other NVU components                
activate and finally the ictogenesis occurs? 
(4) are the alterations/impairments in leukocyte-endothelium adhesion and in         
neutrophils recruitment contributing to the neuroinflammation in brain parenchyma? 
(5) is the cross-talk between cerebral endothelium and brain parenchyma modified in            
epilepsy, and to what extend different signaling molecules (e.g. chemokines) are contributing            
to the mismatched transmission between the NVU partners? 
We will try to tackle these questions, at least in part, in the next chapters of the thesis                  
by using ​in vitro​ and ​in vivo​ models.  
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 Chapter 2. Aim of the study 
 
 
Taking into account the multiple interactions between neurovascular unit components          
that were described in the Introduction chapter, e.g. microglia–astrocytes–neurons         
interactions, glia–endothelium interactions, pericyte-endothelium interactions, cross-talk      
between cerebral endothelium and brain parenchyma, we focused our attention on brain            
endothelium as the first barrier encountered before ”accessing” the brain parenchyma.  
The working hypothesis of our study is that ​any stimulus from the bloodstream that              
acts at the level of the endothelium of brain capillaries, and activates the endothelium, is               
consequently activating the neurovascular unit as a whole by means of the intercellular             
crosstalk ​. Considering this working hypothesis, a stimulus that activates the brain           
microvascular endothelium (e.g. triggering calcium waves, stimulating cytokines release,         
acting on tight junction proteins, stimulating the blood brain barrier leakage etc.) might cause              
neuronal depolarization followed by neuronal hyperexcitability (e.g. seizure-like events). 
Microvasculature alterations play an important role in epilepsy. To date, recent studies            
demonstrated that abnormal capillary vasodynamics, especially cerebral oxygen changes in          
and around microvasculature, contributes to ictal neurodegeneration in epilepsy         
(​Leal-Campanario et al., 2017, Zhang et al. 2017​). Specific cerebrovascular segments have            
been proposed to be differentially implicated in the pathophysiology of epilepsy, and,            
moreover, differences in cerebrovasculature between white and grey matter have been also            
considered (​Librizzi et al., 2017​). In this context, it is important to evaluate the effects of                
different stimuli acting on the brain endothelium, as part of the neurovascular unit, and their               
possible contribution to the abnormal neuronal activity. 
 
The main objectives of the thesis were: 
O1. To evaluate the effect of Qtracker ​®​800 vascular labels on brain microvascular            
endothelial cells 
O2. To perform an extended functional description of the muscarinic receptors in            
brain microvascular endothelial cells 
O3. To evaluate the effect of pilocarpine on brain microvascular endothelial cells 
 
 
 
O1. To evaluate the effect of Qtracker​®​800 vascular labels on brain microvascular            
endothelial cells 
 
Previous studies from Fabene’s group (​Salvetti 2014, ​Doctoral thesis ​; Fabene et al.,            
2015​) demonstrated that Qtracker​®​800: (i) accumulate in tissues and cross the blood brain             
barrier, remaining in the organs, including the brain for at least 3 weeks, (ii) induce               
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 alterations in proinflammatory cytokines levels in the liver and hippocampus, (iii) determine            
alterations in behaviour and in the electroencephalographic rhythms, (iv) exacerbate the effect            
of unrelated inflammatory conditions and pro-convulsive agents in the brain. These studies            
concluded that conventional ​in vivo tests used as first screening tools in toxicology, may not               
be enough to highlight the nanoparticle-induced functional alterations involving the brain. 
Qtracker​®​800 are commonly used for ​in vivo deep tissue vasculature imaging, but our             
previous data have determined us to question if this nanoparticles are only ”inert dyes” for               
imaging vasculature or there are also interacting with the vasculature. Considering their            
prolonged presence in the animal body upon injection (up to 3 weeks, which is far beyond the                 
imaging window), it is important to understand if these nanoparticles are able to exert a direct                
action on brain endothelium and if this action would contribute to the alterations in neuronal               
excitability.  
We have first characterized the nanoparticles by employing dynamic light scattering           
and electron microscopy methods. Then, we evaluated the functional interaction between           
Qtracker​®​800 and brain microvascular endothelial cells (in primary and immortalized cell           
cultures) by means of ratiometric calcium imaging and cell viability analysis. In order to              
avoid experimental biases, the effect of Qtracker​®​800 was also tested on human umbilical             
vein endothelial cells in primary culture from different donors. The complete description of             
the technical aspects, the results, and the conclusions of this study are further detailed in               
Chapter 3​. 
 
  
O2. To perform an extended functional description of the muscarinic receptors in            
brain microvascular endothelial cells 
 
Our goal is to evaluate the effect of pilocarpine on brain microvascular endothelial             
cells, and in this context, after the screening of the literature become obvious that a complete                
description of the functional expression of muscarinic receptors in mouse brain endothelium            
was missing. It is already known that pilocarpine is partial agonist of the muscarinic receptors               
and a chemo-convulsant used in the epilepsy-induced models (​Schaafsma et al., 2006; ​Marchi             
et al., 2007; Thomas et al., 2009; Nezu et al., 2015​). Given the potential importance of this                 
receptor family as non-neuronal drug targets (​Zhang et al., 2014​), and the increasing use of               
mAChR knockout mice as models for common neurological disorders (​Zhang, 2006;           
Langmead et al., 2008; Wess et al., 2003​) a detailed characterization of muscarinic receptors              
expression and functionality in the mouse brain microvasculature is a high priority and             
become one of the goals of this thesis. 
We first evaluated the gene and protein expression, respectively, for the muscarinic            
receptors in brain microvascular endothelial cells (in primary and immortalized cell cultures)            
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 by means of reverse transcription polymerase chain reaction, immunofluorescence and          
MALDI-TOF mass spectrometry. Then, the functional expression of these receptors was           
tested by ratiometric calcium microfluorimetry technique. Finally, the pharmacological         
characterization of these receptors was performed by ratiometric microfluorimetry imaging          
technique and results were compared with the molecular docking data. 
The complete description of the technical aspects, the results, and the conclusions of             
this study are further detailed in ​Chapter 4​. 
 
 
O3. To evaluate the effect of pilocarpine on brain microvascular endothelial cells 
 
After bringing more light into the functional characterization of muscarinic receptors           
in brain microvascular endothelial cells (​O2.​), the next step was to focus our attention on               
deciphering the complex mechanisms by which pilocarpine is able to permeabilize the blood             
brain barrier. The starting point of this study was based on previous data the literature               
indicating that pilocarpine administration caused seizures and lethality in wild-type and           
M​2​-M​5 ​knockout mice​, but had no effect in the M​1 knockout mice (​Hamilton et al., 1997​) or                 
had reduced effect in the mice knockout for M​1 in the parvalbumin-positive inhibitory             
neurons (​Yi et al., 2015​). Previous studies have focused their attention on the effects of M​1                
receptor knockout at the neuronal level, and our working hypothesis was that M​1 receptor              
knockout in brain endothelium also plays a critical role in ictogenesis. 
We first quantified the levels of cytokines released upon pilocarpine treatment in an ​in              
vivo mouse model (pilocarpine-induced epilepsy model) and an ​in vitro cell culture model             
(brain microvascular endothelial cells exposed to pilocarpine) using MAGPIX technology.  
Using the ​in vitro ​model of hippocampal slices exposed to pilocarpine, we evaluated             
by patch-clamp technique the capacity of pilocarpine to produce seizure-like events or to             
induce amplitude and frequency changes of spontaneous postsynaptic potentials.  
Using the ​in vitro ​model of brain microvascular endothelial cells exposed to             
pilocarpine we evaluated the adhesion molecules expression by immunofluorescence and          
flow cytometry, and we correlated our results with previous data in brain capillaries after              
status epilepticus (​Fabene et al. 2008​). The gene and protein expression, respectively, for the              
muscarinic receptors and tight junctions proteins in brain microvascular endothelial cells           
upon pilocarpine treatment were quantified by means of reverse transcription polymerase           
chain reaction and immunofluorescence. We also quantified the gene and protein expression,            
respectively, for the tight junctions proteins in brain microvascular endothelial cells upon            
pilocarpine treatment, and we tried to correlate these data with changes in permeability of the               
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 blood brain barrier model using spectrophotometric quantification of the FITC-dextran          
diffusion through the endothelial monolayer. 
Using the same ​in vitro ​model of brain microvascular endothelial cells exposed to              
pilocarpine, we tested the capacity of pilocarpine to trigger intracellular calcium release by             
ratiometric microfluorimetry imaging technique. The competition of pilocarpine and         
acetylcholine on the binding site of the muscarinic receptors was evaluated ratiometric            
microfluorimetry imaging technique and results were compared with the molecular docking           
data. 
The complete description of the technical aspects, the results, and the conclusions of             
this study are further detailed in ​Chapter 5​. 
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 Chapter 3. Are they in or out? The elusive 
interaction between Qtracker® 800 vascular labels 
and brain endothelial cells 
 
 
3.1. Summary 
Aim: Qtracker​®​800 Vascular labels (Qtracker​®​800) are promising biomedical tools         
for high-resolution vasculature imaging; their effects on mouse and human endothelia,           
however, are still unknown. ​Materials & methods: ​Qtracker​®​800 were injected in Balb/c            
mice, and brain endothelium uptake was investigated by transmission electron microscopy           
(TEM) 3-hrs post-injection. We then investigated, ​in vitro​, the effects of Qtracker​®​800            
exposure on mouse and human endothelial cells by calcium imaging. ​Results: TEM images             
showed nanoparticle accumulation in mouse brain endothelia. A subset of mouse and human             
endothelial cells generated intracellular calcium transients in response to Qtracker​®​800.          
Conclusion: ​Qtracker​®​800 nanoparticles elicit endothelial functional responses, which        
prompts biomedical safety evaluations and may bias the interpretation of experimental studies            
involving vascular imaging. 
Keywords​: nanoparticles; calcium imaging; cytosolic calcium transients; nanoparticle        
uptake; mouse brain endothelium; human umbilical vein endothelial cells; transmission          
electron microscopy. 
 
3.2. State-of-art 
 
Cerebral vasculature imaging is required in the diagnosis of cerebrovascular pathology           
and healthcare stakeholders are increasingly interested in safer, cheaper, and higher-resolution           
clinical imaging solutions. In the last decade, the field of nanotechnology has exploded, and              
new nanomedicine and nano-neuromedicine approaches have been proposed as alternative or           
complementary solutions to already existing vasculature imaging tools (e.g., MRI- and/or           
CT-based angiography). 
 
The data presented in this chapter have been published as: ​Radu BM​, Radu M, Tognoli C, Benati D,                  
Merigo F, Assfalg M, Solani E, Stranieri C, Ceccon A, Fratta Pasini AM, Cominacini L, Bramanti P, Osculati F,                   
Bertini G, Fabene PF. (2015) Are they in or out? The elusive interaction between Qtracker​® 800 vascular labels                  
and brain endothelial cells. ​Nanomedicine (Lond)​. 10(22):3329-42. 
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 Several metallic and organic nanomaterials have been approved by the Food and Drug             
Administration (FDA) are at different clinical trial stages of clinical trials as diagnostic tools;              
semiconductor nanomaterials (e.g. quantum dots) are, on the other hand, generally considered            
for research use only (​Kim et al., 2010; Clift and Stone, 2012​). Recently, a new generation of                 
fluorescent silica nanoparticles called Cornell dots (C-dots), with efficient urinary excretion           
(​Burns et al., 2009​) and effective cancer-targeting properties (​Benezra et al., 2011; Bradbury             
et al., 2013​), received FDA approval for clinical use. This FDA approval opens a new era for                 
nanomedicine, and deeper understanding of cell-specific action of semiconductor-based         
nanoparticles is urgently needed.  
Rapid nanotechnology advances in preclinical brain vasculature imaging (​Ding et al.,           
2013; Jaruszewski et al., 2014; Li et al., 2014; Keunen et al., 2014; Radu and Radu, 2015​)                 
have substantially increased our ability to unveil vascular contributions to the pathogenesis of             
brain ischemia, brain tumor formation, Alzheimer disease, and epilepsy (​Fabene et al., 2008;             
Burrel et al., 2013; Hyun et al., 2013​).  
Quantum-dot nanoparticles (QDs) gained popularity over the last decade (​Zhu et al.,            
2013​), due to their superior optical properties with respect to conventional organic dyes             
(​Medintz et al., 2005; Michalet et al., 2005; Stylianou and Skourides, 2009​). In particular,              
Qtracker® vascular labels (Qtracker​®​565, Qtracker​®​605, Qtracker​®​655, Qtracker​®​705 and        
Qtracker​®​800, named according to their emission wavelength) have been designed for ​in vivo             
deep-tissue imaging of blood vessel distribution and morphological properties in small           
animals (​http://www.thermofisher.com/order/catalog/product/Q21071MP​). The   
high-wavelength Qtracker​®​800 allows the deepest imaging of tissue vasculature of the series.            
Preclinical ​in-vivo imaging studies of the vessels using Qtracker​®​800 have already been            
carried out to highlight mouse tumor vascularization (​Mayes et al., 2008​) and bone marrow              
vasculature (​Lo Celso et al., 2011​).  
Biocompatibility is a key requirement for QD-based ​in-vivo vascular imaging. The           
“ideal” QDs should be “inert” with respect to the microenvironment (e.g. circulating and             
endothelial cells). In practice, this desired property is usually sought by coating the QDs with               
a thin polymer layer, one of the most used being polyethylene glycol (PEG), without any               
functional group. This layer reduces the non-specific interaction of coated QDs with the             
surrounding molecular species, including those present on the cell plasma membrane           
(​Bentzen et al., 2005 ​; ​http://www.thermofisher.com/order/catalog/product/Q21071MP​].     
Indeed, PEG coating of QDs drastically minimizes non-specific interactions and decreases           
cellular uptake rate, as proved in three tumor cell lines (​Kelf et al., 2010​;              
http://www.thermofisher.com/order/catalog/product/Q21071MP​). 
A very recent report, however, demonstrated the uptake of PEG-coated silica           
nanoparticles in brain endothelial cells (​Liu et al., 2014​). Since these coated nanoparticles are              
between 25 nm and 100 nm (i.e. almost 5-10 times the core diameter of QDs) and given the                  
authors’ claim that nanoparticle transport across the blood-brain barrier is size-dependent, we            
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 wondered whether PEG-coated QDs might show significant interactions with endothelial          
cells. To our knowledge, there are no published reports describing such direct interaction.  
Based on these premises, we investigated: a) whether ​in vivo Qtracker​®​800 ​are             
uptaken by endothelial cells, and b) the functional consequences of endothelial exposure to             
Qtracker​®​800, studied ​in vitro​. First, the hydrodynamic diameter of Qtracker​®​800 was           
estimated by dynamic light scattering (DLS) and the core size was calculated from electron              
microscopy images in order to characterize the nanoparticles. Next, in a set of ​in vivo               
experiments, Qtracker​®​800 uptake in mouse brain endothelia was investigated by electron           
microscopy. As previously described, many aspects of vascular endothelium physiology are           
regulated by calcium signaling pathways, since most of the stimuli relaxing or contracting             
brain capillaries act directly on the endothelial cells, producing changes in intracellular free             
calcium concentration (​Itoh and Suzuki, 2012; Moccia et al., 2014; Taylor and Francis, 2014​).              
Based on the above, we also investigated ​in vitro the ability of a Qtracker​®​800 flux to induce                 
fluctuations of free cytosolic calcium concentration and/or changes in mouse brain           
endothelial cell viability. We have also extended our ​in vitro ​study to another type of               
endothelial cells (human umbilical vein endothelial cells) in order to discriminate between a             
specific effect on mouse brain endothelial cells and an ubiquitous effect.  
 
3.3. Materials and methods 
 
3.3.1. Chemicals 
Qtracker​®​800 (Q21071MP, lot #1216103, Life technologies, USA) were dissolved in          
0.9% saline solution for the ​in-vivo studies, and in Ringer HEPES-buffered solution (NaCl,             
140 mM; KCl, 5.6 mM; MgCl ​2​, 2 mM; CaCl​2​, 2 mM; glucose, 10 mM; HEPES 10 mM; pH                  
7.4 with NaOH) or phosphate-buffered solution (5 mM; pH 7.4) for the ​in-vitro experiments.              
Fura-2 acetoxymethyl ester (Fura-2 AM) and pluronic acid F-127 (Life technologies, USA)            
were dissolved in Ringer solution. All other reagents were purchased from Sigma-Aldrich (St             
Louis, MO, USA). 
 
3.3.2. Hydrodynamic size measurements by Dynamic light scattering 
Dynamic light scattering was performed on Qtracker​®​800 using a Zetasizer Nano ZS            
instrument (Malvern Instruments Ltd, USA) operating with a 633 nm He-Ne laser light source              
and a fixed detector angle of 173°, as previously described (​Ceccon et al., 2013​).              
Qtracker​®​800, 2-µM stock solution in 50 mM borate buffer, pH 8.3 (Life Technologies, USA)              
was diluted down to 50 nM to the range of 40-80 nM either in Ringer solution or in saline                   
solution (See ​Chemicals​). Lower particle concentrations resulted in poor signal/noise and           
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 large fit errors (using either single or multiple exponential models). Hydrodynamic diameter            
values were determined by averaging the intensity-weighted size distributions obtained from           
20 successive DLS runs of 10 s each. Measurements were repeated 3 times and results are                
reported as mean ± SD. The distribution widths were quantified by the Polydispersity Index              
(PdI). DLS measurements were carried out at 25°C before and after filtration (through             
acetate-cellulose Costar Spin-X Centrifuge Tube Filters, 0.22 μm pore size, Cole Parmer,            
USA) or centrifugation (18000 xg for 15 min) of Qtracker​®​800 solutions. No filtration or              
centrifugation were used on the Qtracker​®​800 solutions employed for the ​in viv​o and ​in vitro               
experiments. 
 
3.3.3. Zeta potential measurements 
Measurements were performed with a Zetasizer Nano ZS instrument (Malvern          
Instruments Ltd, USA). Qtracker​®​800 particles were dispersed at a final concentration of 75             
nM in phosphate buffer, pH 7.4, and transferred to a disposable zeta cell. Measurements were               
carried out at 25 °C after 120 s equilibration time, performing 7 runs comprising 12 sub-runs                
each. The applied voltage was 100 V and the measured conductibility was 4.540 ± 0.334 mS                
cm​-1​. All measurements passed technical quality criteria based on inspection of phase and             
frequency plots, and were reproducible after sample spinning at 18000 xg for 15 min. Zeta               
potential was evaluated from electrophoretic mobility applying the Henry equation.  
 
3.3.4. Animals and QD injection  
Male Balb/c mice acquired from Harlan-Nossan (Udine, Italy) were adapted to the            
laboratory and maintained on a 12-hour inverted light/dark cycle, at 23 ± 1°C, with access to                
food and water ​ad libitum​. Experiments started when animals were 6 weeks old and weighed               
25 ± 5 g. 
Experiments were approved by the University of Verona ethical committee. Animals           
(n = 10) were divided in 2 equal groups, one received injection of saline solution and the                 
other of Qtracker​®​800, and both groups were sacrificed 3 hrs after injection.  
Qtracker​®​800 solutions (or saline) were administered through a single injection (0.4           
μM, 10 μL/g for each mouse) into the tail vein. Mice were then deeply anesthetized               
(zolazepam and tiletamine, i.p. 20 mg/kg), and perfused transcardially with PBS followed by             
phosphate-buffered 4% paraformaldehyde. Cortical brain samples were collected to evaluate          
Qtracker​®​800 presence in the endothelium, based on transmission electron microscopy and           
immunohistochemistry analysis.  
According to the recommendation of the producer, the optimal time-interval for ​in            
vivo vasculature imaging with Qtracker​®​800 is 3 hrs post-injection         
28 
 (​http://www.thermofisher.com/order/catalog/product/Q21071MP)​. Therefore, the 3-hr time     
point is essential in understanding Qtracker​®​800 distribution into the cerebral bloodstream           
and if this time interval is sufficient for the nanoparticles to interact with the mouse brain                
vascular endothelium. 
 
3.3.5. Transmission electron microscopy (TEM) 
Brain tissue samples were fixed in 2% glutaraldehyde in Sorensen buffer pH 7.4 for 2               
hrs, postfixed in 1% osmium tetroxide in aqueous solution (2 hrs), dehydrated in graded              
concentrations of acetone, and embedded in Epon-Araldite mixture (Electron microscopy          
Sciences, Fort Washington, PA, USA). Ultrathin tissue sections (70 nm) were placed on             
Cu/Rh grids with Ultracut E (Reichert, Wien, Austria) and were observed using a Morgagni              
268D microscope (Philips, The Netherlands).  
For imaging the Qtracker 800 in solution, a droplet of nanoparticle solution was put              
on the grid (FCF-150-Cu, Electron Microscopy Science, PA, USA) and, after drying, the grid              
was imaged without any other processing. 
 
3.3.6. Human umbilical vein endothelial cell cultures 
Human umbilical vein endothelial cells (HUVECs) from seven healthy donors were           
individually harvested as previously described (​Fratta Pasini et al., 2012​) and used between             
passages 2 and 5. The medium was refreshed every 2 days. At the beginning of each               
experiment, cells were harvested by trypsinization, using 0.05% trypsin (Sigma-Aldrich, St.           
Louis, Mo, USA) and 0.537 mM ethylenediaminetetraacetic acid (EDTA) in         
phosphate-buffered saline without calcium and magnesium (Seromed, Berlin, Germany).         
Cells were plated at a density of 2*10​4 cells/cm​2 ​onto 24-mm cover glasses for intracellular               
calcium imaging measurements.  
 
3.3.7. Mouse brain endothelial cell cultures 
Primary cultures of brain microvascular endothelial cells (BMVECs from Balb/c          
mice, passage 3-6; #PB-BALB-5023, PELOBiotech, Germany) were cultivated according to          
the producer’s protocol. bEnd.3 (passage 22-30; #ATCC​® CRL-2299™, USA), a Balb/c           
mouse cell line, was grown in Dulbecco’s modified Eagle’s medium (DMEM) with            
Glutamax-I, 10% fetal bovine serum (Gibco), 100 U/ml penicillin, 100 μg/ml streptomycin,            
5% CO​2 (37°C). Cells were plated at a density of 2*10 ​4 cells/cm​2 ​onto 24-mm cover glasses                
for intracellular calcium imaging measurements or 96-well plates for viability assays. 
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3.3.8. In-vitro Qtracker​®​800 studies 
In order to apply Qtracker​®​800 ​in vitro in concentrations comparable to those used for              
the ​in vivo studies, we first estimated that the above described injections yielded blood              
concentrations around 44 nM, based on a mouse whole blood volume of ~ 2 mL (​Endo et al.,                  
2014​). Taking into account this approximate value and the range of concentrations previously             
reported for ​in vitro studies using Qtracker​® 655 (​Zhang and Monteiro-Riviere, 2009​), we             
used between 10 and 40 nM Qtracker​®​800 in our ​in vitro experiments. To shed light on the                 
Qtracker​®​800 direct action against brain microvascular endothelial cells, we performed          
calcium imaging and cell viability measurements on bEnd.3 cells and BMVECs. 
 
3.3.9. Intracellular calcium imaging on endothelial cells 
Fura-2 AM-based, Ca​2+ imaging experiments on endothelial cells were performed as           
previously described (​Radu et al., 2012​). Images were captured using a cooled CCD camera              
(Clara, Andor, Northern Ireland) in a set-up including a monochromator Polychrome V (Till             
Photonics, Germany) coupled to an inverted microscope (Diaphot 200, Nikon, Japan), and            
were acquired on a computer using an image acquisition software (Live Acquisition, Till             
Photonics, Germany). Solutions were delivered on top of the endothelial cells through a 100              
µm quartz perfusion head using an 8-channel valve pressurized perfusion system (ALA            
Scientific Instruments, USA). Cells were incubated with Fura-2 AM (2.5 µM) and pluronic             
acid (F-127, 0.01%) for 45 min. After 15 min, the necessary time for Fura-2AM              
deesterification, the cells were imaged. Before starting the nanoparticle flux, the cell            
monolayer was perfused with Ringer HEPES-buffered for 5 minutes. Cytosolic Ca​2+           
transients were elicited by the administration of 20 nM Qtracker​®​800 for 5 min followed,              
after a Ringer HEPES-buffered wash-out period of 10 min, by the application of either ATP               
(30 μM, 20 s) for BMVECs and bEnd.3 cells, or histamine (10 μM, 20 s) for HUVECs. ATP                  
and histamine are topical vasoactive substances that regulate brain capillary blood flow and             
vascular permeability (​Akdis and Simons, 2006; Itoh and Suzuki, 2012 ​), and were therefore             
used as positive controls for evoking intracellular calcium transients in endothelial cells. Cells             
that did not show a response to the positive control were excluded from subsequent analyses. 
 
3.3.10. Endothelial cell viability by Trypan blue assay 
Trypan blue assay was performed on bEnd.3 and BMVECs in control conditions and             
after 24 hrs treatment with Qtracker​®​800 (10, 20 and 40 nM). Cells were detached by trypsin,                
trypan blue was added (0.2 %) and viable cells were counted (at least 150 cells). The viability                 
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 was calculated relative to controls. Measurements were done in three replicates. Cells            
exposed to 3 mM H​2​O​2​ (1h) were used as positive control.  
 
3.3.11. Data analysis 
Data analysis was performed using OriginPro 8 (OriginLab Corporation, USA),          
Offline Acquisition software (Till Photonics, Germany) and Matlab (​Mathworks, Natick,          
MA)​.  
Intracellular calcium changes were estimated from the ratio R = I​340nm​/I​380nm (I​340 and             
I​380 are the intensities measured at the emission wavelength of 510 nm when Fura-2 was               
excited at 340 nm and 380 nm, respectively). The ratio R was calculated in regions of interest                 
(ROIs) covering each cell in the microscope field, after background subtraction. 
R values were corrected by subtracting baseline signals averaged over the 5 minutes             
of perfusion prior to the application of nanoparticles. The resulting ΔR values were used for               
subsequent analyses. Only responses with an amplitude higher than 3 times the standard             
deviation of the background noise (measured before QD administration) were considered.  
In view of the lack of standard quantitative methods to describe calcium transients in              
the literature (​Taylor and Francis, 2014​), we defined a set of parameters characterising the              
signal envelope (​Figure 3.1​). The onset and offset of the response were marked by the signal                
raising above and descending below a 5% threshold of the peak amplitude (ΔR ​max​). Response              
latency was the time from beginning of nanoparticle perfusion to response onset. Total             
response duration was the interval between response onset and offset. In order to differentiate              
between fast transients with sustained late responses and signals reaching a peak later in time,               
we computed a response asymmetry ratio (b/a), where a is the time from response onset to                
peak, and b is the time from response peak to offset. Total response area was the integral over                  
response duration. Finally, we computed the maximum slope of the ascending transient            
(V​max​). Pairwise correlations (along with Pearson and Spearman coefficients) among these           
parameters were computed with custom Matlab scripts. One-way ANOVAs followed by           
Fisher LSD ​post-hoc ​tests were used to assess BMVEC and bEnd.3 endothelial cell viability,              
comparing cells treated with different concentrations of Qtracker​®​800 to untreated controls. 
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Figure 3.1. ​Relevant parameters in a calcium transient trace. 
 
3.4. Results 
3.4.1. Characterization of nanoparticles (size, hydrodynamic diameter, and        
zeta-potential) 
We measured the hydrodynamic diameter of Qtracker​®​800 by means of the DLS            
technique. DLS measurements were performed on QDs dissolved in saline solution or in             
Ringer HEPES-buffered solution. 
For both saline and HEPES-buffered Ringer solutions, we found in the intensity            
distribution plots a major peak centered near the expected size of Qtracker​®​800 (​Figure 3.2.              
A, B​), as well as a minor peak corresponding to larger components (e.g. aggregates of               
nanoparticles). The DLS graphs in ​Figure 3.2 refer to 50 nM Qtracker​®​800, but note that the                
distribution did not significantly change for the analysed range of nanoparticle concentrations            
(40-80 nM). A global polydispersity index (PdI) of ~0.35 was determined for both solutions.              
The major, lower-diameter peak can be attributed to isolated Qtracker​®​800 particles. Given            
the wider scattering of larger particles, the relative populations of the species corresponding             
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 to the two peaks can be better appreciated after conversion of the data into a number                
distribution (dotted lines) which results in a single peak and confirms the prevalence of              
well-dispersed Qtracker​®​800 particles. 
 
Figure 3.2. Distribution of Qtracker​®​800 particle sizes measured by dynamic light scattering. (A)             
Qtracker​®​800 in Ringer HEPES-buffer solution; ​(B) Qtracker​®​800 in saline solution; ​(C) same as ​(A) after               
centrifugation; ​(D) same as ​(B) after centrifugation. Histograms are size distribution by intensity plots (left               
y-axes). Error bars show the SD of three replicate measurements. Dotted curves in ​(A & B) correspond to                  
number distribution plots (right y-axes) obtained by conversion from the underlying intensity distributions. 
An attempt to remove the larger-size contaminant by filtration was unsuccessful. On            
the other hand, centrifugation followed by DLS measurements on the supernatant resulted in             
very clean samples displaying a single peak in size distribution plots (​Figure 3.2. C, D ​). The                
monomodal distribution observed for these two preparations allowed us to perform a rigorous             
cumulant analysis and evaluate the harmonic intensity-averaged particle diameter         
(Z-average). The Z-average of Qtracker​®​800 was 36.56 ± 0.13 nm in Ringer HEPES-buffer             
(PdI = 0.180) and 35.80 ± 0.34 nm in saline solution (PdI = 0.151). The zeta potential value                  
was -0.0124 ± 0.206 mV, indicating that Qtracker​®​800 particles are essentially neutral at pH              
7.4. Qtracker​®​800 were also characterized by TEM (​Figure 3.3. A​) and their cores, as              
visualized in suspension, were irregular in shape and their longest axis measured on average              
8.27 ± 1.27 nm (SD). 
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3.4.2. Qtracker​®​800 accumulation in mouse brain microvascular endothelium 
We then proceeded to evaluate the interaction of Qtracker​®​800 with the brain vascular             
endothelium in Balb/c mice upon nanoparticle injection. TEM analysis of mouse cortical            
brain sections indicated the presence of Qtracker​®​800 in the brain vascular endothelium 3 hrs              
after the i.v. injection, the time window recommended by the nanoparticle producer for             
vasculature imaging studies (​Figure 3.3. B and C ​). Nanoparticles can be detected in the              
cytoplasm, both concentrated within vesicle-like structures, and free in the cytosol. An            
in-depth histological characterization (sampling different brain regions and cellular         
compartments, different time-points, or even different organs) of the subcellular distribution           
of Qtracker​®​800 nanoparticles distribution is beyond the scope of the present study. 
 
Figure 3.3.​  ​Transmission electron microscopy images on Qtracker​® ​800 and their accumulation in Balb/c             
mouse brain endothelium. (A) Qtracker​®​800 in suspension; scale bar: 100 nm. ​(B) Qtracker​® ​800 ​in vivo               
accumulation in brain vascular endothelium, 3 h after intravenous injection; scale bar: 1 μm. ​(C) Detailed image                 
of nanoparticle accumulation in the endothelium; scale bar: 100 nm. 
 
3.4.3. Qtracker​®​800 treatment does not lead to major cell death ​in vitro 
Given the in vivo accumulation of Qtracker​®​800 in mouse brain endothelium           
demonstrated by TEM data, we have further verified, by ​in vitro tests, if nanoparticle              
administration modified endothelial cell viability. Viability slightly decreased as a function of            
nanoparticle concentration (BMVECs: F(3,8) = 5.25, ​p < 0.05; bEnd.3s: F(3,8) = 5.37, ​p <               
0.05). Fisher ​post-hoc tests confirmed that the reduction was statistically significant only for             
the highest nanoparticle concentration, when viability dropped to about 93% (​Figure 3.4)​. 
 
34 
  
 
Figure 3.4.​  ​Viability of brain microvascular endothelial cells upon 24 h ​in vitro exposure to               
Qtracker​®​800. ​Percentage of viable cells (means ± standard deviation) obtained by Trypan blue assay on brain                
microvascular endothelial cells and bEnd.3 cells exposed for 24 h to 0, 10, 20 and 40 nM Qtracker®800 and 3                    
mM H​2​O​2 (positive control). Statistically significant differences (p < 0.05) from the control (0 nM) conditions                
are indicated by an asterisk (*). bEnd.3: Brain endothelial cell line derived from mice cerebral cortex; BMVEC:                 
Brain microvascular endothelial cells from Balb/c mice in primary culture; QD: Quantum dot. 
 
3.4.4. Qtracker​®​800 generate intracellular calcium transients in mouse brain         
endothelial cells and human umbilical vein endothelial cells 
As in vitro endothelial cell viability tests revealed only small effects on cell survival              
of Qtracker​®​800 in the concentration ranges relevant for ​in vivo imaging studies (see             
Materials & methods, “​in-vitro Qtracker®800 studies” section), we explored the possibility of            
more subtle, functional nanoparticle-induced alterations of endothelial cells, by studying          
intracellular calcium fluctuations. 
Acute (5 min) exposure to 20 nM Qtracker​®​800 generated cytosolic calcium transients            
in BMVECs (​Figure 3.5.A​), bEnd.3 cells (​Figure 3.5.B ​), and HUVECs (​Figure 3.5.C, D​).             
Based on the inclusion criteria described above, we found that 13.7% (52/380 cells) of              
BMVECs and 13.9% (57/410 cells) of bEnd.3 cells were responsive to Qtracker​®​800. Out of              
a total 1796 studied HUVECs, 189 (or 10.5%) responded to Qtracker​®​800. Interestingly, the             
fraction of responsive cells varied significantly between the seven donors (​Figure 3.5.D​),            
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 suggesting the possibility that subjects may be either sensitive (20% or more of responsive              
cells) or non-sensitive (5% or less) to nanoparticles. 
 
Figure 3.5.​  ​Qtracker​®​800 evoked (Ca​2+​)​i transients in mouse and human endothelial cells. ​Representative             
traces of ΔR over time for ​(A) brain microvascular endothelial cells; ​(B) bEnd3, and ​(C) HUVECs. An                 
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 endogenous control response was evoked by ATP (30 μM) in ​A & B​, and by histamine (10 μM) in ​(C)​. ​(D)                     
HUVECs’ sensitivity to Qtracker​®​800 exposure, where responsive cells are considered those able to generate              
intracellular calcium transients upon brief exposure (5 min) to Qtracker​®​800. Percentage of responsive (gray)              
and nonresponsive (white) endothelial cells from different donors. The number of Qtracker​® ​800-responsive cells             
are plotted against the total number of tested cells in separate columns for each donor (D1–D7). The percentages                  
of responsive cells for each donor are: D1: 1.25%; D2: 27.87%; D3: 19.69%; D4: 1.35%; D5: 26.76%; D6:                  
5.45%; D7: 2.29%. ​(E)​ΔR​max for BMVEC, bEnd.3 and HUVEC in response to Qtracker​® ​800 and to ATP or His,                  
respectively​.​bEnd.3: Brain endothelial cell line derived from mice cerebral cortex; BMVEC: Brain            
microvascular endothelial cells from Balb/c mice in primary culture; D: Donor; His: Histamine; HUVEC:              
Human umbilical vein endothelial cell; QD: Quantum dot. 
 
ΔR​max values induced by Qtracker​®​800 perfusion were on average a sizeable fraction            
of those induced in the positive control conditions. Namely, average ΔR​max values for             
BMVEC and bEnd.3 cells were about ⅓ and ½, respectively, of those produced by ATP               
administration; HUVEC cells had an average ΔR​max of about ⅔ of that induced by histamine               
administration. 
The quantitative analysis of calcium imaging recordings revealed a diversity of           
calcium transient profiles generated during the acute exposure of endothelial cells to the             
nanoparticle flux. The majority of observed calcium transients had a sharp onset, followed by              
a longer sustained response and decay (high asymmetry ratios). This pattern was substantially             
more marked in HUVECs than in mouse cells (​Figure 3.5.A-C​ and ​Figure 3.6​). 
In spite of certain commonalities, responses differed in several respects among cell            
types (​Figure 3.6.A​). HUVEC transients showed the highest mean amplitude, area and            
duration (​Figure 3.6.A​) i.e. they produced the strongest responses to nanoparticle           
administration. HUVEC transients were also highly asymmetrical (approx. 3 times more than            
the mouse endothelial transients). Interestingly, the ΔR​max and V​max distributions were           
remarkably similar. Indeed, a strong and highly significant correlation between the two            
parameters was observed (​Figure 3.6.B​, upper panels. See also ​Figures 3.7-3.9​, and ​Tables             
3.1-3.3 for a complete presentation of the correlations and distribution histograms). This            
suggests that a very rapid increase in the ascending phase of the transient tends to produce                
high peak amplitudes. Even more important is the fact that the slope of the linear regression                
was very similar between cell types. This suggests a common mechanism of calcium transient              
triggering, irrespective of endothelial types. 
On the other hand, response latencies were similar across endothelial cell types, again             
suggesting a common triggering mechanism. Additionally, an interesting pattern was          
observed when plotting response latencies against V​max (​Figure 3.6.B​, lower panels). The            
charts suggest that cells with relatively short latencies are characterized by a wide range of               
response transient velocities, while longer latencies were associated with relatively slower           
transients. In other words, delayed transients tended to be restricted to less steep ascending              
transients (smaller V​max​) and consequently smaller amplitude. 
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Figure 3.6.​  ​Analysis of the parameters in Qtracker​®​800-induced calcium transients. (A) Distributions of             
each of the six calcium transient parameters (y-axis label) defined in the ‘Materials & methods’ section. The                 
boxplots show the median, 25th and 75th percentiles. In addition, the mean (□), 1% and 99% percentiles (×), and                   
the minimum and maximum data points (​_​) are reported. ​(B) Correlations between selected parameter pairs for                
each cell type (the linear fit with Pearson coefficient – P, and the confidence level – p – are presented for the                      
upper panels). See Figures 2.7-2.9 for the complete pairwise correlation matrices. BMVEC: Brain microvascular              
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 endothelial cells from Balb/c mice in primary culture; HUVEC: Human umbilical vein endothelial cell; V​max​:               
Maximum slope of the ascending calcium transient. 
 
Figure 3.7. ​Correlations of calcium transients’ parameters (defined in ​Figure 3.1​) induced by Qtracker​® ​800 in               
HUVECs. 
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 Table 3.1. ​Pearson and Spearman correlation coefficients and their probabilities computed for the calcium              
transients’ parameters (see plots in ​Figure 3.7​) induced by Qtracker​®​800 in HUVECs 
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Figure 3.8. ​Correlations of calcium transients parameters induced by Qtracker​® ​800 in bEnd.3 cells 
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 Table 3.2 ​Pearson and Spearman correlation coefficients and their probabilities computed for the calcium              
transients’ parameters (see plots in ​Figure 3.8​) induced by Qtracker​®​800 in bEnd.3 cells 
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Figure 3.9. ​Correlations of calcium transients’ parameters induced by Qtracker​® ​800 in BMVECs 
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 Table 3.3. ​Pearson and Spearman correlation coefficients and their probabilities computed for the calcium 
transients’ parameters (see plots in ​Figure 3.9​) induced by Qtracker​® ​800 in BMVECs 
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 3.5. Discussion 
In this study, we report for the first time a functional interaction of Qtracker​®​800 with               
the brain vascular endothelium. In particular, we found that: a) QDs may be uptaken in vivo                
by brain endothelial cells; b) the interaction between QDs and endothelial cells results in the               
activation of free cytosolic calcium signaling in primary and immortalized brain endothelial            
cells, as well as in human umbilical vein endothelial cells; c) such activation does not appear                
to be related to cytotoxicity, resulting instead in interferences with normal calcium-mediated            
signal transduction pathways ; d) HUVEC data indicate a high inter-individual variability of             
QDs-cell interaction susceptibility. 
 
3.5.1. Non-targeted PEGylated near-infrared emitting Qtracker​®​800 accumulate in 
brain vascular endothelium 
Previous studies demonstrated the uptake by endothelial cells of different          
functionalized and/or targeted PEGylated quantum dots (​Koole et al., 2008; Pollinger et al.,             
2013; Chen et al., 2013 ​), but not of non-targeted Qtracker​® Vascular labels. The latter              
nanoparticles can be uptaken in different cell types (​Maysinger et al., 2007;            
Ryman-Rasmussen et al., 2007; Zhang and Monteiro-Riviere, 2009; Xiao et al., 2010 ​), but to              
our knowledge no reports are available for endothelial cells. Furthermore, uptake of            
Qtracker​®​800 has not been reported for any cell type. 
Endocytosis, which is thought to be the main pathway for nanoparticle internalization            
(​Damalakiene et al., 2013; Kou et al., 2013​), depends on nanoparticle size (​Shang et al.,               
2014​). ​Specifically, endocytosis-mediated uptake of nanoparticles was found to be more           
efficient for hydrodynamic diameter values around 50 nm (​Osaki et al., 2004​). In this respect,               
although the optical qualities of Qtracker 800 make it suitable for deep vasculature imaging,              
their high hydrodynamic diameter (~ 35-36 nm based on our data) compared to the other dyes                
of the Qtracker vascular label series (the second largest being the 26.6 nm Qtracker 705; ​Ho                
et al., 2011 ​), makes them potentially more prone to endocytic internalization.  
In ​in vivo or cell-culture experiments, the issue of nanoparticle fate is further             
complicated by the very complex media (blood, cell-culture medium) with which they            
interact. Very recent reports show the strong dependence of nanoparticle aggregation,           
particularly quantum dots, with respect to medium composition and coating structure           
(​Moquin et al., 2015; Balog et al., 2015​). Even in a simpler solution, bovine serum albumine                
in PBS, the hydrodynamic diameter of Qtracker​®​800, as measured by DLS, increased with             
albumin concentrations, becoming more than double at protein concentrations equivalent to           
those present in the mouse blood serum (​Rampazzo el al., 2012​). Blood fibrinogen was also               
proven to strongly bind Qtracker​®​800 (​Pozzi-Mucelli et al., 2009​). In this context, it is very               
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 difficult to further speculate about the mechanism by which Qtracker​®​800 particles are            
uptaken into the cells.  
A vascular label such as the Qtracker​® ​nanoparticles is expected to be inert with              
respect to the physiology of the target system. Our study, however, shows that non-targeted,              
near-infrared emitting Qtracker​®​800 are captured by the brain vascular endothelium in the            
first 3 hours upon vein injection, which raises important concerns, including the possibility             
that such uptake (and interaction more in general) may lead to alteration of endothelial cell               
functionality.  
 
3.5.2. Qtracker​®​800 alters ‘normal’ calcium signalling in brain endothelial cells 
It was previously shown that acute exposure (5 to 30 min) to non-PEGylated or              
functionalized QDs elicits ​in vitro ​cytosolic calcium increases in different excitable and            
non-excitable cells (​Tang et al., 2008; Tang et al., 2008; Clift et al., 2010; Miragoli et al.,                 
2013​). Our study points out that nanoparticle PEG-ylation, at least in the case of              
Qtracker​®​800, does not prevent functional consequences on the vascular endothelium, as           
revealed by the occurrence of calcium transients during the 5-min exposure. 
The vascular endothelium has mechanosensitive properties, as part of the adaptation           
to the permanent shear stress exerted by the bloodstream. Endothelial cells may react to              
mechanical stimuli through a variety of mechanisms, such as transient receptor potential            
channels, ATP-operated cation channels, GTP-binding protein coupled receptors, and         
adhesion molecules (​Ando and Yamamoto, 2013​). In turn, a variety of downstream            
intracellular signalling pathways are activated, the majority involving either calcium release           
from internal stores, the intake of extracellular calcium, or both (​Tran et al., 2000, Ando and                
Yamamoto, 2013​). The strong positive correlation between calcium release amplitude (ΔR ​max​)           
and steepness (V​max​) shown in the present study has similarities with the previously reported              
amplitude-dependent calcium release in response to local mechanical stimuli (​Yamamoto et           
al., 2000​) and might imply that Qtracker​®​800 act as a mechanical trigger for the              
calcium-induced transients.  
The wide range of calcium event latencies we have observed, and the fact that only a                
subset of cells were activated, lead to the following speculation. Some cells are triggered by a                
probabilistic, direct interaction with the nanoparticles (possibly of mechanical nature) while           
neighboring cells are indirectly recruited in a wave of calcium events through intercellular             
communication mechanisms, as previously described in other endothelial cell types (​Long et            
al., 2012 ​). In this view, while fast and steep transients could be the result of direct                
nanoparticle-to-cell interactions, slower and shallower transients could be related to indirect           
activations.  
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3.5.3. Qtracker​®​800 might activate different components of the neurovascular unit 
It has already been stated that brain microvascular endothelium is a major component             
of the neurovascular unit, playing essential roles in physiological and pathological           
neuronal-activation states (​Fabene et al., 2008, Bertini et al., 2013, Radu et al., 2013 ​). The               
spatio-temporal Ca​2+ dynamics contribute to many physiological properties of the vascular           
intima (​Taylor and Francis, 2014​); asynchronous and synchronous Ca​2+ waves control           
vascular tone (​Mufti et al., 2010​). Local changes at the level of vascular endothelium (e.g.               
leukocyte-endothelial adhesion, leukocyte rolling) can translate into alterations of neuronal          
excitability (​Fabene et al., 2008​). ​In this general context, the Qtracker​®​800​-induced           
intracellular endothelial Ca​2+ transient activation shown by our results ​deserves attention in            
nanomedicine, and might imply not only localised endothelial ​Ca​2+ events but also the             
initiation of a complex signalling pathway involving multiple components of the           
neurovascular unit ​. Previous studies have highlighted the action of nanoparticles on different            
components of the neurovascular unit, by demonstrating that ​Qtracker​®​705: 1) accumulate ​in            
vitro ​in primary cortical cultures; 2) activates astrocytes after microinjection in brain cortex             
(​Maysinger et al., 2007​). Furthermore, large silica (NH​2​) PEGylated nanoparticles ​in vitro are             
uptaken into bEnd.3 cells and, ​in vivo​, are ​transported ​across the blood-brain barrier in               
Balb/c mice (​Liu et al., 2014​). 
Based on our data, we wonder whether Qtracker​®​800-induced alteration of ‘normal’           
calcium signaling in endothelial cells may bias the interpretation of results in studies of brain               
vascular function where nanoparticles are used as labels. 
 
3.5.4. How suitable are Qtracker ​®​800 for translational studies? 
Our results indicate that the nanoparticle-induced endothelial activation is not specific           
to mouse brain vessels, but it extends at least to a different species (human) and a different                 
endothelial cell localisation (umbilical vein). A further generalisation of the observation will            
require ​ad-hoc​ studies on endothelial cells derived from other species and organs. 
A key result in our study is the striking difference in HUVEC sensitivity to              
Qtracker​®​800 from one donor to another (almost an all-or-none effect). Our data agree with              
previously reported donor-dependent variability of HUVECs exposed to laminar shear stress           
(​Feairheller et al., 2011​), and might have implications for the use of near-infrared-emitting             
quantum dots in clinical vascular imaging applications. 
Whether a similar donor-dependent variability of responses in HUVECs exists also in            
rodents is not easy to establish, since ​in-vitro studies make use of sample pooling between               
several subjects (approximately ten mice for a single culture; ​Ruck et al., 2014​). But this is a                 
relevant issue, because if on one hand the mean number of activated cells in mice and in                 
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 humans are comparable (13.7% vs. 10.5%) establishing potential effects based on such            
averages might underestimate the effects on the individuals more prone to QD-induced            
activations. 
  
3.6. Conclusions & Future perspective 
Our study partly fills the knowledge gap regarding the interaction of           
near-infrared-emitting Qtracker​®​800 nanoparticles with biological systems, in particular the         
brain vascular endothelium. Both ​in vitro and ​in vivo data indicate the accumulation of QDs               
in the vascular endothelium as well as functional effects revealed by intracellular calcium             
changes in a subset of cells. In addition, we observed substantial inter-individual differences             
in HUVEC activation. Altogether, the findings raise two types of concern: 1) in studies of               
vascular function in living animals, the use of QD-based labeling might bias the results in               
difficult-to-detect ways; 2) in view of possible clinical applications, the between-subject           
variability in susceptibility may complicate safety assessments. 
Undoubtedly, brain vasculature imaging techniques can greatly benefit from the use of            
nanoparticle labels. On the other hand, as we have shown, such labels may be internalized by                
and functionally interact with blood vessel endothelia, which raises obvious safety concerns.            
It is quite possible that the effects uncovered represent the tip of an iceberg, and that further                 
studies are necessary to better characterize the full extent and consequences of the activations.              
Ideally, the development of novel labels should be focused on reducing or eliminating their              
interactions with biological tissues. Considering the vast potential of these nanoparticles for            
brain vasculature imaging, we hope that further chemical engineering will optimize their            
biostability, biocompatibility, and efficient clearance profile. 
 
 
 
3.7. Executive summary 
Aim 
● To assess the possible interaction of Qtracker​®​800 Vascular labels (Qtracker​®​800),          
a powerful nanotechnology tool for biomedical vasculature imaging, with mouse          
and human endothelium. 
Results 
● Transmission electron microscopy showed Qtracker​®​800 accumulation in mouse        
brain microvascular endothelium 3 h after their administration. 
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 ● Mouse brain endothelial cells, both in primary and immortalized cultures, are           
Qtracker​®​800-sensitive; 14% of cells generate intracellular calcium transients        
during acute 5-min exposures. 
● Human umbilical vein endothelial cells in primary culture derived from different           
donors present substantial variability in transient calcium responses (0 ÷ 30%) when            
acutely exposed to Qtracker​®​800. 
● The chronic ​in vitro exposure to Qtracker​®​800 for 24 h did not reveal major changes               
in endothelial cell viability. 
Conclusion & future perspective 
● We demonstrated a direct action of Qtracker​®​800 on the vascular endothelium in the             
first 3 h after administration, thus overlapping the time window recommended for            
vasculature imaging studies with these fluorescent nanoparticles. 
● Keeping in mind the enormous potential of Qtracker​®​800 deep-tissue penetration in           
biomedical applications, better manufacturing solutions to diminish/eliminate       
endothelium actions should be found. 
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 Chapter 4. Functional expression of murine 
muscarinic acetylcholine receptors in CNS 
microvascular endothelium 
 
 
  
4.1. Summary 
 
Clinical and experimental studies indicate that muscarinic acetylcholine receptors are          
potential pharmacological targets for the treatment of neurological diseases. Although these           
receptors have been described in human, bovine and rat cerebral microvascular tissue, a             
subtype functional characterization in mouse brain endothelium is lacking. Here, we show            
that all muscarinic acetylcholine receptors (M​1​-M​5​) are expressed in mouse brain           
microvascular endothelial cells. The mRNA expression of M​2​, M​3, and M​5 ​correlates with             
their respective protein abundance, but a mismatch exists for M​1 and M​4 mRNA versus              
protein levels. Acetylcholine activates calcium transients in brain endothelium via muscarinic,           
but not nicotinic, receptors. Moreover, although M​1 and M​3 are the most abundant receptors,              
only a small fraction of M​1 is present in the plasma membrane and functions in ACh-induced                
Ca​2+ signaling. Bioinformatic analyses performed on eukaryotic muscarinic receptors         
demonstrate a high degree of conservation of the orthosteric binding site and a great              
variability of the allosteric site. In line with previous studies, this result indicates muscarinic              
acetylcholine receptors as potential pharmacological targets in future translational studies. We           
argue that research on drug development should especially focus on the allosteric binding             
sites of the M​1​ and M​3​ receptors. 
  
4.2. State-of-art 
 
While it is widely known that acetylcholine (ACh) is released by axonal terminals of               
cholinergic neurons, cholinergic receptors are not found solely on target neurons. Rather,            
these receptor subtypes are also expressed by multiple non-neuronal cell types, both in the              
CNS (central nervous system) and peripherally, including endothelial, epithelial, mesothelial          
and immune cells ​(​Eglen, 2006​). This is not surprising, since cholinergic regulatory            
mechanisms have been described even in organisms lacking nervous systems, including           
plants, algae, and bacteria ​ ​(​Wessler and Kirkpatrick, 2012 ​).  
 
The data presented in this chapter have been published as: ​Beatrice Mihaela Radu​, Antonio Marco               
Maria Osculati, Eda Suku, Adela Banciu, Grygoriy Tsenov, Flavia Merigo, Marzia Di Chio, Daniel Dumitru               
Banciu, Cristina Tognoli, Petr Kačer, Alejandro Giorgetti, Mihai Radu, Giuseppe Bertini, Paolo Francesco             
Fabene (2017) All muscarinic acetylcholine receptors (M​1​-M​5​) are expressed in murine brain microvascular             
endothelium. ​Scientific Reports. 7(1):5083. doi: 10.1038/s41598-017-05384-z. 
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Of particular interest is the role of muscarinic cholinergic receptors (mAChR) in             
modulating brain circulation, as it is known that ACh plays an important regulatory role at the                
level of brain arterioles, capillaries and venules (​Sato et al., 2004​). For example, anatomical              
evidence from rats shows that a significant portion of the projections from basal forebrain              
neurons to fronto-parietal cortical microvessels are cholinergic (​Vaucher and Hamel, 1995​).           
Additionally, it has been shown that intrinsic ACh neurons innervate intracortical cerebral            
blood vessels in rats (​Chedotal et al., 1994​). More recently, it has been reported that the                
somatosensory cortex microvasculature is innervated by cholinergic neurons (​Kuznetsova and          
Schliebs, 2013​). The functional effects, such as vasodilation, of ACh and equivalent agonists             
(e.g., carbachol) have been demonstrated on both the luminal and parenchymal sides of brain              
vasculature in humans and hamsters (​Tsukahara et al., 1989; Rivers and Duling, 1992​).             
However, the mechanisms by which ACh may act on the endothelium of brain             
microvasculature (independent of whether direct vascular innervation can be established), are           
not yet fully understood.  
The exchange of signals between the blood stream and the brain parenchyma is             
facilitated by the close proximity of neurons or glial cells to the capillary anastomoses; in the                
mouse cortex, the average distance among the nearest blood capillary and neurons is 15              
microns (​Tsai et al., 2009 ​). ACh has been shown to regulate peripheral vascular homeostasis,              
especially via actions on the endothelium (​Cooke, 2000​), for instance by stimulating            
epoxyeicosatrienoic acids production (​Campbell and Fleming, 2010​). Indeed, cholinergic         
mechanisms in the mouse endothelium have been described in a variety of fresh tissue              
preparations of the macro- and microcirculation (​Peyter et al., 2008; Bagher et al., 2011;              
Gericke et al., 2011a; Gericke et al., 2011b​). ACh has also been detected and quantified in the                 
bloodstream, where it may interact with the luminal side of the endothelium (​Kawashima et              
al., 1998 ​). Notably, however, endothelial cells present a high degree of heterogeneity in the              
expression of surface markers, carrier proteins, and intracellular enzymes, across and within            
tissues (​Cines et al., 1998 ​). 
The localization and functional activity of muscarinic and/or nicotinic ACh receptors           
in brain microvascular endothelia have been described humans, rats, and bovines (​Elhusseiny            
et al., 1999; Luiten et al., 1996; Badaut et al., 1997; Traish et al., 1994; Tracey and Peach,                  
1992​) but not in mice. Given the potential importance of this receptor family as non-neuronal               
drug targets (​Zhang et al., 2014​), and the increasing use of mAChR knockout mice ​as models                
for common neurological disorders (​Zhang, 2006; Langmead et al., 2008; Wess et al., 2003​),               
a detailed characterization of mAChRs ​expression and functionality in the mouse brain            
microvasculature is a high priority. 
The mAChRs are a sub-class of the G-protein-coupled receptors (GPCRs) family,           
comprising 5 subtypes (M​1​-M​5​). M​1​, M​3​, and M​5 are coupled with the G​q protein and, via                
phospholipase C signaling pathway, generate cytosolic calcium transients; M​2 and M​4​, on the             
other hand, couple with the G​i protein inhibiting the adenylyl cyclase ​(Langmead et al., 2008;               
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 Wess et al., 2003​). While obtaining mAChRs subtype-selective ligands is a primary goal in              
drug development (​Langmead et al., 2008; Conn et al., 2009 ​), previous attempts have failed              
due to the highly conserved structure of the orthosteric binding site across the muscarinic              
receptor family members (​Felder et al., 2000; Wess, 2005​). On the other hand, the allosteric               
binding site seems to hold promise as a specific pharmacological target (​Conn et al. 2009​).               
Yet, despite considerable recent progress in crystallography and molecular modeling of           
mAChRs (as well as the successful crystallization of human M​1​, M​2​, M​4​, and rat M​3 receptors                
Haga et al., 2012; Kruse et al., 2012​), no 3D structure predictions based on homology               
modeling studies have been carried out for mouse muscarinic receptors. 
Indeed, previous studies of mAChRs expression in different species reported rather           
contradictory results, possibly due to the different cell sources and/or techniques used.            
Initially, using a radioligand binding assay, the presence of M​1 and M​3 was demonstrated in               
membrane samples from human and bovine microvessels (​Linville and Hamel, 1995​).           
However, subsequent ultrastructural investigations in rat capillaries showed a lack of           
mAChRs at this level; the few samples in which mAChR expression was detected on the               
perivascular astroglia and have been attributed to the endfeet of cholinergic neurons            
innervating the capillary basement membrane (​Luiten et al., 1996; Badaut et al., 1997​). In              
contrast, mAChRs have been reported in human endothelial cells from brain microvessels and             
capillaries (​Elhusseiny et al., 1999 ​). In particular, the M​2 and M​5 receptors (and occasionally              
M​1​) have been identified in cells cultivated from intracortical biopsies obtained from patients             
with temporal lobe epilepsy. In addition, M​3 and M​2 receptors have been found in              
post-mortem fetal cerebral cortex samples (10-18 weeks of gestation). However, the           
peculiarity of these samples limits the generalization of the results. 
Here, we report direct evidence that all 5 mAChRs subtypes are expressed in mouse              
brain microvascular endothelial cells using a combination of quantitative analyses of mRNA            
and protein levels. The M​1 and M​3 subtypes, in particular, show functional and             
pharmacological properties consistent with previous reports in the same tissue types from            
other species. While we confirm the abundant presence of M​3 in mouse brain endothelial              
cells, similar to findings in other species, we report for the first time the expression, but low                 
functional relevance, of M​1 in these cells. We analyzed the conservation of the orthosteric and               
allosteric binding site among receptor subtypes along all annotated (as from GPCRdb, ​Lu and              
Hulme, 1999​) eukaryotic species. Our data confirm the idea that, while the orthosteric cavity              
is highly conserved, the allosteric site is highly variable and thus represents a potential              
pharmacological target for drug design. Our findings support further translational and           
experimental cerebrovascular studies in mice. 
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 4.3. Materials and Methods 
All experimental protocols were approved by the University of Verona ethical           
committee. The methods were carried out in accordance with the relevant guidelines and             
regulations. 
 
4.3.1. Brain endothelial cell cultures 
 
To avoid biases due to contamination from astrocytes and/or terminals (​Elhusseiny et            
al., 1999 ​), we studied mAChRs in primary cultures of endothelial cells separated from brain              
microvascular tissue or in an endothelial cell line. Balb/c mouse primary brain endothelial             
microvascular cells BMVECs (#PB-BALB-5023, PELOBiotech, Germany; passages 3–6) and         
cells from the Balb/c mouse cell line bEnd.3 (#ATCC® CRL-2299™, ATCC, USA; passages             
20–30) were cultivated as previously described (​Radu et al., 2015​). Both endothelial cell types              
were tested for mycoplasma contamination twice per year using the Hoechst (#B2883, Sigma)             
DNA staining protocol. Cells were plated at a density of 2 x 10​4 cells/cm​2 onto 24-mm cover                 
glasses for the intracellular calcium imaging and immunofluorescence protocols, or into 25            
cm​2​ flasks and further harvested for qRT-PCR and protein quantification assays. 
 
4.3.2. Gene expression via qRT-PCR 
 
To quantify the expression levels of ​Chrm1-5 (M​1​-M​5 receptor-encoding genes) in           
mouse brain microvascular endothelial cells, total RNA was extracted using the GenElute            
Mammalian Total RNA MiniPrep Kit (RTN70, Sigma) according to manufacturer’s          
instructions. RNA concentrations were determined via spectrophotometric measurements of         
absorption at 260 and 280 nm (Beckman Coulter DU 730).  
DNase I treatment was used to remove contaminating genomic DNA. In agreement            
with manufacturer guidelines (Sigma), in our experiments the A​260​:A​280 ratio was 2.03 ± 0.06              
(bEnd.3) and 1.93 ± 0.03 (BMVEC). Reverse transcription was performed using the            
High-Capacity cDNA Archive Kit (Applied Biosystems, USA). ​Actb ​and ​Gapdh were used as             
housekeeping genes. The following mouse Taqman primers (Life Technologies, USA) were           
used in accordance with manufacturer guidelines: ​Chrm1 (​Mm00432509_s1 ​), ​Chrm2         
(Mm01701855_s1), ​Chrm3 (Mm01338409_m1), ​Chrm4 (Mm00432514_s1), ​Chrm5      
(Mm01701883_s1), ​Gapdh (Mm999999_g1), and ​Actb (Mm00607939_s1). Further       
information on primer selection for ​Chrm1 and ​Chrm2 is provided in ​Figure 4.1​. The relative               
abundance of ​Chrm1-5 transcripts was assessed via qRT-PCR using the TaqMan           
methodology and the ABI Prism 7300 Sequence Detection System (Applied Biosystems,           
USA). Reactions were carried out in triplicate for 50 cycles.  
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Figure 4.1. Primer screening for optimal quantification of ​Chrm1 and ​Chrm2 mRNA levels. ​Comparative              
threshold cycle (C​T​) values (mean ± SD, N = 5) are plotted for each tested primer. Even if ​Chrm2 primer                    
Mm01701855_s1 (gray shading) reached the threshold at almost the same cycle number as its “white”               
counterpart, reproducibility was better since the latter resulted in amplification in only 3 out of 9 repetitions. In                  
the end, the “grey” primers were used in generating the data presented in the manuscript (Figure 4.2, see also                   
Methods section). 
 
4.3.3. Assessment of muscarinic receptor localization via immunofluorescence and         
confocal microscopy 
 
The cellular localization of the M​1​-M​5 receptors was evaluated via          
immunofluorescence. Brain endothelial cells were treated with a blocking and          
permeabilization solution (0.3% Triton 100, 1% bovine serum albumin, 2% normal goat            
serum) for 30 min and were incubated overnight at room temperature with the primary              
antibody. They were then incubated for 1 h with the secondary antibody followed by an               
incubation with TO-PRO​®​-3 (1:3000, Life Technologies) for 10 min for nuclear staining, and             
were finally mounted with a fluorescent mounting medium. The following polyclonal rabbit            
primary antibodies from Alomone, Israel were used: anti-M​1 (1:100, #AMR-001), anti-M​2           
(1:100, #AMR-002), anti-M​3 (1:100, #AMR-006), anti-M​4 (1:100, #AMR-004), and anti-M​5          
(1:100, #AMR-005). The primary antibody was omitted in negative-control samples. Goat           
anti-rabbit Alexa 488 (1:1000, Life Technologies) was used as the secondary antibody.            
Normal goat serum and fluorescent mounting medium were purchased from Dako, Milan,            
Italy. 
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 Specimens were examined using a confocal fluorescence microscope (LSM 710, Carl           
Zeiss, Germany) equipped with a 63x oil objective. The following acquisition parameters            
were used: pinhole corresponding to 1 Airy Unit for each laser, 62 μm for the 488 nm laser                  
and 66 μm for the 633 nm laser, digital gain of 1.00, and intensity of 5% for each laser. The                    
acquisition parameter settings were kept fixed for each channel across different image            
acquisition sessions. Image acquisition was carried out using Zeiss LSM Image Browser            
software (Carl Zeiss, Germany). A visual evaluation of fluorescence intensity distribution in            
the nucleus, cytoplasm, and plasmalemma was used to characterize the cellular localization of             
the receptors. The green channel intensity was scored as follows: - (not observable), + (low),               
++ (medium) and +++ (high). For each receptor were scored 40 cells. Because of the intrinsic                
difficulty in clearly isolating membrane labeling, we regard this evaluation as strictly            
qualitative.  
 
4.3.4. Protein extraction protocol 
 
We employed a protein immunomagnetic affinity capture technique for the mass           
spectrometry-based quantification of M​1​-M​5 receptors from BMVEC and bEnd.3 cell          
samples. Cells were harvested in microvials and immediately placed on ice. They were then              
homogenized with a series of 10 ultrasonic pulses (Sonopuls HD 2070, Bandelin, Germany),             
1 sec each at 50% of the maximum frequency in 10 mM PBS (pH 7.4, Sigma) supplemented                 
with the Protease Inhibitor Cocktail for use with mammalian cell and tissue extracts (#P8340,              
Sigma), according to the manufacturer’s instructions. Homogenates were subsequently         
centrifuged at 1000x ​g for 10 min at 4°C to remove cellular debris. Cell lysates were               
collected, mixed with Laemmli loading buffer (#161-0737, Bio-Rad, Hercules, CA, USA)           
and heated at 70 °C for 20 min. 
Using 4-15% Criterion™ TGX Stain-Free™ Protein Gels (#567-8084, Bio-Rad), we          
separated 15 μg of the lysate for each cell sample. The total protein profiles of the samples                 
were then visualized using a Bio-Rad ChemiDoc MP imager within a few minutes after the               
completion of electrophoresis to check for protein sample and separation quality (​Figure            
4.2A​). After visualization and image acquisition, UV activation of the bands was performed             
using the ChemiDoc MP system. Gels were split into individual lines, each containing             
separated proteins (from 10 to 250 kDa). Individual lines were then placed in vials containing               
10 mL of distilled water. Next, the water solution and lines of gel were homogenized and                
consequently sonicated in an ultrasonic bath (Sonorex, Germany) for 20 min at 4 °C. Samples               
were then centrifuged at 6500 x​g (room temperature) and supernatants, filtered on a 0.2 mm               
PTFE microfilter were collected. A small volume of the supernatant was used to determine              
the total amount of proteins by the Bradford method (​Figure 4.2B​). Next, 1 mL of               
supernatant (i.e. 10% of the total) was incubated with antibody-coated magnetic particles that             
were prepared as described below.  
We bound undiluted anti-M​1-5 antibodies (1 µL, Alomone) to functionalized magnetic           
particles (Dynabeads® M-280, Tosyl-activated superparamagnetic polystyrene) for       
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 immunoaffinity capture. Protein standards for the M​1​-M​5 receptors were provided by           
Alomone, Israel and were used as calibration controls in the matrix-assisted laser desorption             
ionization time-of-flight (MALDI-TOF) mass spectrometry analysis. 
 
 
 
​Figure 4.2. Representative examples of stain-free gel and mass spectra. ​A. Gel electrophoresis of               
the total proteins extracted from BMVEC and bEnd.3 samples run on 4-15% Criterion™ TGX Stain-Free™               
Protein Gels. The visualization of stain-free gels after gel electrophoresis shows well-separated proteins in the               
range of ~12 to ~200 kDa for both brain endothelial cell extracts. ​B. Total protein content (mean ± SD, N=5)                    
quantified via the Bradford method. Protein levels were significantly higher in bEnd.3 compared to BMVEC               
samples (unpaired t-test, t = 8.384, df = 18, ​p < .0001). ​C-G. MALDI-TOF mass spectra of M1-5 receptors in                    
BMVEC samples (identical MS spectra were obtained for bEnd.3 cells). Receptors were identified based on the                
molecular or fragment peaks in the spectra corresponding to the most abundant, singly charged protein ions. On                 
axis Y - intensity in atomic units, on X - m/z values. 
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 4.3.5. Immunomagnetic isolation followed by MALDI-TOF MS analysis 
We followed our previously published protocol (​Hasuo et al., 1996​) ​with the            
antibodies detailed below. Candidate muscarinic receptors were isolated by using polyclonal           
affinity-purified antibodies purchased from Alomone Labs (as described above). The MALDI           
matrix 1,2-dimethoxy-4-hydroxycinnamic (sinapinic acid) and other chemicals were        
purchased from Sigma-Aldrich (St. Louis, MO, USA) and chemical solvents were purchased            
from Merck (Darmstadt, Germany).  
The following buffers were used during the isolation procedure:  
● Buffer A: 0.1 M sodium-phosphate buffer pH 7.4 
● Buffer B: Phosphate-buffered saline (PBS) pH 7.4 with 0.1% (w/v) bovine           
serum albumin (BSA) 
● Buffer C: 0.2 M Tris pH 8.5 with 0.1% (w/v) BSA; 
● Buffer D: 100 mM glycine (pH 2.5) 
Dynabeads M-280, tosyl-activated superparamagnetic polystyrene beads coated with        
polyurethane, were washed twice in Buffer A to remove sodium azide (NaN​3​) using magnetic              
particle concentrator following the manufacturer’s protocol (Thermo Fisher Scientific,         
Waltham, MA, USA). The above-listed antibodies (1 𝜇L each) were dissolved in 100 𝜇L of               
Buffer A and added to 100 𝜇L suspension of Dynabeads, mixed for 1 min, followed by                
24-hour incubation at 37 ​o​C with mixing. Then, the supernatant was removed and the              
particles were washed twice with Buffer B (500 𝜇L) at 4 ​o​C. Free tosyl groups on the beads                  
were blocked with Buffer C (500 𝜇L; 4 h, 37 ​o​C), followed by washing with Buffer B (500                  
𝜇L; 5 min, 4 ​o​C). Each individual preparation of the antibody-coated magnetic beads was              
resuspended in 1 mL of supernatant and incubated with shaking for 1 h at 37 ​o​C. The                 
supernatants were then removed and the beads were washed five times with Buffer B (500               
𝜇L; 4 ​o​C, 5 min, vortexing). The captured antigens were eluted with Buffer D (50 𝜇L; 4 ​o​C, 1                   
min, vortexing) and the beads were magnetically separated. The eluates were desalted using             
C18 ZipTip (EMD Millipore, Billerica, MA, USA) before analysis by matrix-assisted laser            
desorption ionization-time-of-flight mass spectrometry (MALDI-TOF MS). 
 
4.3.6. MALDI-TOF MS analysis 
MALDI-TOF MS data were acquired on Autoflex mass spectrometer (Bruker          
Daltonics, Germany) with MALDI sample target (600 µm Chip™; Bruker Daltonics).          
Ionization was achieved by irradiation with a nitrogen laser (337 nm) operating at 4 Hz. Ions              
were accelerated at 20 kV with 250 ns of pulsed ion extraction delay. Freshly prepared             
1,2-dimethoxy-4-hydroxycinnamic acid was used as matrix (10 mg/mL) in 50% acetonitrile           
0.1% (v/v) of trifluoroacetic acid. The instrument’s parameters and laser energy were kept             
constant during a series of experiments performed on the same day for the comparison of               
intensity values (cps). 
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 First, we obtained MS spectra of standard receptor proteins (data not shown). The             
areas under the peak of interest were used to construct calibration curves, allowing later on               
the quantification of receptors in our samples. The protonated molecular ion peak (MH+) for              
each protein was detectable to a sub-pmol level with a signal-to-noise ratio > 50. This               
detection limit was comparable with immunochemical assays. 
The MS spectra obtained with our samples showed the MH+ peaks at the expected              
m/z values, matching those observed with the standard proteins. The areas under the peak              
were then normalized against those interpolated from the calibration curves. ​The           
MALDI-TOF MS is a semiquantitative method; however, using rigorous sample preparation           
and data acquisition method, the intensity of the MH+ peak(s) increased linearly with             
increasing quantities of each protein from nanomolar to picomolar ranges. Therefore, in this             
concentration range, the evaluations of protein biomarkers can be considered quantitative           
(​Hasuo et al., 1996​). 
 
4.3.7. Intracellular calcium imaging measurements 
 
Fura-2 AM-based Ca​2+ imaging experiments were performed on brain microvascular          
endothelial cells as previously described (​Radu et al., 2015​). Measurements were performed            
using a cooled CCD camera (Clara, Andor, Northern Ireland) and a Polychrome V             
monochromator (Till Photonics, Germany) coupled to a SliceScope (Scientifica, UK) upright           
fluorescence microscope with a 40x-water immersion objective (Olympus, Japan). Data          
acquisition was performed using Live Acquisition imaging software (Till Photonics,          
Germany), and calcium changes were determined based on the intensity ratio (R =             
I​340nm​/I​380nm​). Ratios were calculated for each cell in the microscope field and were based on               
individually defined regions of interest after background subtraction. Calcium imaging data           
were analyzed using Offline Analysis software (Till Photonics, Germany) and are plotted as             
the mean fluorescence ratio amplitude (​Δ​R = R - R​0​, where R ​0 represents the calcium signals                
recorded in unstimulated cells) ± SEM.  
Solutions were delivered to brain endothelial cells through a 100 µm quartz perfusion             
head using an 8-channel valve pressurized system (ALA Scientific Instruments, USA). The            
Ringer’s solution contained (in mM) 140 NaCl, 5.6 KCl, 2 MgCl​2​, 2 CaCl​2​, 10 glucose, 10                
HEPES (pH 7.4, adjusted with NaOH). Fura-2 acetoxymethyl ester (Fura-2 AM) and pluronic             
acid were purchased from Life Technologies, USA, and all common salts were from             
Sigma-Aldrich, Milan, Italy. Cytosolic Ca​2+ transients resulting from the activation of           
muscarinic acetylcholine receptors were elicited by a 20-s pulse of 1 µM acetylcholine             
chloride (ACh, Sigma) application. The reproducibility of the effect of ACh was tested via a               
double-pulse protocol, with a 10-minute between-pulse Ringer’s washout period. In some           
experiments, we replaced the first pulse of ACh with a pulse of either (±)-muscarine chloride               
hydrate (#M104, Sigma) or (−)-nicotine hydrogen tartrate salt (#SML1236, Sigma) at           
previously described concentrations (100 µM and 300 µM, respectively) (​Moccia et al., 2004;             
Hasuo et al., 1996 ​), followed by the second pulse (1 µM ACh) after a 10-min recovery period.                 
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 Dose-response curves for the mAChR antagonists were obtained by preceding the second            
ACh pulse with a 2-min application of the antagonist. The following antagonists were used:              
J104129 fumarate (M​3 antagonist, Tocris Bioscience, USA), VU 0255035 (selective M​1           
antagonist, Tocris Biosciences), 4-DAMP (1,1-dimethyl-4-diphenylacetyl piperidinium      
iodide; M ​3 antagonist, Sigma), and telenzepine dihydrochloride hydrate (M​1 antagonist,          
Sigma). We also tested the effect of AC-42 (#SML0787, Sigma), a selective allosteric M ​1              
agonist, with the EC​50 = 29 nM (based on a Receptor Selection and Amplification Assays) for                
M​1 and without any effect on M ​2​-M ​5 (​Spalding et al., 1992​) AC-42 was applied at its maximal                 
activation concentration, based on the previously determined EC​50 value of 0.2 µM evaluated             
by a calcium mobilization assay (​Jacobson et al., 2010​). Moreover, we have tested the effect               
of the muscarinic toxin MT-7 (Smartox Biotechnology, France) at its saturation           
concentration, as previously described (​Adem and Karlsson, 1997​), considering its high           
affinity for the M​1 receptor, i.e. k​i = 0.2 nM for M​1 and k​i > 2000 nM for M​2​-M​5 ​(​Adem and                     
Karlsson, 1997 ​). 
 
4.3.8. Homology modeling and molecular docking 
 
The eucaryotic sequences were downloaded from the Pfam database         
(​10.1093/nar/gkv1344​) and the conservation of the residues were calculated as a percentage            
(X/P)*100, where X is the residue and P the length of the multiple sequence alignment. Since                
mouse M ​1​-M​5 lack structural information, homology modeling was carried out to predict their             
3D structures. The sequences were retrieved from the Uniprot database, and the models were              
generated through the GOMoDo web-server (​Sandal et al., 2013​). To enforce the conserved             
structural fingerprints of class A (rhodopsin-like) GPCRs (​Venkatakrishnan et al., 2013​), all            
sequence alignments between targets and templates (illustrated in detail in ​Table 4.1​) were             
verified manually. The 3D structures obtained in the homology modeling step were used to              
perform virtual docking studies using the HADDOCK docking program (​De Vries et al.,             
2010​) through the GOMoDo web-server. We used the GPCRdb generic number position            
(​Isberg et al., 2016​), which generalizes the classical Ballesteros-Weinstein numbering.          
Residues in positions 3.32, 3.33, 3.36, 3.37, 4.57, 5.39, 5.42, 6.48, 6.51, 7.39, and 7.43 were                
considered as ‘Active Residues’ to guide the docking. These residues have already been             
characterized as being involved in agonist/antagonist binding (​Goodwin et al., 2007; Lu and             
Hulme, 1999 ​). The structures of the four antagonists were downloaded from the ZINC             
database (​Irwin et al., 2012​), and were parametrized with ACPYPE (​Sousa da Silva and              
Vranken, 2012​). The docking protocol included three stages: (a) a rigid-body energy            
minimization, (b) a semi-flexible refinement in torsion angle space, and (c) a final refinement              
in an explicit solvent. We chose 1000 structures for the first step and 200 structures for the                 
second and third docking steps, using default parameters. We selected the best structure for              
each docking as the one corresponding to the most populated cluster with the lowest energy               
value. Figures were generated with Chimera (​Pettersen et al., 2004​). 
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 Table 4.1​. Mouse muscarinic receptor ​in silico docking. Summary of the residues involved in the most                
important interactions with each of four antagonists, arranged by bond type. 
 
Antagonist M​1 M​2 M​3 M​4 M​5 Interaction 
4-DAMP D​3.32 D​3.32 D​3.32 D​3.32 D​3.32 salt bridge 
Y​3.33​ S​3.36 
Y​6.51 
Y​3.33   Y​6.51 h-bond 
V​3.40​ W​4.50 
F​5.40​ T​5.42 
F​5.47​ W​6.48 
W​4.50​ F​5.40 
T​5.43​ Y​6.51 
W​6.48 
Y​3.33​ F​5.40 
T​5.42​ V​6.55 
F​5.40​ T​5.42 
W​7.34 
W​7.36​ F​5.40 hydrophobic 
  Y​6.51 F​185  pi-stacking 
Telenzepine D​3.32 D​3.32 D​3.32 D​3.32 D​3.32 salt bridge 
Y​6.51​ ​N​6.52 Y​3.33 Y​6.51​ ​Y​7.39 Y​6.51​ ​Y​7.43 
N​6.52 
Y​3.33​ ​S​.57 h-bond 
W​4.50​ Y​7.39 F​101 F​224​ L​224 
T​5.40 
F​188​ L​226 
T​5.40 
L​226​ T​5.40 
W​6.48 
hydrophobic 
Y​3.33     pi-stacking 
VU 0255035 D​3.32     salt bridge 
S​3.36​ ​Y​7.39  Y​7.39 Y​6.51​ ​Y​7.43  h-bond 
W​4.50​ Y​6.48 
ECL3 W​7.34 
W​4.50​ T​5.41 
ELC3 Y​7.39 
Y​7.43 
T​5.40​ ECL3 
T​5.43​ W​7.34 
ECL2 T​5.40 
T​5.43 
W​7.34​ T​5.40 
T​5.43​ ECL2 
W​4.57 
hydrophobic 
W​7.35 Y​3.33 W​6.48 Y​3.33  pi-stacking 
J104129 
fumarate 
D​3.32  D​3.32  D​3.32 salt bridge 
Y​3.33​ ​Y​6.51 Y​7.38 Y​3.33​ ​Y​6.51  Y​3.33​ ​Y​6.51 h-bond 
W​4.50​  T​5.41 
Y​7.39​  W​7.35 
W​6.48 
Y​3.33 ​  T​5.41 
W​4.57​  Y​7.39 
W​4.50​  Y​5.41 
Y​6.51​  Y​7.39 
I​2.52​  L​3.31 
V​3.34​  W​4.50 
W​4.54 
W​4.50​  T​5.40 
T​5.43​  Y​7.39 
hydrophobic 
  Y​7.39   pi-stacking 
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 4.3.9. Data analysis 
 
Quantitative RT-PCR data were obtained by normalizing ​Chrm1​-​Chrm5 mRNA levels          
to those of ​Gapdh ​and ​Actb using the 2(-Delta C(T)) method, as previously described (​Livak               
and Schmittgen, 2001​). The results were expressed as log​10​-fold changes due to their extended              
scale distribution and were plotted as the mean ± SD. 
The Hill formalism (​Collison et al., 2000​) was used to fit both the ACh              
concentration–response and the inhibition curves determined via calcium imaging recordings          
from BMVECs and bEnd.3 cells. For the concentration-response curves, the following           
equation was used: 
/R  C /(C ) R max =  α α + ECα50 (​4.1​) 
 
C corresponds to the agonist concentration, ​Δ​R​max is the amplitude ratio for the maximal              
response to 10 µM ACh, EC​50 is the concentration of agonist required to elicit a half-maximal                
response, and α is the Hill coefficient describing cooperativity and mAChR receptor            
occupancy (​Collison et al., 2000 ​). Inhibition curves resulting from the calcium imaging data             
analysis were fitted with the following equation: 
 
/R 1 (X )C /(C )R max =  +  − 1 α α + ICα50  (​4.2​) 
 
IC​50 is the antagonist concentration required to reduce the agonist response by 50%, C              
is the agonist concentration (1 µM), α is the Hill coefficient. In equation (1) and (2) a Hill                  
coefficient value of 1 indicates that only one molecule of agonist/antagonist is            
activating/inhibiting one receptor). X = 0 for telenzepine, J104129 fumarate and 4-DAMP,            
and X = the fitting parameter for VU 0255035. 
The apparent dissociation constant was calculated using the Cheng–Prusoff equation,          
as follows: 
 
 
           ​K​a​ = IC​50 ​/ (1 + C/EC​50​) (​4.3​) 
 
Protein abundance was determined in the MALDI/TOF MS analysis, as described           
previously (​Schlosser et al., 2007​). Briefly, the area under the curve of the most abundant               
mass band ​(peak) for each protein standard or sample was calculated in series of ten               
repetitions, and the computed average was used to determine the concentration of each             
muscarinic receptor protein. The mass band (peak) identification and quantification of each            
muscarinic receptor protein in our samples was determined in relation to the protein standard              
peak. Next, protein contents for each muscarinic receptor were normalized to the total amount              
of proteins in the sample.  
Statistical analyses comparing the expression of the 5 receptor subtypes were carried            
out as follows. Differences in mRNA expression based on RT-PCR data were analyzed with              
one-way ANOVA (according to ​Yuan et al., 2006​) followed by post-hoc Bonferroni tests.             
Protein quantification based on MALDI-TOF data were analyzed with one-way ANOVA           
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 followed by post-hoc Holm-Sidak 2 test. Analysis and data plotting were performed using             
OriginPro 8 (OriginLab Corporation, USA) and GraphPad Prism version 7.00 (GraphPad           
Software, La Jolla California USA). 
 
 
4.4. Results 
 
4.4.1. All muscarinic acetylcholine receptor subtypes are expressed by mouse brain           
microvascular endothelial cells 
 
We first sought to identify and quantify mRNA expression of mAChRs M​1​-M​5 in two              
types of mouse brain microvascular endothelial cells. Quantitative real-time PCR (qRT-PCR)           
analyses using both β-actin (​Actb​) and glyceraldehyde 3-phosphate dehydrogenase (​Gapdh​) as           
reference genes indicated that both brain microvascular endothelial cells (BMVECs) and brain            
endothelial cells (bEnd.3) express mRNA transcripts for ​Chrm1-5​, which encode mAChRs           
M​1 ​- M​5​. The ranking of mRNA levels in BMVECs and bEnd.3 cells was as follows: Chrm3                  
> Chrm4 ​ ​ Chrm1 ​ ​ Chrm5 > Chrm2 ​(​Figure 4.3.A-D​). 
These rankings were consistently observed when data were normalized against either           
reference gene, despite the different functional roles of the latter. The most abundant             
muscarinic receptor gene, ​Chrm3​, was approximately 10​5 times more abundant than ​Chrm2,            
and about 200 times, 500 times and 3000 times more than Chrm4, Chrm1 and Chrm5​,               
respectively.  
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 Figure 4.3. mRNA levels for ​Chrm1 - Chrm5​, respectively encoding the M​1​-M​5 receptors, quantified via               
qRT-PCR in BMVECs (​A, C​) and bEnd.3 cells (​B, D​). Data are normalized against two different reference                 
genes, ​Gapdh ​(A, B) and ​Actb ​(C, D), and are plotted as mean ± SD (N = 5), from three different cell batches.                       
One-way ANOVA analysis indicated: (A) F(32) = 80, ​p ​< 0.001; (B) F(25) = 56, ​p ​< 0.001; (C) F(25) = 58, ​p ​<                        
0.001; (D) F(14) = 121, ​p ​< 0.001. Statistical pairwise significance is indicated with asterisks (* 0.01 < ​p ​< 0.05;                     
** 0.001 < ​p ​< 0.01; *** ​p ​< 0.001) followed by the compared variant. 
 
We next confirmed the presence of all muscarinic receptor subtypes and their            
subcellular distribution in both BMVECs and bEnd.3 cells via immunofluorescence staining           
(​Figure 4.4​). A qualitative analysis did not reveal substantial differences in receptor            
expression between the two cell types; however, each subtype showed a specific subcellular             
localization pattern (​Table in Figure 4.4​). In particular, most subtypes (M​1​-M​4​) are strongly             
present in the cytoplasm (mainly in the perinuclear region), while M​5 was much more              
concentrated in the plasmalemma. Interestingly, an important fraction of M​1 was localized in             
the nucleus, and was almost absent from the plasma membrane. M​3 was abundant in the               
cytosol, but its presence partly extended to the plasma membrane. 
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Figure 4.4.​ (​see the second part of the figure on the next page​) 
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Figure 4.4. ​Detection of M​1​-M​5 receptors by means of immunofluorescence in BMVECs and bEnd.3 cells. The                
labeling obtained with anti-M​1-5 antibodies (green) is here merged with TO-PRO​®​-3 nuclear staining (blue);              
scale bar: 10 µm. The table shows qualitative estimates of protein abundance in the plasma membrane (PM),                 
cytoplasm (Cyt), and nucleus (N). The evaluation was based on visual assessment of green fluorescence               
intensity on 40 cells per antibody, scored from not observable (-) to very intense (+++). 
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 4.4.2. M​1​, M ​3, and M ​4 are the most abundant receptors in brain microvascular             
endothelial cells 
 
With the transcriptomic expression and subcellular distribution of mAChRs         
established, we next confirmed and quantified mAChR protein expression in mouse brain            
microvascular endothelial cells (BMVECs and bEnd.3 cells). ​Using the matrix-assisted laser           
desorption ionization time-of-flight (MALDI-TOF) mass spectrometry, we examined the         
amount of all muscarinic receptor proteins in brain microvascular endothelial cells (​Figure            
4.2C-G​). Ratios of each mAChR (x10​-6​) normalized to the total amount of protein were              
calculated. One-way ANOVA analyses showed significant differences between subtypes for          
BMVEC cells (F(64) = 62.03, ​p ​< .0001) and b.End3 cells (F(34) = 222.8, ​p ​< .0001).                 
Followed Holm-Sidak ​post-hoc tests indicated much higher levels of M​1​, M​3 and M​4             
compared to M ​2 and M​5 subtypes in both BMVECs (​Figure 4.5A​) and b.End3 cells (​Figure               
4.5B​). Moreover, M​1 expression was significantly higher than M​3 and M​4 in BMVECs             
significantly higher expression than M​4​ in bEnd.3 cells. 
 
 
Figure 4.5. ​Relative protein abundance of M​1​-M​5 receptors in brain microvascular endothelial cells (mean ± SD,                
N = 5). One-way ANOVA analyses showed significant differences between subtypes for both cell types: (​A​)                
F(64) = 62.03, ​p ​< .0001; (​B​) F(34) = 222.8, ​p ​< .0001. The ​Table ​shows the results (t values) of pairwise                      
Holm-Sidak ​post-hoc​ tests (* ​p ​< .05; ** ​p ​< .0001) .  
66 
  
We also found that, for each mAChR subtype, expression in bEnd.3 cells was almost              
double that in BMVECs, and very similar results were obtained by means of the Bradford               
method (unpaired t-test, t = 8.384, df = 18, ​p < .0001, ​Fig. 4.5 B​) thereby excluding potential                  
biases due to overall differences in protein expression. Similar discrepancies in mAChR            
expression between primary and immortalized endothelial cells have been reported between           
freshly isolated and cultured bovine aortic endothelial cells (​Tracey and Peach, 1992​). 
Protein quantitation data indicates that the M​1 and M​4 subtypes are present in both cell               
types in amounts comparable to M​3​, in spite of significantly lower mRNA levels. A mismatch               
between mRNA and protein levels is not surprising ​per se​, as such correlation in complex               
biological samples has been reported to be poor ​(​Maier et al., 2009​). Different normalization              
factors between methods can play a role as well. Total protein loading control was reported to                
be more reliable than the housekeeping proteins loading controls (​Colella et al., 2012​). We              
also examined the levels of β-actin and α-tubulin to see if they can be used as a reliable                  
loading control under our experimental conditions. We found that the protein expression level             
for β-actin is ~ 3.8 times higher in BMVEC than in bEnd.3 cells, the level of α-tubulin is ~                   
5.6 times higher (​data not shown​). Therefore, the total amount of protein in our samples was                
used as the normalization factor.  
 
4.4.3. Cholinergic activation of calcium signaling pathways in brain microvascular          
endothelial cells depends on muscarinic, but not on nicotinic receptors 
 
The finding of muscarinic receptor transcripts and proteins, together with their           
subcellular localization in brain microvascular endothelial cells, prompted the         
characterization of their functional properties, which we pursued by means of calcium            
imaging recordings. As already mentioned, M​1​, M​3 and M​5 have been shown to trigger              
calcium transients in the cytosol in response to the binding of specific muscarinic agonists              
(​Langmead et al., 2008​). The typical response to ACh for both BMVECs and bEnd.3 cells               
began with a sharp peak, followed by a smaller but sustained response (see ​Figures 4.6 - 4.8,                 
for representative examples), particularly after higher ACh concentrations (1 µM and 10 µM;             
Figure 4.6 ​). This is consistent with the slow but sustained influx through store-operated             
calcium channels located in the plasma membrane that follows the peak in            
muscarinic-mediated vascular endothelial Ca​2+​ signaling​ ​(​Moccia et al., 2012​)​.  
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Figure 4.6. ​Representative traces of mean fluorescence ratio (​Δ​R) changes induced by acetylcholine in              
BMVECs (​left​) and bEnd.3 cells (​right​) during calcium imaging recordings. 
 
 
Figure 4.7. ​The effect of four mAChR antagonists on the ACh (1 μM)-induced calcium signal in bEnd.3 cells.                  
Representative traces of relative fluorescence ratio (​Δ​R/​Δ​R​max​) changes are plotted. The double-pulse protocol             
was used, and antagonists were applied 2 min prior to the second ACh pulse (only the second pulse is                   
represented in the graph, and the black bar marks the ACh application period). 
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Figure 4.8. ​The effect of four mAChR antagonists on the ACh (1 μM)-induced calcium signal in BMVEC cells.                  
Representative traces of relative fluorescence ratio (​Δ​R/​Δ​R​max​) changes are plotted. The double-pulse protocol             
was used, and antagonists were applied 2 min prior to the second ACh pulse (only the second pulse is                   
represented in the graph, and the black bar marks the ACh application period). 
 
Since ACh is an agonist for both nicotinic and muscarinic receptors, we examined the              
contribution of each receptor type to the overall ACh-induced Ca​2+ signal. To accomplish             
this, we used a double-pulse protocol, starting with the application of the specific agonist              
(either nicotine or muscarine) followed by a 10-minute washout period, and subsequent            
application of ACh as a positive control (​Figure 4.9​). The 10-minute delay was confirmed to               
be sufficiently long in control experiments where ACh was applied both before and after the               
washout, triggering responses of similar amplitude in both trials (​Figure 4.9 A, ​B​).             
Muscarine administration (100 µM) induced an intracellular calcium signal amplitude similar           
to the one triggered by 10 µM ACh (​Figure 4.9 ​C, D​), while nicotine (300 µM) did not                  
produce any response (​Figure 4.9 ​E, F​). These results demonstrate that nicotinic receptors             
did not contribute to ACh-dependent calcium mobilization in our preparation and that the             
elicited signal depended entirely on GPCR muscarinic receptors. 
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Figure 4.9. ​Representative traces (each trace was recorded for an individual cell) of mean fluorescence ratio                
(​Δ​R) changes induced by acetylcholine (10 μM) (​A, B​)​, muscarine (100 µM) (​C, D​)​, and nicotine (300 µM) (​E,                   
F​)​ in BMVECs (​A, C, E​) and bEnd.3 cells (​B, D, F​). 
 
 
 
70 
  
We further characterized muscarinic receptor functionality by investigating the         
concentration-response curve for ACh concentrations in the range of 1 nM to 10 µM.              
Increased ACh concentrations produced higher-amplitude calcium peaks (representative        
traces are shown in ​Figure 4.6​). The best-fit curve for the data by the Hill equation (eq (1),                  
details in Methods section) was obtained with α = 1. The fit concentration-response curve              
yielded EC​50 values of 0.216 ± 0.016 µM (mean ± S.E.M) for BMVECs and 0.290 ± 0.035                 
µM for bEnd.3 cells (​Figure 4.10​). Our data are in the same range as the EC ​50 values at 0.4                   
µM previously calculated for ACh-induced calcium signals in the HLE-B3 human lens            
epithelial cell line (​Collison et al., 2000​)​. ​Interestingly, no direct correlation was observed             
between the abundance of M​1​-M​5 receptor proteins (​Figure 4.5​) and the EC​50 curve left-shift              
(​Figure 4.10​) or the maximal mean fluorescence ratio induced by ACh (​Figure 4.6​).             
Moreover, our results indicate that primary BMVEC cells are more sensitive to agonist             
exposure compared to the immortalized counterparts, their EC​50 curve being left-shifted.           
These data are in accordance with the distinct Ach-induced calcium response of muscarinic             
receptors in primary cultivated vs. immortalized human lens epithelial cells (​Collison et al.,             
2000​). 
 
Figure 4.10. ​Concentration-response curves for ACh-induced increases in the normalized fluorescence ratio            
(ΔR/ΔR​max​) in BMVECs and bEnd.3 cells. Curves were fitted with eq. (1). Acetylcholine was used at                
concentrations ranging from 0.001 - 10 μM. Data are plotted as the mean ± SEM, N = 30 independent cells, from                     
three different cell batches. 
 
71 
 4.4.4. Selective blocking of M​3 receptors (but not M​1​) reduces ACh-induced calcium            
signals 
 
The differential functional contribution of muscarinic receptor subtypes expressed by          
BMVECs and bEnd.3 cells was next investigated by calcium imaging, adding muscarinic            
orthosteric antagonists to the medium two minutes before ACh application. The results            
(​Figure 4.11​) indicate that the M ​1 receptor antagonist VU 0255035 was ineffective in             
blocking ACh-induced calcium signals, while 3 other antagonists (M​3 receptor antagonists           
J104129 fumarate and 4-DAMP, and M​1 receptor antagonist telenzepine dihydrochloride          
hydrate) completely inhibited the signals triggered in response to 1 µM ACh (representative             
traces are presented in ​Figure 4.7 for bEnd.3 cells and in ​Figure 4.8 for BMVECs). The                
significant difference between the poor inhibition induced by the VU 0255035 and complete             
inhibition produced by telenzepine, both of them being accepted as M​1 antagonists, can be              
explained by the difference in their affinity to M​3 (8-fold less than for M​1 in the case of                  
telenzepine and 58-fold less for VU 0255035). Thus, at high concentrations, the former also              
inhibited M​3​ while the latter did not. 
Inhibition curves for the 3 effective antagonists, when fit to a sigmoidal function (eq              
(2)), yielded a Hill coefficient near 1 and absolute IC​50 values in the range of 1 nM to 200 nM                    
(​Figure 4.11 and ​Table 4.2​). The maximal inhibition produced by VU 0255035 in the tested               
range of concentrations, as determined by the fit to eq (2), was found to be less than 20%, and                   
the relative IC​50 was in the range of 75 nM to 150 nM. These data indicate that despite                  
comparable protein expression levels for M​1 and M​3​, the number of functional M​1 receptors in               
the plasma membrane is much less compared to M​3 receptors. Unfortunately, the lack of              
commercially available M​5​-specific antagonists limited our pharmacological characterization.        
The functional expression of mAChRs in BMVECs and bEnd.3 cells was also evaluated by              
applying agonists/antagonists targeting the allosteric site of the receptors. We found that the             
selective allosteric M ​1 antagonist MT-7 (20 nM, ​Fruchart-Gaillard et al., 2008​) did not exert              
any inhibitory effect on the ACh-induced calcium signal in either type of brain microvascular              
endothelial cells (​Figure 4.12A​). In line with these findings, the selective allosteric M​1             
agonist (​Jacobson et al., 2010​) AC-42 (10 µM), did not elicit any calcium signals (​Figure               
4.12 B). ​Taken together, these results lead to the conclusion that only low levels of the                
functional form of the M​1​ receptors are present on the plasma membrane. 
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Figure 4.11. Inhibition curves of the response to acetylcholine (1 μM) in BMVECs (​A​) and bEnd.3                
cells (​B​) in the presence of mAChR antagonists telenzepine, VU 0255035, J104129 fumarate, and 4-DAMP.               
Results are expressed as average fractions (±SEM on N = 40 independent cells) of the maximal fluorescence                 
ratio (recorded at 10 µM ACh) produced by the lowest concentration in the tested range. Ratios (ΔR/ΔR​max​) are                  
plotted as a function of antagonist concentration. Curves were fitted with eq. (2), and IC​50 values are presented in                   
Table 1. 
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 Table 4.2. ​Effects of 4 different muscarinic antagonists on the response of BMVECs and bEnd.3 cells to 1 μM                   
ACh. Absolute IC​50 values and affinity constants K​a were calculated based on eq. (2) and (3), respectively, from                  
the data presented in Fig. 5. For comparison, previously reported affinity constants for M​1 and M​3 receptors (K​i​),                  
determined on individual clones expressed in testing cell lines, are also shown. *For VU 0255035, the absolute                 
value of IC​50 could not be established, due to this antagonist’s very low efficacy in blocking the calcium signal;                   
**K​i values were determined via a radioligand binding assay (​Michel et al., 1989; Sheffler et al., 2009​), but the                   
authors note that the K​i ​values obtained via a calcium mobilization assay could be at least two times higher than                    
those determined in the radioligand binding assay. 
 
 
 BMVEC bEnd.3 Published reports 
mAChR 
antagonist IC​50​ (nM) 
K​a 
(nM) IC​50​ (nM) K​a​ (nM)  K​i ​(nM) 
Telenzepine 191.29 ± 28.51 33.98 162.08 ± 21.86 36.43 
M​1 
M​3 
2.5 (​Tanda et al. 2007​) 
20.7 (​Tanda et al. 2007​) 
VU 0255035* > 10​4 >1770 > 10​4 >2250 
M​1  
M​3 
14.9 (​Michel et al., 1989; Sheffler 
et al., 2009​) 
877** (​Michel et al., 1989; 
Sheffler et al., 2009​) 
J104129 
fumarate 33.81 ± 3.80 6.00 43.31 ± 3.62 9.74 
M​1  
M​3 
19 (​Mitsuya et al. 2000​) 
4.2  (​Mitsuya et al. 2000​) 
4-DAMP 1.96 ± 0.48 0.42 1.39 ± 0.25 0.31 
M​1  
M​3 
1 (​Dorje et al., 1991; Lazareno et 
al., 1990​) 
0.6 (​Dorje et al., 1991; Lazareno et 
al., 1990​) 
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Figure 4.12. ​Representative traces of mean fluorescence ratio (​Δ​R) changes induced by MT-7 (20              
nM), a potent M​1 antagonist (​A, C​), and AC-42 (10 μM), an M​1 specific agonist (​B, D​) in bEnd.3 cells (​A, B​),                      
and BMVECs ​(C, D)​. 
 
4.4.5. The variability of mouse muscarinic receptors lies in the allosteric binding site 
 
We next complemented our functional analyses with a bioinformatics approach,          
analyzing residues’ conservation of both allosteric and orthosteric binding sites. The multiple            
sequence alignment of muscarinic receptors, along eukaryotic species, reflects the fully           
conservation of the residues present in the orthosteric site (​Wess, 2005; Goodwin et al., 2007​)               
(​Figure 4.13​). Conversely, the residues present in the allosteric binding site (​Kruse et al.,              
2012​) emerges as highly variable (​Figure 4.13 A, B​). This suggests a clear selectivity role of                
the allosteric cavity in ligand binding and activation mechanism. We performed docking            
experiments on M​1​-M​5 modeled mouse muscarinic receptors with the four antagonists           
(​Figures 4.14 - 4.17​): Telenzepine, J104129 fumarate, VU 0255035 and 4-DAMP. Within the             
limitations of the method, it can be observed that, while three of these antagonists              
(Telenzepine, J104129 fumarate, 4-DAMP) interact with residues located in the orthosteric           
binding site, VU 0255035, due to its larger size, interacts also with residues positioned in the                
allosteric binding site (​Figure 4.13 A, Table 4.3​). Hence differences in affinities could be              
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 explained by the observation that VU 0255035 network of interactions involves a less             
conserved region (​Figure 4.15​). 
 
 
Figure 4.13​: Conservation of orthosteric and allosteric site residues among annotated eukaryotic            
muscarinic receptors. (​A​) Conservation values of residues located in allosteric (red) and orthosteric (blue)              
binding sites. (​B​) Orthosteric and allosteric binding-site residues mapped on the M​3 solved structure (PDB code:                
4MQS). The residues are indicated as colored balls, following the same color code as in (A). (​C​) Plot of                   
residues’ conservation values; residues of the orthosteric binding site (blue) and residues in the allosteric binding                
site (red).  
 
 
Table 4.3. Muscarinic receptors homology modeling templates for mouse M​1​-M​5​. Each entry in             
black represents the template PDB code and the sequence identity (S.I.), for the receptors for which 3D                 
structures were obtained through homology modeling. 
 M​1 M​2 M​3 M​4 M​5 
Template 4DAJ 3UON 4U16 3UON 4DAJ 
S.I. 77.27% 97.24% 97.10% 83.50% 78.79% 
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Figure 4.14​. 4-DAMP docking at the binding sites of the M​1​-M​5 mouse receptors. The chemical               
structure of the antagonist, is shown in a 2D representation at the center of the figure, receptors are shown in a                     
ribbon representation, ca of residues located in the orthosteric cavity are shown in blue.  
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Figure 4.15​. VU 0255035 docking at the binding sites of the M​1​-M​5 mouse receptors. The chemical                
structure of the antagonist, is shown in a 2D representation at the center of the figure, receptors are shown in a                     
ribbon representation, ca of residues located in the orthosteric cavity are shown in blue and ca of residues located                   
in the allosteric cavity are shown in red.  
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Figure 4.16​. Telenzepine docking at the binding sites of the M​1​-M​5 mouse receptors. The chemical               
structure of the antagonist, is shown in a 2D representation at the center of the figure, receptors are shown in a                     
ribbon representation, ca of residues located in the orthosteric cavity are shown in blue.  
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Figure 4.17​. J104129 fumarate docking at the binding sites of the M​1​-M​5 mouse receptors. The               
chemical structure of the antagonist, is shown in a 2D representation at the center of the figure, receptors are                   
shown in a ribbon representation, ca of residues located in the orthosteric cavity are shown in blue. 
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 4.5. Discussion and Conclusions 
 
 
The results obtained in immortalized and primary cell cultures of the mouse brain             
microvasculature, including capillaries, lead to the conclusion that all muscarinic          
acetylcholine receptor subtypes are present in mouse brain endothelial cells. To our            
knowledge, this is the first report in which all mAChRs have been studied in terms of both                 
mRNA expression and protein quantification in these cell types, thereby filling a gap in the               
existing literature, which focused on specific subsets. In addition, we provide a functional             
characterization of M​1 and M ​3 and argue that the distribution of M​1-5 receptors may provide               
important insight into the endothelial response to cholinergic stimuli. 
The analysis of transcripts revealed a gradient of mRNA expression by receptor            
subtype, with M3 representing the most abundant and M2 the lowest. In a previous study               
conducted in mouse retinal arterioles (​Gericke et al., 2011a​), mRNA levels for the M​3              
receptor were similar to those reported here, but no other subtypes were detected. The              
discrepancy may be due to the substantial difference in detection thresholds, since in that              
study the cut-off was set at 10​-4 relative to β-actin, which is above the levels we report here                  
for the other 4 subtypes. Low levels of M​2 (mRNA and protein abundance) in our brain                
microvascular endothelial cells are consistent with data reported recently for the proteome of             
mouse cerebral arteries (​Badhwar et al., 2014​). 
An important finding in the present work concerns the cellular localization of            
mAChRs as revealed by immunofluorescence. Aside from the plasma membrane, labeling           
was found in both the nucleus and the cytoplasm, with a subtype-specific distribution. This              
result fits within the framework of a novel paradigm that has emerged in the last ten years,                 
indicating that GPCRs (the receptor family which mAChRs belong to) are able to engage in               
signaling even when positioned inside the cell, including the nucleus (​Gobeil et al., 20006​). In               
particular, we found M​1 mostly distributed in nuclear and cytoplasmic compartments,           
similarly to what has been reported for M​1 in other cell types (​Lind and Cavanagh, 1993​),                
where the intracellular localization was explained either on the basis of constitutive            
internalization through a clathrin-dependent mechanism (​Uwada et al., 2014​) or via agonist            
exposure-dependent internalization (​Thomas et al., 2009​). In another report, the intracellular           
localization of M​1 in neuroblastoma cells was considered associated with a distinct signalling             
pathway from the same receptors located in the plasma membrane (​Uwada et al., 2011​). On               
the other hand, the demonstration of intracellular mAChRs is not in itself proof of their               
involvement in specific alternative pathways. For one thing, receptor proteins must be present             
in the cytoplasm during their folding and maturation process until insertion in the             
plasmalemma. Additional experiments are necessary to describe the role of these intracellular            
fractions of mAChRs in brain endothelial cells. 
Acetylcholine can trigger cytosolic calcium messenger pathways via both nicotinic          
and muscarinic receptors. The mechanisms of action of these receptors are very different;             
81 
 nicotinic receptor activation allows direct calcium ion influx from outside the cells, while the              
activation of Gq-coupled muscarinic receptors (M​1​, M​3 and M​5​) triggers the IP​3 calcium             
pathway. Our results show that nicotine could not elicit any calcium signaling in mouse brain               
microvascular preparations, which is in accordance with previous reports on rat coronary            
microvascular endothelial cells (​Moccia et al., 2004​). We therefore suggest that the measured             
calcium signals are due exclusively to the contribution of muscarinic acetylcholine receptors,            
e.g., M ​1​, M ​3​, and M​5 receptors coupled to the phosphatidylinositol signaling pathway (​Eglen,             
2006​), and not to nicotinic acetylcholine receptors. As M​2 and M​4 do not contribute to the                
calcium signaling pathway, we did not include these receptors in the functional study.             
However, the high M​4 ​protein expression levels, comparable to those of M​1 (​Fig. 4.5​), prompt               
further investigations into the role of this receptor in brain endothelial cells function. 
In spite of the very recent availability of an M​5​-specific antagonist, VU 0488130             
(ML381) (​Gentry et al. 2014 ​), we opted to exclude M​5 from our functional characterization,              
due to its very low expression levels compared to M​1 or M​3 (​Fig. 4.3 and Fig 4.5​). Moreover,                  
an attempt to isolate the M​5 response by saturating M​1 and M​3 with specific antagonists would                
be most likely unsuccessful because of the very small difference in the affinity of 4-DAMP to                
M​3 and M ​5​. In addition, no data are available on the affinity of J104129 fumarate to M​5​.                 
According to ​Table 4.2​, the affinity of 4-DAMP to M​5 is only twice as high as for M​3 which                   
suggests that the antagonist, at concentrations saturating M​3​, will also strongly inhibit the M​5              
signal. We also report here that the selective blocking of M​1 ​receptors does not reduce               
ACh-induced calcium signals. The functional expression of M​1 receptors in brain           
microvascular endothelial cells is particularly important, not only because of their high            
relevance in murine models of neurological diseases (​Sheffler et al., 2009; Xiang et al., 2012;               
Puri et al., 2015​), but also because their role is often neglected in favor of their neuronal                 
counterparts.  
Our data show a mismatch between M​1 mRNA levels and protein abundance.            
Previous studies have described that the synthesis, trafficking and localization of muscarinic            
receptors is influenced by multiple mechanisms (​Nathanson, 2008​), including         
chaperone-assisted synthesis and transport (for example, it has been shown that small            
G-protein ARF6 modulate trafficking of M​2 receptor, ​Nathanson, 2008​). These processes           
might exert a major influence on how much mRNA is translated into functional proteins. In               
this context, one of the major findings revealed by the pharmacological characterization of             
mAChRs in our cells was the very low efficacy of VU 0255035 in inhibiting ACh-triggered               
signals. Considering the affinities of this antagonist for M​1 and M​3​, we speculate that the               
small amount of inhibition we did observe was due to its binding to M​3 and not to M​1​. This                   
argument is supported by the fact that MT-7 (the most specific allosteric M​1 antagonist, with               
no affinity for any mAChR subtypes other than M​1​, Adem and Karlsson, 1997​) also did not       
diminish the ACh signal. In turn, M​3 antagonist J104129 fumarate completely inhibited the             
ACh signal over a range of concentrations corresponding to its specific affinity value. This              
strongly suggests that even if the protein expression of M​1 was comparable to that of M​3 (as                 
shown by the MALDI-TOF data) the level of functional, plasma membrane-embedded M​1            
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 receptors is very low. This hypothesis is in accordance with previously reported values from              
mouse retinal arterioles (​Gericke et al., 2011a​), where the presence of M​3 was shown based               
on both mRNA quantification and a functional assay. In addition, the suggestion agrees with              
the low M​1 levels revealed by immunofluorescence in the plasma membrane, with the             
majority of the protein being located near the nucleus. These data are further supported by the                
lack of M​1 receptor activation in the presence of its very specific agonist, AC-42 (​Spalding et                
al., 2002 ​). 
Another key result of the present study is that the allosteric binding site of muscarinic               
receptors, including mouse receptors, is highly variable. Despite the commonly reported           
blocking specificity of J104129 fumarate, 4-DAMP, and telenzepine for M​3 and M​1​, these             
antagonists can bind to all mAChRs, and the differences between their binding affinities for              
each receptor subtype are not very prominent (​Lazareno et al., 1990; Michel et al., 1989​)               
(​Table 4.4​). From our molecular docking experiments it can be appreciated that these three              
antagonists interact with highly conserved residues mainly located in the orthosteric binding            
site. We paid instead particular attention to VU 0255035 and VU 0488130 (a high affinity M5                
antagonist) and found that they could both interact with residues located in both the              
orthosteric and allosteric sites. The variability in the allosteric site could explain the             
differences in antagonist binding affinities. 
 
Table 4.4. Affinity constants of different antagonists for muscarinic acetylcholine obtained from the             
literature. The values for the affinity constants that match our experimental data for the effect of each antagonist                  
on the total ACh-induced calcium signal recorded for BMVECs and bEnd.3 cells are shown in bold. 
 
Antagonist Binding affinities for mAChR subtypes 
(nM) 
M 
subtype 
 
Biologic source 
M​1 M​2 M​3 M​4 M​5 
Telenzepine 2.52 43.8 20.7 12.4 49.9 1 membranes from frozen rat 
brain (​Tanda et al. 2007​) 
2-5 human receptors in CHO cells 
(Tanda et al. 2007​) 
VU 0255035 14.87 661.33 876.93 1177.67 2362.33 1  CHO cells stably expressing 
rat receptor (​Sheffler et al. 
2009​) 
2,3,5 CHO cells stably expressing 
human receptors (​Sheffler et 
al. 2009​) 
4 rat receptor expressed by 
stably transfected CHO-K1 
cells (​Sheffler et al. 2009​) 
J104129 
fumarate 
19 490 4.2   1-3 membranes from CHO cells 
expressing cloned human 
receptors (​Mitsuya et al. 2000​) 
4-DAMP 1.02 7.08 0.56   1 rat cortex (​Lazareno et al. 
1990​) 
2 rat heart​ ​(​Lazareno et al. 1990​) 
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 3 rat submandibular gland 
(​Lazareno et al. 1990​) 
0.6 3.8 0.5 1.17 1.05 1-5  cloned human cells expressed 
in CHO cells ​ ​(​Dorje et al, 
1991​) 
 
Early reports demonstrated the presence of M​1​, M​3 and M​5 in the human brain               
microcirculation (​Linville and Hamel, 1995; Elhusseiny et al., 1999​), which makes a full             
characterization of all three subtypes in the mouse very important. We excluded M​5 from our               
functional investigation because the data indicated low levels of both gene and protein             
expression, and there is limited knowledge on binding specificity of M​5 antagonists (​Gentry             
et al., 2014​) to these receptors. The functional characterization that we performed for M​1 and               
M​3 receptors is physiologically relevant and in line with recent reports providing evidence on              
the importance of M ​1 and M​3 in controlling blood pressure in various districts (i.e. mouse               
thoracic aorta and mesenteric artery, ​Yuan et al., 2016​; rat mesenteric artery, ​Tangsucharit et              
al., 2016​; human umbilical vein, ​Pujol Lereis et al., 2006​). Altogether, the present results              
provide an encouraging platform for future mouse-to-human translational studies. In          
particular, further experiments will be needed to fill a gap in our study, i.e. the functional                
characterization of the M ​4​ subtype. 
In summary, our findings highlight M​3 receptors as major players in mouse brain             
microvasculature endothelium. On the other hand, the role of M​1 receptors in            
microvasculature should not be discounted, in spite of its low functional contribution to the              
ACh-induced calcium signaling, since a high amount of protein was found expressed in the              
cells. As previously mentioned, the presence of this receptor family in brain microvasculature             
endothelia holds promise for the identification of novel non-neuronal drug targets. Our data             
specifically point out the M​1 and M ​3 subtypes as interesting targets in translational studies              
when designing drugs that act on the blood brain barrier. Moreover, the levels of M​4 protein                
expression found in our study, almost as high as M​1​, prompt further investigations that might               
extend our understanding of the role of muscarinic receptor subtypes in controlling brain             
endothelial cells. 
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4.6. Executive summary 
Aim 
● To assess the expression of all five muscarinic acetylcholine receptors in mouse            
brain microvascular endothelial cells, with a special focus on the functional           
expression of M​1​ and M​3​ receptors. 
Results 
● The mRNA expression of M​2​, M​3, and M​5 ​correlates with their respective protein             
abundance, but there is a mismatch for M​1​ and M​4​ mRNA versus protein levels.  
● Although M​1​, M ​3 and M​4 are the most abundant receptors, only a small fraction of               
M ​1​ is present in the plasma membrane and functions in ACh-induced Ca​2+​ signaling. 
● Cholinergic activation of calcium signaling pathways in brain microvascular         
endothelial cells depends on muscarinic, but not on nicotinic, receptors. 
● Selective blocking of M​1 receptors does not, while selective blocking of M3            
receptors does, reduce ACh-induced calcium signals. 
● Bioinformatic analyses performed on eukaryotic muscarinic receptors demonstrate         
a high degree of conservation of the orthosteric binding site and a great variability              
of the allosteric site.  
 
Conclusion & future perspective 
● Our study indicates muscarinic acetylcholine receptors as potential pharmacological         
targets in future translational studies. 
● We argue that future research on drug development should especially focus on the              
allosteric binding sites of the M​1​ and M​3​ receptors. 
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 Chapter 5. Pilocarpine acts on  
multiple targets  
of the CNS microvascular endothelium 
 
  
5.1. Summary 
 
Clinical and experimental epilepsy studies demonstrated the blood brain barrier          
permeabilization during seizures. Although in epileptogenesis the main focus is on seizures,            
the aim of study is to understand if blood brain barrier permeabilization is preceding or               
following neuronal hyperexcitability. We tested the effects of pilocarpine ​in vivo in mice, and              
in vitro on hippocampal slices and brain endothelial cells. We demonstrated that pilocarpine:             
(1) induces the ​in vivo and ​in vitro cytokines release (e.g. IL-6, KC, MCP-1, and TNF-α), (2)                 
upregulates the expression of adhesion molecules (e.g. VCAM-1, ICAM-1) in brain           
microvascular endothelial cells, (3) elicits calcium transients in a percentage of brain            
microvascular endothelial cells but is not inducing epileptic-like discharges in hippocampal           
pyramidal neurons, (4) downregulates the expression of tight junction proteins (e.g. ZO-1,            
claudin 5) and permeabilizes the monolayers of brain microvascular endothelial cells, (5)            
competes with acetylcholine on the same binding site of the muscarinic receptors, (6)             
downregulates M​1 and M​3 receptors, while upregulates M​2​, M​4 and M​5 receptors in brain              
microvascular endothelial cells. In conclusion, our study indicates that brain endothelium is            
an important site of action for pilocarpine, and the epileptogenesis mechanisms should be             
revisited. 
 
5.2. State-of-art 
 
The neuron-centered paradigm that epileptic seizures can be initiated only by           
epileptic-like neurons has been recently challenged. Although there is an increased interest on             
elucidating mechanisms of seizure generation and epileptogenesis based on the investigations           
of cerebral blood flow and permeability of cerebral microvessels, the temporal sequence            
linking seizures to peripheral inflammation and BBB dysfunction remains to be clarified            
(​Janigro et al., 2012 ​). In the mouse model of pilocarpine-induced epilepsy was previously             
showed that seizures induce elevated expression of vascular cell adhesion molecules and            
enhanced leukocyte rolling and arrest in brain vessels (​Fabene et al., 2008​), and was proposed               
the emerging role for leukocytes and leukocyte adhesion mechanisms in seizure generation            
(​Fabene et al., 2013​).  
Muscarinic acetylcholine receptors have been proposed as potential pharmacological         
targets and/or disease-biomarkers in various CNS pathologies, e.g. schizophrenia (​Gibbons et           
al., 2013; Melancon et al., 2013; Carruthers et al., 2015​), Alzheimer’s disease (​Melancon et              
al. 2013; Colloby et al. 2015; Waqar et al. 2015; Manuel et al. 2016​), Parkinson’s disease                
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 (​Shen et al., 2015​), depression (​Witkin et al., 2014; Gibbons et al., 2016; Small et al., 2016​),                 
psychosis (​Andersen et al. 2015​), and epilepsy (​Hamilton et al., 1997; Schneider et al., 2013;               
Capannolo et al., 2014; Yi et al., 2015​). In order to delineate the physiological roles of the                 
muscarinic cholinergic system, different muscarinic receptor ​knockout ​mice have been          
engineered ( ​Bymaster et al., 2003​). 
In epilepsy, there are several pieces of evidence pointing out that M​1 receptor plays a               
key role in mediating seizures. To date, pilocarpine administration caused seizures and            
lethality in wild-type and M​2​-M​5 knockout mice, but had no effect in the M​1 knockout mice                
(​Hamilton et al., 1997​) or had reduced effect in the mice knockout for M​1 in the                
parvalbumin-positive inhibitory neurons (​Yi et al., 2015​). Intraperitoneal injection of          
VU0255035 (selective antagonist of M​1 receptor) reduced pilocarpine-induced seizures in          
mice without severe cognitive deficits, and inhibited the carbachol-induced potentiation of           
NMDA currents in hippocampal pyramidal cells from rat slices ​(Sheffler et al., 2009​). Despite              
the importance of these studies in elucidating the seizure-based mechanisms, there is a major              
limitation in interpreting results by considering only the contribution of neuronal muscarinic            
receptors (​Cataldi et al., 2011​), and ignoring how the gene deletion affected other cellular              
components of the neurovascular unit (e.g. astrocytes, endothelial cells, pericytes, microglia           
etc.).  
Clinical and experimental studies indicated that neurovascular unit activation plays an           
essential role in ictogenesis (​Fabene et al., 2008; Fabene et al., 2013; Bertini et al., 2013;                
Radu et al., 2013​). In particular, brain endothelium alterations and blood brain barrier barrier              
permeabilization seem to have an important contribution in epileptogenesis (​Uva et al., 2008;             
Fabene et al. 2008; Gorter et al., 2015; Librizzi et al., 2017​). Recently, we described the                
functional expression of all five muscarinic receptors in mouse brain microvascular           
endothelial cells (​Radu et al., 2017a​). Therefore, the aim of study is to understand if blood                
brain barrier permeabilization is preceding or following neuronal hyperexcitability, which a           
special focus on the possible contribution of muscarinic receptors expressed in the brain             
endothelium. 
 
5.3. Materials and Methods 
 
5.3.1. Brain endothelial cell cultures 
Balb/c mouse primary brain endothelial microvascular cells BMVEC (PELOBiotech,         
Germany; passages 3 – 6) and the Balb/c mouse cell line bEnd.3 (ATCC, USA; passages 20 –                 
30), were cultivated as previously described (​Radu et al., 2015​). Cells were plated at a density                
of 2 x 10 ​4 cells/cm​2 onto 24-mm cover glasses for intracellular calcium imaging and              
immunofluorescence protocols, or onto 25 cm​2 flasks and further harvested for qRT-PCR and             
protein quantification assays. 
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 5.3.2. In vitro pilocarpine treatment protocol 
Brain endothelial cells were treated for 2 hrs, 6 hrs and 24 hrs with 100 μM                
pilocarpine hydrochloride (#P6503; Sigma) for the qRT-PCR, immunofluorescence staining         
and protein quantification assays protocols.  
Rat slices were treated for 10 min with pilocarpine at 10 μM (​Nagao et al., 1996​), 100                 
μM and 200 μM (​Marchi et al., 2007​), and further whole-cell and local field potential               
recordings were done. 
5.3.3. Gene expression by qRT-PCR 
To quantify the expression levels of ​chrm1-5 (M​1​-M​5 receptor-encoding genes), ​Tjp1           
(tight junction protein 1 encoding gene) and ​Cldn5 ​(claudin 5 encoding gene) in the mouse               
brain microvascular endothelial cells, total RNA was extracted using the GenElute           
Mammalian Total RNA MiniPrep Kit (RTN70, Sigma) according to the manufacturer’s           
instructions. RNA concentrations were determined by spectrophotometric absorption        
measurements at 260 and 280 nm (Beckman Coulter DU 730). DNase I treatment was used to                
remove contaminating genomic DNA. In agreement with the manufacturer guidelines          
(Sigma), in our experiments the A​260​:A​280 ratio was 2.03±0.06 (bEnd.3) and 1.93±0.03            
(BMVEC). Reverse transcription was performed using the High-Capacity cDNA Archive Kit           
(Sigma). The following mouse Taqman assays (Life Technologies, USA) were used in            
accordance to the manufacturer’s guidelines: ​Chrm1 (​Mm00432509_s1​), ​Chrm2        
(Mm01701855_s1), ​Chrm3 (Mm01338409_m1), ​Chrm4 (Mm00432514_s1), ​Chrm5      
(Mm01701883_s1), ​Tjp1 ​(Mm00493699_m1), ​Cldn5 ​(Mm00727012_s1), ​Gapdh      
(Mm999999_g1), ​Actb ​(Mm00607939_s1). The relative abundance of ​Chrm1-5, Tjp1 ​and          
Cldn5 transcripts was assessed by qRT-PCR using TaqMan methodology and the ABI Prism             
7300 Sequence Detection System (Applied Biosystems, USA). Reactions were carried out for            
50 cycles in triplicate. The β-actin gene (​Actb​) and the glyceraldehyde 3-phosphate            
dehydrogenase ​gene (​Gapdh​) were chosen as housekeeping genes, as previously described in            
other studies of gene quantification in mouse brain endothelial cells (​Wang et al., 2006;              
Navone et al., 2013; Winkler et al., 2015; Radu et al., 2017a​). 
5.3.4. Immunofluorescence staining of muscarinic receptors and tight junction         
proteins in brain endothelial cells 
The cellular localisation of M​1​-M​5 receptors, ZO-1 and claudin-5 was evaluated by            
immunofluorescence in control and pilocarpine treatment conditions. Brain endothelial cells          
were treated with blocking and permeabilization solution (0.3% Triton-100, 1% bovine serum            
albumin, 2% normal goat serum) for 30 min, incubated overnight at room temperature with              
the primary antibody, incubated for 1h with the secondary antibody followed by TO-PRO ​®​-3             
(1:3000, Life Technologies) for 10 min, for nuclear staining, and finally mounted with             
fluorescent mounting medium. The following polyclonal rabbit primary antibodies from          
Alomone, Israel were used: anti-M​1 (1:100, #AMR-001), anti-M​2 (1:100, #AMR-002),          
anti-M​3 (1:100, #AMR-006), anti-M​4 (1:100, #AMR-004), anti-M​5 (1:100, #AMR-005),         
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 anti-PMCA1 (1:200, #ACP-005). Additionally, the polyclonal rabbit primary antibodies from          
Life Technologies, USA, were used: anti-ZO1 (1:100; #61-7300), anti-claudin5 (1:100;          
#34-1600). The primary antibody was omitted in negative-control samples. Goat anti-rabbit           
Alexa 488 (1:1000, Life Technologies) was used as secondary antibody. Normal goat serum             
and fluorescent mounting medium were purchased from Dako, Milan, Italy. 
Specimens were examined using a confocal fluorescence microscope (LSM 710, Carl           
Zeiss, Germany). The following acquisition parameter settings were used: pinhole          
corresponding to 1 Airy Unit for each laser, 62 μm for laser 488 nm and 66 μm for laser 633                    
nm; digital gain was 1.00 for each one; laser intensity was 5% for each one. Acquisition                
parameter settings were kept fixed for each channel in different image acquisition sessions.             
Image analysis was carried out using the Zeiss LSM Image Browser software (Carl Zeiss,              
Germany). 
5.3.5. Immunofluorescence staining of adhesion molecules in brain endothelial         
cells 
bEnd.3 cells were seeded at a concentration of 20 x 10​3​/mL on a glass coverslip in                
24-well plates containing DMEM supplemented with 10% FCS. Cells were stimulated with            
15 μM pilocarpine for 18 h in DMEM with 1% FCS. As positive control, cells were treated                 
with 25U/ml of TNF-α for 18 h in DMEM with 1% FCS. bEnd.3 cells were rinsed with PBS                  
and fixed with 4% PFA for 10 min. After washing with PBS, cells were incubated with                
blocking solution for 1 h at RT and then overnight at 4°C with the primary antibody at the                  
following concentration: anti-VCAM (50 μg/ml) and anti-ICAM (10 μg/ml). Cells were           
rinsed with PBS, incubated with 7.5 μg/ml biotinylated secondary antibody for 1h at room              
temperature and with 25 μg/ml Avidin-TexasRed for 1 h at room temperature. Finally, 1              
μg/ml DAPI was used for 5 min in the dark. Slides were mounted with Dako and images                 
acquired at Tandem Confocal Scanning-SP5 microscope (Leica, Germany). 
5.3.6. Intracellular calcium imaging measurements 
Fura-2 AM-based Ca​2+ imaging experiments based were performed on brain          
microvascular endothelial cells as previously described (​Radu et al., 2015​). Measurements           
were done using a cooled CCD camera (Clara, Andor, Northern Ireland) and a Polychrome V               
monochromator (Till Photonics, Germany), coupled to a the SliceScope (Scientifica, UK)           
upright fluorescence microscope with 40x-water immersion objective (Olympus, Japan). Data          
acquisition was done using Live Acquisition imaging software (Till Photonics, Germany) and            
calcium changes were determined based on the ​R = I​340nm​/I​380nm intensity ratio. Ratios were              
calculated for each cell in the microscope field, based on individually defined regions of              
interest, after background subtraction. Calcium imaging data were analysed using Offline           
Analysis software (Till Photonics, Germany) and plotted as mean fluorescence ratio           
amplitude ( = ​R - R ​0​, where R​0 represents the calcium signals recorded in unstimulated R  Δ              
cells)  ± SEM.  
Solutions were delivered over brain endothelial cells through a 100 µm quartz            
perfusion head using an 8-channel valve pressurized system (ALA Scientific Instruments,           
USA). Ringer solution contained (in mM): NaCl 140, KCl 5.6, MgCl​2 2, CaCl​2 ​2, glucose 10,                
HEPES 10 (pH 7.4 with NaOH). Fura-2 acetoxymethyl ester (Fura-2 AM) and pluronic acid              
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 were purchased from Life Technologies, USA, and all common salts were from            
Sigma-Aldrich, Milan, Italy. Cytosolic Ca​2+ transients resulting from the activation of           
muscarinic acetylcholine receptors were elicited by a 20-s, 1 µM acetylcholine chloride            
(ACh, Sigma) or by different concentrations of pilocarpine application. The reproducibility of            
the ACh effect was tested on a double-pulse protocol with a 10-minute between-pulse             
washing interval with Ringer, as previously described (​Radu et al., 2017a​). In some             
experiments, we precede the second ACh pulse with a 2-min application of pilocarpine. 
5.3.7. In vitro endothelial cell monolayer permeability assay 
Cells were grown on gelatin-coated inserts (0.4 μm ​pore size ​plexiglass membrane) of             
Transwell​® Permeable Supports (​24-well; Corning, Lowell, MA) to confluence. Cells on the            
inserts were incubated with 100 μM pilocarpine for 24 h, and incubated with 1 mg/mL 70                
kDa FITC-dextran (Sigma) for the last 60 min. The amount of 70kDa FITC-dextran diffused              
through the endothelial monolayer into the lower chamber was measured by Victor​TM X4             
2030 multilabel reader (Perkin Elmer, USA) using WorkOut2.5 software and diffusive           
permeability was calculated as previously described (​Li et al., 2010​). 
5.3.8. Viability testing on mouse brain microvascular endothelial cells  
Trypan blue assay was performed on bEnd.3 and BMVECs in control conditions and             
after pilocarpine treatment, as previously described (​Strober et al., 2001; Radu et al., 2015​).              
Cells were detached by trypsin, trypan blue was added (0.2%) and viable cells were counted               
(at least 150 cells). The viability was calculated relative to controls. Measurements were done              
in three replicates.  
5.3.9. Cytokine level quantification 
The cytokines level was quantified in mice plasma (control, methyl-scopolamine,          
methyl-scopolamine & pilocarpine; see Animals section) and in the supernatant of BMVEC            
and bEnd.3 cells in control and pilocarpine treatment conditions. The following cytokines            
were quantified: interleukin 6 (IL-6), interleukin 1 beta (IL-1β), chemokine C-X-C motif            
ligand 1 (CXCL-1, or KC), monocyte chemoattractant protein-1 (MCP-1 or CCL2),           
macrophage inflammatory protein 1 alfa (MIP-1α), and tumor necrosis factor alfa (TNF-α)            
using MAGPIX technology (Mouse Magnetic Cytokines/Chemokines Panel - 5 Plex kit,           
Millipore). 
5.3.10. Flow cytometry analysis of endothelial–leukocyte adhesion molecules 
Flow cytometry analysis was performed on bEnd.3 cells for monitoring the following            
endothelial–leukocyte adhesion molecules: the endothelial expression of intercellular        
adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and P-selectin          
(P-sel). We first evaluated the dose-response effect of pilocarpine (ranging from 1 to 15 μM)               
after 2 and 6 hrs of treatment, on the expression of adhesion molecules (​data not shown​).                
Then, bEnd.3 cells were stimulated with pilocarpine (15 μM) in DMEM with 1% FCS for 2                
hrs and 6 hrs. As positive control, cells were treated with 25U/ml of TNF-α for 18 h in                  
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 DMEM with 1% FCS. bEnd.3 were rinsed with PBS and fixed with 4% PFA for 10 min.                 
After washing with PBS, cells were incubated with blocking solution and labeled 40 min at               
4°C with the following primary antibodies: anti-VCAM (50 μg/ml), anti-ICAM (10 μg/ml),            
and anti-P-sel (5 μg/ml). Cells were acquired by flow cytometry with MACSQuant Analyzer             
(Miltenyi Biotec). Data were analyzed using FlowJo software. The percentage of gated cells             
and the median channel of uorescent intensity (MFI) was calculated.  
 
5.3.11. Animals and in vivo pilocarpine treatment 
 
Young Balb/c male mice (30–50 days of age, weight range: 18–24 g) from             
Harlan-Nossan (Udine, Italy) were adapted to the laboratory and maintained on a 12-h             
inverted light/dark cycle, at 23 ± 1°C, with access to food and water ​ad libitum​. Mice were                 
divided in six groups, n = 5 per group (​Figure 5.1 ​): Group 1 - saline intraperitoneal injection,                 
Group 2 - methylscopolamine (MS, Sigma, 1 mg/kg i.p., ​Fabene et al., 2008​) followed by               
blood collection after 2 hrs, Group 3 - MS i.p. followed by blood collection after 6 hrs, Group                  
4 - MS i.p. followed after 30 min by pilocarpine (P, 300 mg/kg i.p. diluted in 0.01 M PBS,                   
pH 7.4) and blood collection 2 hrs after SE; Group 5 - MS i.p. followed after 30 min by                   
pilocarpine i.p. and blood collection 6 hrs after SE; Group 6 - MS i.p. followed after 30 min                  
by pilocarpine i.p. and blood collection 24 hrs after SE; Group 7 - MS i.p. followed after 30                  
min by pilocarpine i.p. and blood collection 24 hrs after SE. No group was treated only with                 
pilocarpine due to the peripheral cholinergic effects in the absence of methylscopolamine            
(​Clifford et al., 1987​). Blood samples were collected retro-orbital and further processed for             
the cytokine level quantification. 
Adult Wistar rats from Harlan-Nossan (Udine, Italy) were adapted to the laboratory            
and maintained on a 12-hrs inverted light/dark cycle, at 23 ± 1°C, with access to food and                 
water ​ad libitum​. Rats (n = 6) were anaesthetised with isoflurane and transverse hippocampal              
slices were prepared.  
All procedures were carried out in accordance with European Community laws and            
policies and were approved by the University of Verona and by the University of Rome               
‘Sapienza’ ethical committee, respectively. 
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Figure 5.1​. Description of the treatment in six mice groups.  
 
5.3.12. Whole-cell recordings on hippocampal pyramidal neurons in rat slices 
Rat transverse hippocampal slices (300 μm) were cut in glycerol-based artificial           
cerebrospinal fluid (ACSF) with a vibratome (Leica VT 1000S) immediately after surgical            
resection. Slices were placed in a slice incubation chamber at room temperature with             
oxygenated ACSF and transferred to a recording chamber within 1–2 h after slice preparation.              
ACSF had the following composition (in mM): NaCl 125; KCl 2.5; CaCl​2 ​2; NaH​2​PO​4 ​1.25;               
MgCl​2 ​1; NaHCO​3 ​26; glucose 10; Na-pyruvate 0.1; pH 7.35. Glycerol-based ACSF solution             
contained (in mM): glycerol 250; KCl 2.5; CaCl​2 ​2.4; MgCl​2 1.2; NaH​2​PO​4 ​1.2; NaHCO​3 26;               
glucose 11; Na-pyruvate 0.1; pH 7.35. Whole-cell patch clamp recordings were performed on             
pyramidal neurons at 21–23°C. Patch pipettes were filled with the following solution (in             
mM): K-gluconate 140; HEPES 10; 1,2-bis(2-aminophenoxy) ethane-N,N,N,N-tetraacetic       
acid (BAPTA) 5; MgCl ​2 2; Mg-ATP 2; pH 7.35. The effect of pilocarpine on the neuronal                
activity was measured both in voltage- and current-clamp configuration. Membrane currents           
were recorded in voltage-clamp by using glass electrodes (3–4 MΩ), at a -50 mV holding               
membrane potential, in order to distinguish between excitatory (inward) and inhibitory           
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 (outward) synaptic activity. Under these experimental conditions cells were stable and           
healthy for 1–2 hrs. Spontaneous postsynaptic currents (sPSCs) were filtered at 1 kHz,             
digitized at 2 kHz, and analyzed with pClamp10 programs (Molecular Devices, Sunnyvale,            
CA). sPSCs were automatically identified by the software as trace deflections crossing area             
and amplitude thresholds, and then inspected by eye to avoid misclassification. Amplitude            
and frequency of spontaneous postsynaptic potentials (sPSPs) were recorded in current-clamp           
mode and analyzed as sPSCs.  
 
5.3.13. Molecular docking 
GOMoDo web-server (​Sandal et al., 2013​) was used to predict the 3D structures of              
mouse M ​1 and M​3 acetylcholine receptors, using the hidden Markov model based-profiles            
(HMM-profiles) alignments. We use the structure of rat M​3 muscarinic receptor as template             
(PDB code: 4U15). The sequence alignments between targets and template were checked            
manually in order to enforce the conserved structural fingerprints of class A (rhodopsin-like)             
GPCRs (​Venkatakrishnan et al., 2013​). The models were evaluated on the basis of structural              
parameters as previously described (​Sandal et al., 2013​). The models obtained in the             
homology modeling step were used then to perform virtual docking experiments using the             
HADDOCK docking program (​de Vries et al., 2010​) through the GOMoDo web-server. We             
used the GPCRdb generic number position (​Isberg et al., 2014​), which generalized the             
classical Ballesteros-Weinstein numbering. Residues in positions 3.32, 3.33, 3.36, 3.37, 4.57,           
5.39, 5.42, 6.48, 6.51, 7.39, 7.43 were considered as ‘Active Residues’ in order to guide the                
docking. These residues were already characterized as involved in agonist/antagonist binding           
(​Lu and Hulme, 1999; Goodwin et al., 2007​). The structures were downloaded from the ZINC               
database (​Irwin et al., 2012​) and the ligands were parametrized with ACPYPE (​Sousa da              
Silva and Vranken, 2012 ​) in terms of topology, including charge, and structural parameters.             
The charge of both agonist was cross checked using the MarvinSketch program            
(http://www.chemaxon.com) at pH 7.4. The docking protocol included three stages: (a) a            
rigid-body energy minimization, (b) a semi-flexible refinement in torsion angle space, and (c)             
a final refinement in explicit solvent. We chose 1000 structures for the first step and 200                
structures for the second and third docking steps with default parameters. We selected the              
best structure for each docking as the one corresponding to the most populated cluster with               
the lowest energy value. Docking figures were generated with Chimera (​Pettersen et al.,             
2004​). 
 
5.3.14. Data analysis 
Quantitative RT-PCR data were obtained by normalizing ​chrm1-chrm5, Tjn1, Cldn5          
mRNA levels against those of ​Gapdh or ​Actb​, using the 2(-Delta C(T)) method as previously               
described (​Livak and Schmittgen, 2001​). qRT-PCR results were expressed as log​10​-fold           
change, due to their extended scale distribution, and were plotted as mean ± SEM. Statistical               
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 analysis for qRT-PCR data was done by one-way ANOVA followed by Fisher LSD ​post hoc               
tests. Data of intracellular calcium imaging were expressed as mean fluorescence ratio            
amplitude ± SEM, and statistical significance was assessed by unpaired t-test. One-way            
ANOVAs followed by Fisher LSD ​post hoc tests were used to assess BMVEC and bEnd.3               
endothelial cell viability, comparing cells treated with different concentrations of pilocarpine           
to untreated controls. A two-tailed Student's t test was employed for statistical comparison of              
two flow cytometry samples and multiple comparisons were performed employing analysis of            
variance (ANOVA) with the Bonferroni correction of P. * p<0.05. Patch-clamp data were             
reported as means ± SEM and statistical significance was assessed by ANOVA tests.             
Statistical analysis and data plotting were done using OriginPro 8 (OriginLab Corporation,            
USA) and GraphPad Prism version 6.00 for Mac (GraphPad Software, La Jolla California             
USA). 
 
5.4. Results  
 
5.4.1. Pilocarpine stimulates the in vivo and vitro release of cytokines 
 
In order to characterize the inflammatory effect induced by pilocarpine in the            
pilocarpine-based mouse model of epilepsy, we first quantified the cytokines serum levels            
(e.g. IL-6, KC, MCP-1, MIP-1α, IL-1β, and TNF-α) in 6 mice groups (​Figure 5.2​). The mice                
groups have been treated as follows: saline, methylscopolamine (MS; 2 hrs and 6 hrs),              
methylscopolamine followed by pilocarpine (P; 2 hrs and 6 hrs) and pilocarpine (24 hrs) (for               
details of the protocol see ​5.3. Materials and Methods, 5.3.11. Animals​). The treatment             
scheme followed the protocol of pilocarpine-based mouse model for epilepsy which involves            
in a first step the treatment with methylscopolamine and afterwards the addition of             
pilocarpine. Methylscopolamine alone proves being able to induce significant increases in           
some of the analysed cytokines: IL-6 (6 hrs), MCP-1 (2 and 6 hrs), MIP-1 α (6 hrs) and IL-1β                   
(2 and 6 hrs). For this reason, the comparison of data sets have been done with                
methylscopolamine treated groups as control instead of saline (the one-way ANOVA test was             
performed only for MS 2 hrs, MS 6 hrs, MS+P 2 hrs and MS+P 6 hrs data sets).  
Among the analyzed cytokines, by far IL-6 is the most affected cytokine being             
~100-fold up-regulated at 2 hrs and ~3-fold at 6 hrs, one-way ANOVA F = 10.57, p =                 
4.46*10 ​-4​, (​Figure 5.2 A​). Similarly, KT is strongly upregulated at 2 hrs (~10-folds) and 6 hrs                
(~2.5-folds), one-way ANOVA F = 12.48, p = 1.46*10 ​-4​, (​Figure 5.2 B​). MCP-1 is also               
up-regulated ~3-fold at 2 hrs and ~2-fold at 2 hrs, one-way ANOVA F = 16.59, p = 2.68*10​-5​,                  
(​Figure 5.2 C​). TNF-α is significantly up-regulated only at 6 hrs, one-way ANOVA F = 2.67,                
p = 0.07, ​post hoc Fisher test ​p < 0.05, but an increasing trend is observed also at 2 hrs                    
(​Figure 5.2 D​). No significant changes was observed for other two cytokines (MIP-1 α and               
IL-1β) (​Figure 5.2 E, F​). An interesting observation shows that at 24 hrs the MS+P effect is                 
vanished, no significant differences with respect to saline being revealed.  
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Figure 5.2​. In vivo ​cytokine release in mouse serum after status epilepticus. The serum levels for IL-6 (​A​),                  
KC (​B​), MCP-1 (C), TNF-α (D), MIP-1α (E), and IL-1β (F) (one-way ANOVA followed by ​post hoc Fisher                  
test, *p<0.05,**p<0.01)  
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Figure 5.3. ​In vitro cytokines release by brain microvascular endothelial cells. ​The release of KC (A and B)                  
and MCP-1 (C and D) by brain microvascular endothelial cells (bEnd3 and BMVEC) was evaluated upon                
pilocarpine treatment (10, 100, 1000 microM; 2, 6 and 24 hrs) by Luminex xMAP Technology. The statistical                 
significance was analyzed by one-way ANOVA followed by​ post-hoc​ Fisher test (* p < 0.05, ** p < 0.01)  
 
We also quantified the ​in vitro release of the same cytokines by brain microvascular              
endothelial cells exposed to pilocarpine (10, 100, 1000 μM) for 2, 6 or 24 hrs. Only KC and                  
MCP-1 had detectable values for all the timepoints and doses of pilocarpine (​Figure 5.3.              
A-D​). It should be mentioned that in control conditions after 24 hrs, brain endothelial cells               
(BMVEC and bEnd.3) release in the culture medium KC and MCP-1 at levels significantly              
higher compared to 2 hrs or 6 hrs cell maintenance (unpaired t-​test, ​p ​< 0.0.1). There is                 
significant decrease of the KC production at 24 hrs, after exposure to 10 μM, 100 μM or 1000                  
μM compared to control (one way ANOVA, F = 18.73, p < 5.63*10​-4​), in bEnd.3 (​Figure 5.3                 
A​). Similarly, there is a significant decrease of the MCP-1 production at 24 hrs, after               
exposure to 10 μM, 100 μM and 1000 μM compared to control (one way ANOVA. F = 27.82,                  
p = 1.39*10​-4​), in bEnd.3 (​Figure 5.3 C​). Oppositely, there is an increase at 24 hrs, after                 
exposure to 10 μM, 100 μM or 1000 μM compared to control (one way ANOVA: F=28.43,                
p​=1.28*10​-4​), in BMVEC (​Figure 5.3 D​). Only a slight enhancement of KC in BMVEC at               
1000 μM was observed (one way ANOVA: F = 11.64, p = 0.01). IL-6, IL-1β, TNF-α, did not                  
had detectable values (​data not shown​).  
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 5.4.2. Pilocarpine upregulates the expression of adhesion molecules in brain          
microvascular endothelial cells 
 
We also tested the ​in vitro effect of pilocarpine on the expression of adhesion              
molecules on the brain endothelial cell line bEnd.3. Considering the already known ability of              
TNF-α to up-regulate adhesion molecules expression (​Kirchhofer et al., 1994​), it was used as              
positive control. ​Figure 5.4 up ​shows the flow-cytometry quantification of adhesion           
molecule expression of bEnd.3 cells stimulated with pilocarpine represented as fold increase            
compared to basal condition of mean fluorescence intensity (MFI) and % of positive cells              
among whole cell population (% of gated cells). 
 
 
 
Our data show that the MFI expression of P-selectin was slightly increased on             
pilocarpine-stimulated cells when compared to unstimulated ones, moreover the percentage          
of cells expressing P-selectin was significantly increased at 2 hrs and 6 hrs after pilocarpine               
treatment (​Figure 5.4 A​). We observed no statistically significant differences in % of positive              
cells for E-selectin after pilocarpine treatment, however MFI expression trend to increase            
after 6 hrs. 
Interestingly, we observed a significant increase of bEnd.3 cells expressing the           
integrin-ligands ICAM-1 and VCAM-1 after 2 hrs of pilocarpine treatment and the effect was              
maintained at 6 hrs (​Figure 5.4 B. C​), although the MFI did not reach statistical significance                
after 2 hrs treatment.  
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Figure 5.4. Expression of adhesion molecules in brain endothelial bEnd.3 cells upon pilocarpine             
treatment. ​Expression of adhesion molecules ICAM-1 (​A​), VCAM-1 (​B​), and P-selectin (​C​) in unstimulated              
cells and upon 2hrs and 6hrs of cell stimulation with pilocarpine (15 μM) and TNF-alfa, by flow-cytometry; ​(D​)                  
Expression of adhesion molecules ICAM-1 and VCAM-1 in control unstimulated conditions and upon             
stimulation with pilocarpine (15 μM; 18 hrs) and TNF-alfa, by fluorescence microscopy. 
 
 
By immunofluorescence staining, we evidenced that after 18 hrs treatment with 15 μM             
pilocarpine, there is a significant up-regulation of VCAM-1 and ICAM-1 compared to            
unstimulated control cells. ICAM-1 was constitutively expressed at low levels on bEnd.3            
cells, however 18 hrs treatment with pilocarpine led to a significant increase of ICAM-1              
expression (​Figure 5.4 D​). VCAM-1 was not expressed at basal condition on bEnd.3 cells              
and pilocarpine treatment highly up-regulated its expression (​Figure 5.4 D​). 
 
5.4.3. Pilocarpine elicits calcium transients in brain microvascular endothelial cells          
but is not inducing neuronal epileptic-like discharges  
 
The application of pilocarpine (10 min, 10 μM; ​Nagao et al., 1996​) on whole-cell              
voltage-clamped CA3 hippocampal pyramidal neurons in slices produced a significant          
enhancement of the mean frequency of spontaneous excitatory postsynaptic currents          
(sEPSCs), from 0.4 ± 0.2 Hz to 0.9 ± 0.2 Hz (n = 5; ​p < 0.05; ​Figure 5.5​). Pilocarpine at a                      
higher concentration, similar to the level found in cerebrospinal fluid of pilocarpine-treated            
rats (200 μM; ​Marchi et al., 2007​), induced in the same type of neurons a comparable increase                 
of the sPSECs mean frequency, from 0.4 ± 0.1 Hz to 0.7 ± 0.1 Hz (n = 7; ​p < 0.05; ​Figure                      
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 5.5​). Similarly, the frequency of spontaneous inhibitory postsynaptic currents (sIPSCs) was           
significantly increased by pilocarpine at both concentration, 10 μM and 200 μM, from 0.18 ±               
0.09 Hz to 0.3 ± 0.1 Hz (n = 5; ​p < 0.05, ​Figure 5.5​) and from 0.16 ± 0.05 Hz to 0.4 ± 0.1 Hz                          
(n = 8, ​p < 0.05; ​Figure 5.5 ​), respectively. The amplitude of both excitatory and inhibitory                
spontaneous synaptic events was not significantly affected by pilocarpine (​not shown​).           
Furthermore, when current-clamped, hippocampal pyramidal neurons exhibited a similar         
increase of the frequency of spontaneous excitatory postsynaptic potentials (sEPSPs). In these            
cells the pilocarpine application did not elicit any paroxystical depolarization or other            
epileptiform activity (n = 10). 
 
Figure 5.5. Pilocarpine is not producing any epileptic-like discharge in rat hippocampal slices. Pilocarpine              
modulates the frequency of both excitatory and inhibitory spontaneous synaptic activity​. ​A. top, typical              
trace recorded from a CA3 hippocampal pyramidal neuron in whole-cell voltage-clamp configuration at -50 mV.               
Note that inward and outward currents represent excitatory and inhibitory events, respectively. Bottom, enlarged              
trace of the top trace, showing the kinetics of individual events. ​B. trace recorded from the same neuron as A, in                     
the presence of pilocarpine 10 μM. Note the frequency increase of both excitatory and inhibitory events. Mean                 
amplitudes were not affected. ​C. Histograms representing the effect of pilocarpine at 10 μM and 200 μM on the                   
mean frequencies of sEPSCs (left) and of sIPSCs (right). *, significantly different from control, p<0.05. 
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 Brief exposure (2 min) of BMVEC and bEnd.3 cells to pilocarpine (10, 100, and 1000               
μM; ​Figure 5.6​) elicited three types of responses: (type 1) peak-like calcium transients; (type              
2) continuous plateau-like calcium increases; (type 3) no response. The maximal amplitude            
(∆R) for the type 1 response was obtained at 10 μM pilocarpine (​Figure 5.6 A, B​), where the                  
response amplitude is almost double for BMVEC compared to bEnd.3 cells, representative            
traces being presented in ​Figure 5.6B​, and ​Figure 5.6A ​, respectively.  
 
Figure 5.6. Pilocarpine elicits calcium transients in a certain percentage of the brain endothelial cells, 
without significant changes in cell viability. (A) ​ Pilocarpine elicits three types of responses in bEnd.3 cells 
(​A​) and BMVEC (​B​),  (​C​) bEnd.3 endothelial cells were exposed to pilocarpine (100 μM) for 6 hrs, then 
recovered for 6 hrs (white bars) or 24 hrs (hatched bars), followed by Trypan blue viability test. 
 
The percentage of type 1 responsive cells is presented in ​Table 5.1​, where it is evident                
that at 10 μM pilocarpine the percentage of responsive BMVEC (13%) is triple compared to               
the percentage of responsive bEnd.3 cells (4%), the primary microvascular endothelial cells            
being more sensitive to the exposure of pilocarpine at this dose. However, at 100 μM               
pilocarpine, the percentage of type 1 responsive cells becomes almost equal for BMVEC and              
bEnd.3, and at 1000 μM pilocarpine, none of these cells presents the type 1 response. Further,                
we questioned if the dose-dependent decrease in the maximal amplitude of the type 1              
response and the ‘absence’ of type 1 response at higher concentration could not be the               
consequence of altered cell viability. We performed the Trypan blue viability test in bEnd.3              
cells (​Figure 5.6 C​), and no significant changes were obtained after 6 hrs exposure to               
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 pilocarpine (100 μM). Therefore, we might suppose that brief exposures (<5min) to            
pilocarpine would not determine any change in cell viability. 
 
Table 5.1​. Percentages of type 1 responsive cells at different pilocarpine concentrations  
[Pilo]   /   µM 10 100 1000 
Percentage of peak-responding 
bEnd.3 cells 
4 % 
(2/55) 
17 % 
(28/164) 
0 % 
(0/71) 
Percentage of peak-responding 
BMVECs 
13 % 
(24/183) 
19 % 
(11/56) 
0 % 
(0/36) 
 
In the pilocarpine-induced epilepsy model, it should be considered the presence of            
pilocarpine in the animal's bloodstream, in particular in brain capillaries, and the exposure of              
of brain endothelium lining to pilocarpine. It is interesting to understanding how brain             
endothelial cells respond to the repeated exposure to pilocarpine. Therefore, we have tested             
the effect of a double-pulse pilocarpine application (​Figure 5.7 A​) on the calcium transients              
in brain microvascular endothelial cells, with a 5 min interval of recovery between drug              
applications. We obtained several patterns of response that consist in combinations of (i)             
peak-like response and (ii) very little linear increase of calcium during pilocarpine            
application. Two of these patterns are presented as examples in ​Figure 5.7B and ​Figure              
5.7C​.  
 
 
Figure 5.7. Double-pulse pilocarpine application on brain endothelial cells (BMVEC). (A) ​Pilocarpine            
elicits three patterns of calcium transients when a double-pulse of drug is applied (2 min application, 5 min                  
Ringer perfusion between pulses). Two examples of individual patterns are presented: (​B​) no peak-like in the                
first application followed by peak like response, in the second application, and (​C​) no peak-like response in both                  
of pilocarpine applications. 
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5.4.4. Pilocarpine downregulates the expression of tight junction proteins and          
permeabilizes the monolayers of brain microvascular endothelial cells  
 
Therefore, we used a simple model of BBB and we have exposed a monolayer of brain                
microvascular endothelial cells to pilocarpine (100 μM) for 24 hrs and we have measured the               
monolayer permeability to Dextran 70 kDa by spectrofluorimetric measurements. In control           
conditions. diffusive permeability was calculated to be 3.04 x 10​-6 cm/s (n = 5) for the        .54  ± 0         
b.End3 cell monolayer and 2.69 x 10​-6 cm/s (n = 5) for the BMVEC cell monolayer     .98± 0             
(​Figure 5.8​). Upon 24 hrs treatment with pilocarpine (100 μM), the diffusive permeability             
significantly increases for both types of endothelial cells to 5.55 x 10​-6 cm/s (n = 5; ​p          .58  ± 0        
< 0.01, unpaired ​t test), and respectively to 6.98 x 10​-6 cm/s (n = 5; p ​< 0.01, unpaired         .12  ± 1           
t ​test).  
 
 
Figure 5.8​. Permeability of​ in vitro​ BBB model to the Dextran 70kDa is increased by pilocarpine 
treatment (100 μM, 24 hrs). 
 
The immunofluorescence analysis of the ZO-1 and claudin 5 expression in BMVEC, in             
control conditions and upon exposure to pilocarpine (100 μM) for 2 hrs, 6 hrs and 24 hrs,                 
revealed similar results (​Figure 5.9 ​). In control conditions, the tight junctions are well             
delineated, but starting from 2 hrs up to 24 hrs, their expression progressively diminished in               
the plasma membrane while the protein becomes internalised in the cytoplasm (​Figure 5.9A​).             
The mean fluorescence intensity was quantified as total pixel green levels in the microscopy              
images (​Figure 5.9B​), but it is difficult to further interpret these data in the absence of                
colocalization with fluorescent markers specific for different cellular compartments. To detail,           
due to the delocalization of the tight junction proteins from the plasma membrane to the               
cytoplasm, there is difficult to analyze the protein content from the immunofluorescence            
images (​Figure 5.9A​) only by the total mean fluorescence intensity values (​Figure 5.9B​).  
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 The immunofluorescence analysis of the ZO-1 and claudin 5 expression in bEnd.3 cells             
(​Figure 5.10A, Figure 5.10B​), in control conditions and upon exposure to pilocarpine (100             
μM) for 2 hrs, 6 hrs and 24 hrs, indicated the significant upregulation of ZO-1 after 24 hrs                  
exposure to pilocarpine (one-way ANOVA, F=16.87, ​p​=2.26*10​-8​, Fisher ​post-hoc test),          
while the significant downregulation of claudin 5 after 2 hrs and 6 hrs exposure to pilocarpine                
(one-way ANOVA, F=11.13, ​p​=5.31*10​-4​, Fisher ​post-hoc​ test). 
We also quantified the mRNA levels for genes encoding tight junctions proteins (e.g.             
Tjp1 and ​Cldn5​) in control conditions and upon exposure of brain microvascular endothelial             
cells to pilocarpine (100 μM) for 2 hrs, 6 hrs and 24 hrs (​Figure 5.9C​, and ​Figure 5.10C​). In                   
BMVEC, the mRNA for ​Tjp1 is significantly downregulated after 6 hrs of exposure to              
pilocarpine (F=9.04, ​p​=0.004, Fisher ​post-hoc test, with respect to 2 hrs and 24 hrs              
conditions; ​Figure 5.9C​). Oppositely, in bEnd.3 cells, the mRNA for ​Tjp1 is significantly             
upregulated after 6 hrs of exposure to pilocarpine (​Figure 5.10C​). The mRNA for ​Cldn5 is               
significantly downregulated for both endothelial cells tested after 2hrs and 6 hrs exposure to              
pilocarpine, but the downregulation is more accentuated after 2 hrs in BMVEC (​Figure             
5.9C​), while the downregulation is higher after 6 hrs in bEnd.3 cells (​Figure 5.10C ​).  
It is difficult to make a direct correlation between the permeabilization results obtained             
on monolayers of endothelial cells (​Figure 5.8 ​) and the tight junction proteins regulation             
(​Figure 5.9​, and ​5.10​) due to methodological limitations.  
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Figure 5.9​. Pilocarpine downregulates tight junctions proteins (ZO-1 and claudin 5) in brain             
microvascular cells (BMVEC)​. (​A​) Expression of tight junction proteins in control and upon exposure to               
pilocarpine (100 μM) at 2 hrs, 6 hrs, and 24 hrs by immunofluorescence microscopy; green (Alexa 488), blue                  
(TO-PRO​®​-3), Scale bar 10 μm. (​B​) Fluorescence intensity expressed pixel grey level. Statistical analysis was               
done for the ZO-1 expression (one-way ANOVA, F=8.12, p=8.95*10​-5​, Fisher ​post-hoc test, ** ​p ​< 0.01), and                 
claudin-5 expression (F=7.96, p=0.0035, Fisher ​post-hoc test, ** ​p ​< 0.01, * ​p ​< 0.05). (​C​) Fold change in                   
mRNA level by qRT-PCR. One-way ANOVA test was used, excluding the control, to analyze the statistical                
significance of ​Tjp1 gene expression (F=9.04, p=0.004, Fisher ​post-hoc test, ** ​p ​< 0.01 with respect to 2 hrs                   
and 24 hrs conditions), and of ​Cldn5 expression (F=12.67, p=0.0014, Fisher ​post-hoc test, ** ​p ​< 0.01 with                  
respect to 24 hrs condition). 
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Figure 5.10​. Pilocarpine downregulates tight junctions proteins (ZO-1 and claudin 5) in brain             
microvascular cells (bEnd3)​. (​A​) Expression of tight junction proteins in control and upon exposure to               
pilocarpine (100 μM) at 2 hrs, 6 hrs, and 24 hrs by immunofluorescence microscopy; green (Alexa 488), blue                  
(TO-PRO​®​-3). Scale bar 10 μm. (​B​) Fluorescence intensity expressed pixel grey level. Statistical analysis was               
done for the ZO-1 expression (one-way ANOVA, F=16.87, p=2.26*10​-8​, Fisher ​post-hoc test, ** ​p ​< 0.01), and                 
claudin-5 expression (one-way ANOVA, F=11.13, p=5.31*10​-4​, Fisher ​post-hoc test, ** ​p ​< 0.01, * ​p ​< 0.05).                 
(​C​) Fold change in mRNA level by qRT-PCR. One-way ANOVA test was used, excluding the control, to                 
analyze the statistical significance of ​Tjp1 gene expression (one-way ANOVA, F=40.27, p=3.33*10​-4​, Fisher             
post-hoc test, ** ​p ​< 0.01 with respect to 2 hrs and 6 hrs conditions), and of ​Cldn 5 expression (one-way                     
ANOVA, F=62.21, p=9.74*10​-5​, Fisher ​post-hoc​ test, ** ​p ​< 0.01 with respect to 24 hrs condition). 
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 5.4.5. Pilocarpine competes with acetylcholine on the same binding site of the            
muscarinic receptors and regulates their expression 
 
We evidenced that 10 μM pilocarpine is enough to diminish ~50% of the maximal              
fluorescence amplitude of the ACh-induced calcium transients, in both endothelial cell           
preparations (bEnd.3, ​Figure 5.11A, B​; and BMVEC, ​Figure 5.11C, D ​). Moreover, 100 μM             
pilocarpine almost abolished the ACh-induced calcium transients in bEnd.3 cells, and           
diminished ~75% of the ACh-induced calcium transients in BMVEC.  
 
 
 
Figure 5.11. Pilocarpine competes with acetylcholine on the binding site of the muscarinic receptors.              
Pilocarpine (10, 100 μM) significantly diminishes the acetylcholine (1 μM)-induced cytosolic calcium transients             
in brain microvascular endothelial cells, bEnd.3 (​A,  B​) and BMVEC (​C, D​).  
 
 
As we previously demonstrated that all five muscarinic receptors are expressed in brain             
microvascular endothelial cells (​Radu et al., 2017a​), the next step in our study was to analyze                
if pilocarpine distinctly regulates the expression of these receptors in endothelial cells. We             
evidenced the mRNA downregulation for ​Chrm1 and ​Chrm3​, and the upregulation of Chrm2​,             
Chrm4 and ​Chrm5 in BMVEC (​Figure 5.12 A​). In bEnd.3 cells was observed the              
downregulation  of ​Chrm3​ and upregulation of ​Chrm2​ (​Figure 5.12 B ​).  
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Figure 5.12. Pilocarpine regulates the levels of mRNA encoding muscarinic receptors in brain             
microvascular endothelial cells. ​qRT-PCR measurements evidenced that pilocarpine downregulates the mRNA           
level for M​1 and M​3 receptors, while it upregulates the mRNA level for M​2​, M​4 and M​5 receptors in BMVEC (​A​)                     
and bEnd.3 cells (​B​). The mRNA encoding ​Chrm1-Chrm5 have been first normalized to the mRNA encoding                
Gapdh​, followed by the normalized to the control (cells unstimulated with pilocarpine). Statistical analysis was               
done using one-way ANOVA (excluding the control), followed by ​post-hoc Fisher test for each receptor subtype                
in order to evidence the effect of pilocarpine at different timepoints of exposure with respect to 24 hrs, **​p ​<                    
0.01, *​p ​< 0.05. 
 
 
We have also analyzed the changes in protein expression of the muscarinic receptors             
(M​1​-M ​5​) upon exposure to pilocarpine (2 hrs, 6 hrs and 24 hrs) by immunofluorescence              
(​Figure 5.13 ​, ​Figure 5.14​) As we previously demonstrated, in control conditions, the M​1             
receptor is localized in the plasma membrane, and also nuclear and perinuclear, while the              
other receptors M​2​-M​5 are mostly expressed in the plasma membrane and/or cytoplasm (​Radu             
et al., 2017a​). Upon exposure to pilocarpine, M​1 and M​3 are downregulated after 2 hrs and 6                 
hrs, and recovers after 24 hrs at control levels in BMVEC and in bEnd.3 cells.  
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Figure 5.13. Pilocarpine regulates the muscarinic receptor expression in brain microvascular endothelial            
cells (BMVEC). ​Immunofluorescence images in control conditions and upon 2hrs, 6 hrs and 24 hrs exposure to                 
pilocarpine evidence the downregulation of M​1 and M​3 receptors, and upregulation of M​2​, M​4 and M​5 receptors                 
in BMVEC; (green) Alexa488, (blue) TO-PRO​® ​-3, scale bar 10 μm. 
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Figure 5.13. Pilocarpine regulates the muscarinic receptor expression in brain microvascular endothelial            
cells (bEnd.3). ​Immunofluorescence images in control conditions and upon 2hrs, 6 hrs and 24 hrs exposure to                 
pilocarpine for the M​1​, M​2​, M​3​, M​4 and M​5 receptors in bEnd.3 cells. (green) Alexa488, (blue) TO-PRO​®​-3,                 
scale bar 10 μm. 
 
 
As mentioned in the previous paragraph, pilocarpine competes with acetylcholine on           
the same binding site of M​1​-M​5 muscarinic receptors. The binding site of acetylcholine was              
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 demonstrated to be the orthosteric cavity (​Karen J Gregory et al., 2007​). We thus used this                
information to drive the docking of both molecules (pilocarpine and acetylcholine) inside the             
orthosteric binding cavity. We docked the two molecules only with M​1 and M​3 muscarinic              
receptors since, i) the latter are the most abundant among the five muscarinic receptors in               
microvascular endothelial cells (​Radu et al., 2017a​), and ii) pilocarpine was shown to exhibit              
higher selectivity values for the M​1 and M​3 subtypes (​Figueroa et al., 2009​). As shown in                
Figure 5.14​, both the molecules interact in the same cavity of M​1 and M​3 receptors, but                
interacting with slightly different aminoacids. While acetylcholine’s quaternary amino group          
(indicated with (+1) in Figure 5.14, panel C and D), interacts with D3.32, in agreement with                
previous studies (​Yinglong et al., 2013​); pilocarpine establishes several π-stacking          
interactions with aromatic residues of the orthosteric binding cavity like Y3.33, W4.57, and             
Y6.51. In particular, our models are in agreement with the work of Heitz and collaborators               
(​Heitz et al., 199 ​9), that observed that the mutation of W4.57A resulted in a greater than                
100-fold decrease in affinity for pilocarpine. Finally, from Figure 5.14 it can be noticed that               
both molecules interact with polar residues, i.e T5.39 and T5.42, forming h-bonds. We can              
conclude that, within the limitations of the method, pilocarpine probably binds muscarinic            
receptors in the orthosteric binding cavity, acting as a competitor of acetylcholine.  
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Figure 5.14​. ​In silico docking poses of M​1 and M​3 muscarinic receptor with pilocarpine              
(panel A and B) and acetylcholine (panel C and D) agonists, respectively. Receptors backbone              
are shown in transparent green, residues side chains allocated in the orthosteric cavity are              
shown in green. Both agonists are colored in orange with oxygen atoms in red and nitrogen                
atoms in blue. Π-stacking interactions, salt bridges and hydrogen bonds are highlighted with             
black, blue and red dashes respectively. The charge of acetylcholine agonist is indicated with              
(+1). 
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 5.5. Discussion and Conclusions 
 
 
5.5.1. Pilocarpine triggers the proinflammatory cytokines release and upregulates         
the adhesion molecules in brain microvascular endothelial cell 
 
Some of the cytokines we analyzed were significantly up-regulated (IL-6, KC,           
MCP-1, and TNF-α) by pilocarpine following the ​in vivo administration protocol specific to             
pilocarpine mouse model. According to this administration protocol, firstly the mice are            
treated with methylscopolamine, and our data show a significant stimulation of some            
cytokines production triggered by this treatment alone. This result is not in line with a               
previous report showing that ​in vitro exposure of rat brain microvascular endothelial cells             
co-cultured with white blood cells, exposed to relevant concentrations (similar to values            
measured in serum immediately before status epilepticus) as 1.5 mM of pilocarpine and 4 μM               
of methylscopolamine, elicits the level of IL-1β at similar values independent of the presence              
of methylscopolamine after 30 min of treatment (​Marchi et al., 2007​). Contrary, our data              
show that the methylscopolamine alone stimulate the cytokines release at 2 and 6 hrs time               
points. This is a relevant result since a subsequent effect of pilocarpine has to be compared                
with what methylscopolamine already produced. Moreover, the elevation of IL-1β reported           
in the same paper by Marchi ​et al as being induced ​in vivo ​by pilocarpine is matching the                  
increase observed in our records as being produced by methylscopolamine, the subsequent            
pilocarpine treatment did not producing any significant changes. We conclude that           
methylscopolamine treatment (a mandatory step in pilocarpine mouse model) is triggering by            
itself an inflammatory response and the pilocarpine may eventually increase or not this effect.              
TNF-α was reported by Marchi ​et al as being insensitive to the pilocarpine treatment. In our                
records TNF-α is slightly increasing, the change becoming significant at MS+P 6 hrs             
condition. The difference with respect to Marchi’s report is probably due to the short period               
of record used in their protocol (30 min after pilocarpine injection). On the other hand, the                
pilocarpine clearance period in the mouse brain was reported to be of ~3 hrs, with a peak of                  
pilocarpine (~1 mM) at 30 min, and an elevated concentration (above 100 μM) until 3 hrs                
(​Mazzuferi et al., 2012​). With respect to this time evolution of pilocarpine concentration in              
brain, our results show that the inflammatory response is rapidly triggered by            
methylscopolamine and eventually enhanced by pilocarpine during the clearance period.          
However, the elevated level of cytokines at 6 hrs after pilocarpine injection, proves an              
sustained inflammation even after pilocarpine was cleared.  
The duration of ​status epilepticus in pilocarpine-induced epilepsy models for different           
mice strains was reported between 10 min to 4 hrs when stopped with diazepam (​Chen et al.,                 
2013​), or spontaneously remitted 5–6 hrs after pilocarpine administration (​Curia et al., 2008​),             
and this period corresponds with the clearance period for pilocarpine (​Mazzuferi et al., 2012​).              
Our data indicate the elevation of IL-6, KC and MCP-1 released in the blood of mice treated                 
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 with pilocarpine after 2 to 6 hrs, suggesting a role of local inflammation in triggering the                
status epilepticus​. 
In the pilocarpine-induced model of epilepsy, it is important to identify if the             
pilocarpine determines the cytokines release in the serum by stimulating brain microvascular            
endothelial cells, or only the immune blood circulating cells. Our ​in vitro data indicate that               
pilocarpine stimulate the release of KC and MCP-1 by BMVEC only after 24 hrs. The               
stimulation yield monotonically increases with pilocarpine concentration. This result is in line            
with the ​in vivo recorded data. However, the panel of cytokines stimulated by pilocarpine in               
in vivo tests is larger including also IL-6 and TNF-α. Such result is expected since the                
immune cells are well-known to have an important contribution to the cytokines release in the               
blood stream due to a neuroinflammatory insult (​Duque and Descoteaux, 2014​). IL-6 and             
TNF-α are included in the panel of cytokines released by macrophages (​Duque and             
Descoteaux, 2014​). Surprisingly, the same cytokines are downregulated with respect to           
control in bEnd.3 cells, also only after 24 hrs of stimulation. 
 
5.5.2. Pilocarpine activates brain microvascular endothelial cells and the neuronal          
hyperexcitability might be a secondary phenomenon 
 
Pilocarpine, a well-known agonist for muscarinic receptors and chemo-convulsant used          
in the epilepsy-induced models, when applied on mice hippocampal slices did not elicit             
seizure-like discharges even at high concentrations (10-500 μM; ​Marchi et al., 2007​).            
Additional studies reported that arterial perfusion of the ​in vitro isolated guinea-pig brain with              
pilocarpine (<1 mM) did not cause epileptiform activity, except if co-perfused with            
compounds that enhance blood brain permeability, such as bradykinin or histamine (​Uva et             
al., 2008​). Our results indicated that pilocarpine (10 ​μM​, 200 ​μM) applied on rat hippocampal               
slices determines an increased frequency of the excitatory and inhibitory spontaneous synaptic            
events, but without any paroxystical depolarization or other epileptiform activity. The absence            
of ictal-like activity in our recordings, when exposing mice brain slice to pilocarpine (at              
physiological concentrations, ​Mazzuferi et al., 2012 ​), was in line with previous reports in the              
same range of pilocarpine concentrations without any further depolarization (​Marchi et al.,            
2007​). However, in terms of epileptogenesis mechanisms, we consider relevant to be in the              
physiological range of pilocarpine concentrations, that was detected in serum (150-320           
μg/mL) or brain (150-180 μg/g) after 10 min up to 1 hr upon its injection in mice (​Mazzuferi                  
et al., 2012​), and not beyond these limits (​Poulsen et al., 2002​). It is important to point out                  
that the duration of 1 hr of pilocarpine-induced status epilepticus is sufficient to develop              
chronic epilepsy in mice, and was described to be associated with the mossy fiber sprouting               
but not neuronal death (​Chen et al., 2013​), and the majority of our in vitro ​experiments                
mimicked the exposure of brain endothelium at doses of pilocarpine corresponding to this             
post-SE period. In conclusion, pilocarpine ​per se ​is not able to determine seizure-like activity              
in brain hippocampal slices, without any dose-dependence. 
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 Exposure of mice hippocampal slices to pilocarpine in the presence of 6 mM             
extracellular K​+ concentration, triggered epileptiform activity, due to neuronal depolarization          
(​Marchi et al., 2007​). Moreover, rat hippocampal slices exposed to pilocarpine (0.1-5 mM)             
induces ictal-like activity in almost 50% of the pyramidal neurons (​Poulsen et al., 2002​),              
either due to the slightly increased extracellular K​+ at 5.4 mM or to the high pilocarpine                
concentrations. In some preliminary tests, we also reproduced the epileptiform activity in            
hippocampal brain slices (​data not shown​) when pilocarpine was associated with increased            
extracellular K​+ concentration (4-8 mM). In conclusion, pilocarpine ​per se is not able to              
produce ictal-like events in brain slices, but in the presence of elevated extracellular K​+              
neurons present seizure-like discharges. In this context, it is important to understand if             
increased extracellular K​+ ​mimics or not the consequences of in vivo opening of the BBB and                
subsequent loss of brain homeostasis. It is still an opened issue the extent of K​+ increase in the                  
brain parenchyma after BBB opening, as limited information is available regarding the            
buffering capacity of glial cells. 
Interestingly, pilocarpine concentrations were quantified in brain and blood at different           
timepoints, and have been reported to equalize after 30 min (​Römermann et al., 2015​) or 1 hr                 
(​Mazzuferi et al., 2012​). However, the mechanism of pilocarpine entrance into the brain             
parenchyma remains to be understood.  
Considering the paradigm of neurovascular unit activation in ictogenesis (​Bertini et al.,            
2013​), we tested if pilocarpine has a direct effect on brain endothelial microvascular cells.              
Our data clearly show a percentage of brain microvascular endothelial cells that elicit calcium              
transients. Extending our data to a broader scenario, we could hypothesize that pilocarpine in              
the bloodstream acts directly on brain endothelium and triggers calcium waves, as described             
in the literature for acetylcholine (​Tallini et al., 2007​). 
Beside the acute effect of pilocarpine that triggers calcium transients by activating the             
muscarinic receptors, chronic exposure to pilocarpine modulates the expression of these           
receptors. Our results indicating the down-regulation of M​1 and M​3 in brain microvascular             
endothelial cells upon ​in vitro exposure to pilocarpine for 24 hrs prove that pilocarpine not               
only act as an muscarinic receptors agonist, but also is able to inhibit the expression of these                 
receptors. The results are in line with previous reports showing that exposure of Chinese              
hamster ovary (CHO) cells to orthosteric agonists (e.g. pilocarpine) determines the M​1            
receptor internalization and down-regulation, while exposure to allosteric agonists cause some           
receptor internalization, but not down-regulation (​Thomas et al., 2009​). 
Previous studies have hypothesized that the ability of pilocarpine to induce ​status            
epilepticus depends on activation of the M​1 muscarinic receptor, since M​1 receptor knockout             
mice do not develop seizures in response to pilocarpine (​Hamilton et al., 1997​), but this               
knowledge remained confined around the idea that pilocarpine acts on the neuronal M​1             
muscarinic receptor (​Cataldi et al., 2011 ​). Our study brings new insights showing the             
115 
 importance of these receptors expressed in the brain endothelium when exposed to            
pilocarpine. 
 
5.5.3. Pilocarpine activates brain microvascular endothelial cells by multiple         
mechanisms that contribute to the blood brain barrier permeabilization 
 
Pilocarpine was demonstrated to have partial agonistic effects on Ca​2+ responses           
(​Schaafsma et al., 2006; ​Nezu et al., 2015​) and it is documented to act on the orthosteric                 
binding site of the muscarinic receptors (​Thomas et al., 2009​). We tested if these properties of                
pilocarpine as partial agonist are also present in the muscarinic receptors expressed in the              
brain microvascular endothelial cells. 
It was demonstrated the association between blood brain barrier permeabilization and           
seizures (​Uva et al., 2008; Fabene et al. 2008; Gorter et al., 2015; Librizzi et al., 2017​). As                  
brain microvascular endothelial cells are an important component of the neurovascular unit,            
and pilocarpine was demonstrated to activate calcium transients in these cells, the next step in               
understanding its mechanism of action was to elucidate if there is any effect of pilocarpine on                
the blood brain barrier integrity. Considering our results pointing out that pilocarpine            
permeabilizes the monolayer of brain microvascular endothelial cells for large molecules (i.e.            
Dextran 70kDa), we focused our attention on understanding the mechanism of           
permeabilization. Taking into account that tight junction proteins are well-known          
‘gate-keepers” of the BBB integrity (​Luissint et al., 2012​), our data are relevant as we proved                
that pilocarpine downregulates the tight junctions proteins (e.g. ZO-1 and claudin 5, except             
for the ZO-1 that was upregulated in bEnd3 cells at 24 hrs) in terms of protein and gene                  
expression. Alghouth these preliminary studies are encouriging, further analysis of the           
pilocarpineʹs effect in more complex ​in vitro systems mimicking the blood brain barrier             
and/or the neurovascular unit are necessary.  
We have previously shown that the acute seizure activity following pilocarpine           
administration leads to enhanced vascular expression of leukocyte adhesion molecules on           
brain endothelial cells (​Fabene et al., 2008 ​). Interestingly, we found that pilocarpine mediates             
the upregulation of selectins on bEnd.3 cells, these adhesion molecules are of particular             
importance for the initial binding of neutrophils on vascular endothelium. Above all, the             
induction of P-selectin expression on brain endothelial cells is fundamental considering its            
proven involvement in the recruitment of neutrophils in the brain during acute seizures.             
Moreover, pilocarpine upregulates ICAM-1 and VCAM-1, and this indicates that pilocarpine           
directly activates brain microvascular endothelial cells by inducing an augmented expression           
of adhesion molecules and potentially allowing leukocyte adhesion.  
To resume, complex events occur at the brain endothelium level when exposed to             
pilocarpine, including cytokines release, calcium waves triggering, changes        
leukocyte-endothelium adhesion, activation/down-regulation of M​1 and M​3 muscarinic        
receptors, tight junctions loosening, blood brain barrier permeabilization etc. In conclusion,           
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 our study indicates that brain endothelium is an important site of action for pilocarpine, and               
neurons’ exposure to pilocarpine is not triggering seizure-like activity, therefore          
epileptogenesis mechanisms should be revisited. 
 
5.6. Executive summary 
Aim 
● To assess the action of pilocarpine on brain microvascular endothelium in an ​in             
vitro​ model of epileptogenesis 
Results 
● Pilocarpine induces the ​in vivo and ​in vitro cytokines release (e.g. IL-6, KC,             
MCP-1, and TNF-α) 
● Pilocarpine upregulates the expression of adhesion molecules on brain         
microvascular endothelial cells, and interferes with leukocyte-endothelium adhesion        
and neutrophils recruitment  
● Pilocarpine elicits calcium transients in a percentage of brain microvascular          
endothelial cells 
● Pilocarpine is not inducing epileptic-like discharges in hippocampal pyramidal         
neurons in the absence of a depolarization induced by K ​+ ​extracellular increase 
● Pilocarpine downregulates the expression of tight junction proteins and         
permeabilizes the monolayers of brain microvascular endothelial cells 
● Pilocarpine competes with acetylcholine on the same binding site of the muscarinic            
receptors 
● Pilocarpine downregulates M​1 and M​3 receptors, while upregulates M​2​, M​4 and M​5            
receptors in brain microvascular endothelial cells 
 
Conclusion & future perspective 
● We demonstrated that endothelium of brain microvasculature is an important site of            
action for pilocarpine 
● The epileptogenesis mechanisms should be revisited by understanding if the          
blood-barrier barrier permeabilization precedes or follows neuronal       
hyperexcitability 
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 Chapter 6. General discussions 
 
 
 
Multiple studies are dealing with the cholinergic signaling in the neuronal tissue, but             
limited information is available on the cholinergic signaling in the non-neuronal tissue, in             
particular in the brain capillaries. Therefore, we have focused our attention on the brain              
endothelium of the cerebral microvasculature. Moreover, pilocarpine action (as a common           
chemo-convulsant) agent is frequently analyzed in the neuronal tissue and its effects on the              
neuronal excitability are extensively studied. However, ​the mechanisms of pilocarpine action           
directed against the first barrier encountered (the blood brain barrier) ​in the bloodstream             
are largely neglected​.  
Cerebral microvasculature is commonly imaged in different animal studies targeting          
physiological and pathological conditions (including epilepsy) and the deep-tissue bright          
nanoparticles-based agents are prefered. Generally, ​the direct action of the fluorescent           
nanoparticles on brain microvascular endothelium is considered negligible​.  
In this thesis, we intended to understand the particularities of nanoparticles-based           
imaging agents action on the cerebral microvasculature and the cholinergic signaling in brain             
endothelium under physiological and pathological conditions (e.g. epilepsy). For this purpose           
we brought together ​in vitro, ​in vivo and ​in silico models, and several ​limitations of our                
studies have been identified: 
L1. Use of in vitro cell culture models 
L2. Use of in vivo animal models  
L3. Use of in silico models 
 
L1. Use of in vitro cell culture models. ​An important limitation of the experimental              
studies described in this thesis was the use of ​in vitro cell cultures models ​, e.g. brain                
microvascular endothelial cells. 
In Chapter 3, we used mouse brain microvascular endothelial cells in primary and             
immortalized cell cultures, and human umbilical vein endothelial cells. Similar ​in vitro ​studies             
on brain endothelial cells have been performed on PEG-coated silica nanoparticles (​Liu et al.,              
2014​). The main limitation of our ​in vitro tests was the use of brain microvascular endothelial                
cells that represent only one of the many pieces in the complex puzzle of the neurovascular                
unit. Considering the diversity of available 2D and 3D models static/dynamic models for the              
blood brain barrier and the neurovascular unit (​Radu and Radu, 2015​), future ​in vitro studies               
should also consider testing the effect of Qtracker​®​800 on these models. Further ​in vivo              
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 imaging analysis of Qtracker​®​800 effect at the level of brain microvasculature should provide             
more insights on the mechanism of action of nanoparticles.  
In Chapter 4 and 5, we also used mouse brain microvascular endothelial cells in primary               
and immortalized cell cultures for the functional expression analysis of the muscarinic            
receptors in control and pilocarpine treatment conditions. The main limitation of this            
approach is related to the use of a simplified ​in vitro model (i.e. brain microvascular               
endothelial cells), where several important actors of the NVU are missing (especially the             
neuronal component) and the ​in vivo distribution/expression of the receptors might be altered.             
More complex in vitro models, including 2D and 3D models static/dynamic models, should             
be further used to mimic the cross-talk between cerebral endothelium and brain parenchyma.             
Moreover, combining ​in vivo patch-clamp recording with two-photon imaging could provide           
simultaneous information on neuronal excitability and microvasculature activity/dynamics.  
In our studies, we proposed the ​in vitro pilocarpine model​, where brain microvascular             
endothelial cells are exposed to pilocarpine to mimic the effects of the chemo-convulsant in              
the bloodstream. Of course, the model has several limitations related to its simplicity and the               
use of only one type of cells involved in the NVU, but it represents the initial step in                  
understanding the first steps in ictogenesis mechanisms. If more complex ​in vitro​/​in vivo             
models will confirm our data, this model could be further used as ​an in vitro platform for                 
pharmacological screening.  
 
L2. Use of in vivo animal models. ​Another limitation of the study is the use of animals                 
models in some experiments presented in Chapter 3 and Chapter 5 of the thesis.  
In Chapter 3, we used a ​mouse model to test fluorescent imaging dyes (e.g.              
Qtracker​®​800) for biomedical deep-tissue imaging applications. Animal models have been          
previously used to test Qtracker​®​800 for ​in-vivo vasculature imaging applications (​Mayes et            
al., 2008; Lo Celso et al., 2011​). Limitations of using animal models in testing fluorescent               
dyes for deep-tissue vasculature imaging should be considered: (1) mouse-to-human ​in vivo            
differences of the dye biodistribution and kinetics/dynamics in brain microvasculature, (2)           
mouse-to-human differences between the imaging procedures.  
In order to increase the translational value of our data, we have also tested the effect of                 
Qtracker​®​800 on human umbilical vein endothelial cells in primary culture derived from            
different donors. Further ​in vivo testing of Qtracker​®​800 (and other fluorescent           
engineered-improved nanoparticles) for deep tissue imaging applications should also consider          
intravital microscopy experiments to monitor the activation of local calcium waves and their             
eventual propagation in brain microvasculature.  
In Chapter 5, we used the ​pilocarpine-induced animal model ​in order to quantify the              
changes in cytokines serum levels. This model was already used in previous studies of              
Fabene​'​s group (​Fabene et al., 2008; Paradiso et al. 2009; Marchi et al. 2011​) for showing that                 
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 that leukocyte trafficking plays a key role in seizure generation; this study has a good               
translational outcome supported by recent clinical observations suggesting that therapies able           
to interfere with leukocyte trafficking may have a therapeutic effect in human epilepsy. In our               
study, we have tried to diminish the possible experimental biases by comparing the             
methylscopolamine+pilocarpine animal group with the methylscopolamine animal group, as         
the methylscopolamine administration is a mandatory step in the pilocarpine mouse model for             
preventing peripheral cholinergic effects.  
The advantages/disadvantages of using this animal model of epilepsy have been           
extensively described in several reviews (​Löscher, 2011; Kandratavicius et al., 2014; ​Radu et             
al., 2017b​). In animal models, pilocarpine administration was demonstrated to: (i) induce            
neuropathological alterations (i.e. cell loss, reduced arborization or lesions in different areas,            
including subiculum, hippocampus, neocortex), (ii) cause cognitive and memory deficits and           
(iii) triggers kindling and chronic spontaneous recurrent seizures (​Turski et al., 1983;            
Cavalheiro et al., 1991; Mudò et al., 1996; Wozny et al., 2003; Knopp et al., 2005; Pauli et al.,                   
2006​), thus mimicking human temporal lobe epilepsy. Although chemical-induced epilepsy          
models (namely, the kainic acid and pilocarpine administration models) are largely used and             
reproduce some of the neuropathological, behavioral, cognitive, and psychiatric findings of           
temporal lobe epilepsy, they share significant limitations in translational medicine studies           
(​Kandratavicius et al., 2014​) that should not be neglected.  
 
L3. Use of in silico models. ​The third important limitation of the study is the use of ​in                  
silico ​ models​ in some analysis presented in Chapter 4 and Chapter 5 of the thesis.  
The ​in silico models for the molecular docking analysis present several limitations: (i)             
since mouse M​1​-M​5 lack structural information (​Haga et al., 2012; Kruse et al., 2012​),              
homology modeling was carried out to predict their 3D structures, (ii) the plasma membrane              
environment is missing in molecular docking studies, (iii) the ligand-specific conformational           
changes of the receptors in different tissues is lacking in ​in silico models. Despite these               
limitations, the predictive power of the ​in silico methods should not be neglected and their               
contributions in the pharmaceutical industry for the design of specific receptor           
agonists/antagonists. 
 
The guiding idea in all the experiments contained in this thesis was that cerebral              
microvasculature (e.g. cerebral microvascular endothelium) plays an active role in          
physiological and pathological conditions. The ​main questions​ addressed in this thesis were: 
Q1. Is cerebral microvascular endothelium reactive/non-reactive to fluorescent        
intravital imaging dyes? 
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 Q2. Is cerebral microvascular endothelium activity regulated in physiological         
conditions by acetylcholine by means of the muscarinic receptors? 
Q3. How muscarinic receptors expressed in cerebral microvascular endothelium         
are contributing to epileptogenesis mechanisms? 
 
Q1. Is cerebral microvascular endothelium reactive/non-reactive to fluorescent        
intravital imaging dyes? ​In particular, it is important to understand if fluorescent            
nanoparticles (QDs800) used for deep intravital imaging are just crossing through the            
bloodstream or if there are active against the cerebral blood vessels walls, and thus              
introducing a methodological bias. Beside the accumulation of QDs in the endothelium, we             
have brought an essential contribution by proving the ​activation of calcium transients in             
brain microvascular endothelial cells upon exposure to nanoparticles​. Our result          
questions the accuracy of the experiments in which QDs800 are used for fluorescent imaging              
of the cerebral vasculature for small animals. A second contribution of this study that              
deserves to be emphasized is the patient-dependent calcium activation in endothelial cells            
exposed to QDs800​. This result is crucial in terms of translational potential of QDs800 in               
imaging techniques applied in patients and limits/prevents the use of these nanoparticles for             
medical applications. In conclusion, we demonstrated a direct action of Qtracker​®​800 on the             
vascular endothelium in the first 3 hrs after administration, thus overlapping the time window              
recommended for vasculature imaging studies with these fluorescent nanoparticles. 
In perspective, keeping in mind the enormous potential of Qtracker​®​800 deep-tissue           
penetration in biomedical applications, better manufacturing solutions to diminish/eliminate         
endothelium actions should be found. Several open questions are emerging: ​(i) how safe are              
the contrast agents (Qtracker®800) used for deep tissue microvasculature imaging in small            
animals?, (ii) are they suitable to image microvasculature in different animal models or their              
long-term presence into the animal body might induce alterations (including seizure-like           
events)? (iii) do contrast agents interfere with the quality of the recorded data or does the                
imaging results on brain microvasculature in different physiological/pathological conditions         
are altered by the presence of nanoparticles ​per se​? 
 
Q2. Is cerebral microvascular endothelium activity regulated in physiological         
conditions by acetylcholine by means of the muscarinic receptors? Our study demonstrated            
the ​expression of all muscarinic acetylcholine receptors in mouse brain microvascular           
endothelial cells​. Functional calcium testing also demonstrated that acetylcholine acts on           
muscarinic, but not nicotinic, mouse receptors. It should be also highlighted that our study              
brings ​the first evidence that M​1 receptors​, together with M​3 receptors, ​are functionally             
expressed in mouse brain microvascular endothelium​. Taking into account the extensive           
use of mouse models in mimicking pathological conditions (e.g. epilepsy), the second result             
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 of this study is very important in explaining the roles of muscarinic acetylcholine receptors in               
the cerebral mouse microvasculature. In conclusion, our study suggests muscarinic          
acetylcholine receptors as potential pharmacological targets in future translational studies. 
In perspective, we argue that future research on drug development should especially            
focus on the allosteric binding sites of the M​1 and M​3 receptors. Several issues should be                
further studied: (i) the functional expression of M​4 and M​5 in mouse brain microvascular              
endothelium, (ii) the distinct contribution of the muscarinic receptors in cholinergic signaling            
that controls the dynamics of brain microvasculature in physiological conditions, (iii) the            
functional expression of muscarinic receptors in human brain microvasculature using          
appropriate models mimicking the physiological condition (e.g. human iPS cell-derived brain           
microvascular endothelial cells, or human brain microvascular endothelial cells), (iv) the ​in            
vivo​ muscarinic cholinergic receptor imaging of brain microvasculature in animal models. 
 
Q3. How muscarinic receptors expressed in cerebral microvascular endothelium are          
contributing to epileptogenesis mechanisms? Using a pilocarpine induced model, our study           
identified multiple mechanisms by which cerebral microvasculature contributes to         
ictogenesis. We demonstrated that ​pilocarpine exerts a synergic action on muscarinic           
receptors, tight junctions proteins, adhesion molecules, and cytokines release,         
determining a joint increase of the blood brain barrier permeability​. We propose that the              
mechanism of action involves the competition of pilocarpine with acetylcholine on the            
orthosteric site of muscarinic receptors expressed in cerebral microvascular endothelial cells.           
We also might speculate that pilocarpine interferes with the ”normal” processes of            
leukocyte-endothelium adhesion and neutrophils recruitment by altering the adhesion         
molecules on the surface of brain microvascular endothelium. In conclusion, we demonstrated            
that endothelium of brain microvasculature is an important site of action for pilocarpine.  
In perspective, the epileptogenesis mechanisms should be revisited by understanding if           
the blood-barrier barrier permeabilization precedes or follows neuronal hyperexcitability.         
Multiple aspects remain to be further deciphered: (i) to test the alteration of             
leukocyte-endothelium adhesion in the presence of pilocarpine by employing 3D artificial           
capillary models and/or 3D dynamic NVU model, (ii) to evidence the changes underwent by              
the glycocalyx of the brain microvascular endothelium upon exposure to pilocarpine and how             
is affected the leukocyte-endothelium adhesion, (iii) to understand the mouse-to-human          
translational potential of our data, and (iv) to evaluate the utility and limitations of using the                
in vitro​ pilocarpine model for pharmacological screening. 
 
As a ​general conclusion​, this thesis revealed some pieces in the complex puzzle of              
mouse brain microvascular endothelium activation in the presence fluorescent vasculature          
imaging agents and its role in the pilocarpine-induced ictogenesis model. 
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